<SEC-DOCUMENT>0001193125-18-142664.txt : 20180430
<SEC-HEADER>0001193125-18-142664.hdr.sgml : 20180430
<ACCEPTANCE-DATETIME>20180430150555
ACCESSION NUMBER:		0001193125-18-142664
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		12
CONFORMED PERIOD OF REPORT:	20180620
FILED AS OF DATE:		20180430
DATE AS OF CHANGE:		20180430
EFFECTIVENESS DATE:		20180430

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CareDx, Inc.
		CENTRAL INDEX KEY:			0001217234
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				943316839
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36536
		FILM NUMBER:		18788983

	BUSINESS ADDRESS:	
		STREET 1:		3260 BAYSHORE BOULEVARD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		415-287-2300

	MAIL ADDRESS:	
		STREET 1:		3260 BAYSHORE BOULEVARD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XDx, Inc.
		DATE OF NAME CHANGE:	20071010

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXPRESSION DIAGNOSTICS INC
		DATE OF NAME CHANGE:	20030203
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d472342ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<HTML><HEAD>
<TITLE>DEF 14A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 14A
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Proxy Statement Pursuant to Section 14(a) of the </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Securities Exchange Act of 1934 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the
Registrant&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Filed by a Party other than the
Registrant&nbsp;&nbsp;&#9744;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Preliminary Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Proxy Statement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Definitive Additional Materials</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Soliciting Material Pursuant to &#167;240.14a-12</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>CareDx,
Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Registrant as Specified In Its Charter) </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name of Person(s) Filing Proxy Statement, if other than the Registrant) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">No fee required.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Title of each class of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Aggregate number of securities to which transaction applies:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing
fee is calculated and state how it was determined):</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proposed maximum aggregate value of transaction:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(5)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Total fee paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Fee paid previously with preliminary materials.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(1)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Amount Previously Paid:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(2)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Form, Schedule or Registration Statement No.:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(3)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filing Party:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(4)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date Filed:</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAREDX, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3260 Bayshore Blvd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Brisbane, California&nbsp;94005 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To Be Held at&nbsp;10:00 a.m. Pacific Time on Wednesday, June&nbsp;20, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholder: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cordially invited to attend
the&nbsp;2018 annual meeting of stockholders (the &#147;Annual Meeting&#148;) of CareDx, Inc., a Delaware corporation (&#147;CareDx,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; or the &#147;Company&#148;). The Annual Meeting will be held
on <B>Wednesday, June</B><B></B><B>&nbsp;20, 2018,</B> <B>at 10:00 a.m. Pacific Time</B>, at our headquarters, located at&nbsp;3260 Bayshore Blvd., Brisbane, California&nbsp;94005, for the following purposes, as more fully described in the
accompanying proxy statement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">To elect two Class&nbsp;I directors to serve until the 2021 annual meeting of stockholders or until their successors are duly elected and qualified; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">To ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">To approve an amendment to the Company&#146;s 2014 Equity Incentive Plan (the &#147;2014 Plan&#148;) to increase the number of shares of common stock that may be issued under the 2014 Plan by 1,600,000 shares and to
eliminate the fixed share cap included in the evergreen provision; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">To conduct any other business properly brought before the Annual Meeting and any adjournments or postponements thereof. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has fixed the close of business on April&nbsp;23, 2018 as the record date for the Annual Meeting. Only stockholders of record on
April&nbsp;23, 2018 are entitled to notice of and to vote at the Annual Meeting. Further information regarding voting rights and the matters to be voted upon are more fully described in the accompanying proxy statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On or about May&nbsp;2, 2018, we expect to mail our stockholders a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) containing
instructions on how to access our proxy statement and our annual report. The Notice provides instructions on how to vote via the Internet or by telephone and includes instructions on how to receive a paper copy of our proxy materials by mail. The
accompanying proxy statement and our annual report can be accessed directly at <U>http://investors.caredxinc.com/annuals-proxies.cfm</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>YOUR VOTE IS
IMPORTANT. Whether or not you plan to attend the Annual Meeting, we urge you to submit your vote via the Internet, telephone or mail as soon as possible so that your shares can be voted at the Annual Meeting in accordance with your instructions.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for your continued support of CareDx. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">By order of the Board of Directors, </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Peter Maag, Ph.D. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Peter Maag, Ph.D.<I> </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:54%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><I>Chief Executive Officer and President</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brisbane, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">April&nbsp;30, 2018 </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_1">QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_2">PROPOSAL NO. 1 ELECTION OF DIRECTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_3">Nominees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_4">Vote Required</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_5">BOARD OF DIRECTORS AND CORPORATE GOVERNANCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_6">Nominees for Director</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_7">Continuing Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_8">Director Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_9">Board Leadership Structure</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_10">Legal Proceedings with Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_11">Agreements with Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_12">Board and Committee Meetings</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_13">Considerations in Evaluating Director Nominees</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_14">Stockholder Recommendations for Nominations to the Board of
Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_15">Communications with the Board of Directors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_16">Corporate Governance Guidelines and Code of Business Conduct and
Ethics</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_17">Board of Directors&#146; Role in Risk Oversight</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_18">Director Compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_19">PROPOSAL NO. 2 RATIFICATION OF APPOINTMENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_20">Changes in Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_21">Fees Paid to the Independent Registered Public Accounting Firm</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_22">Auditor Independence</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_23">Audit Committee Policy on <FONT STYLE="white-space:nowrap">Pre-Approval</FONT> of
 Audit and Permissible <FONT STYLE="white-space:nowrap">Non-Audit</FONT> Services of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_24">Recommendation and Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_25">AUDIT COMMITTEE REPORT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_26">PROPOSAL NO. 3 AMENDMENT TO THE 2014 PLAN TO (1)&nbsp;
INCREASE THE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED UNDER THE 2014 PLAN BY 1,600,000 SHARES, AND (2)&nbsp;ELIMINATE THE FIXED SHARE CAP INCLUDED IN THE EVERGREEN PROVISION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_27">Reasons for Approving the Amended 2014 Plan</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_28">Description of the Amended 2014 Plan</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_29">Federal Income Tax Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_30">New Plan Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_31">Plan Benefits</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_32">Equity Compensation Plan Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_33">Recommendation and Vote</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_34">EXECUTIVE OFFICERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_35">Legal Proceedings with Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_36">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_37">Processes and Procedures for Compensation Decisions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_38">Summary Compensation Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_39"><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_40">Employment Agreements for Named Executive Officers</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_41">Potential Payments and Benefits upon Termination or Change of Control for Officers
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_42">401(k) Plan</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_43">Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End
</FONT></A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_44">Hedging and Pledging Policies</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_45">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</A></P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_46">RELATED PERSON TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_47">Conditional Share Purchase Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_48">CareDx International AB Subordinated Promissory Note</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_49">Investors&#146; Rights Agreement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_50">Indemnification Agreements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_51">Policies and Procedures for Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_52">OTHER MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_53">Section&nbsp;16(a) Beneficial Ownership Reporting Compliance</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_54">Available Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:Times New Roman"><A HREF="#toc472342_55">Company Website</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAREDX, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PROXY STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR&nbsp;2018 ANNUAL MEETING OF STOCKHOLDERS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>To Be Held at&nbsp;10:00 a.m. Pacific Time on June&nbsp;20, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We sent you this proxy statement and the enclosed proxy card because the Board of Directors (&#147;Board of Directors&#148;) of CareDx, Inc. (sometimes
referred to as &#147;we&#148;, &#147;CareDx&#148; or the &#147;Company&#148;) is soliciting your proxy to vote at the Company&#146;s 2018 annual meeting of stockholders (the &#147;Annual Meeting&#148;) and any postponements, adjournments or
continuations thereof. The Annual Meeting will be held on Wednesday, June&nbsp;20, 2018, at&nbsp;10:00 a.m. Pacific Time, at our headquarters, located at&nbsp;3260 Bayshore Blvd., Brisbane, California&nbsp;94005. You are invited to attend the Annual
Meeting and we request that you vote on the proposals described in this Proxy Statement. However, you do not need to attend the Annual Meeting to vote your shares. Instead, you may complete, sign and return the enclosed proxy card or submit your
proxy through the Internet or by telephone according to the instructions contained in the enclosed proxy card. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Notice of Internet Availability of
Proxy Materials (the &#147;Notice&#148;) containing instructions on how to access this proxy statement and our annual report is first being mailed on or about May&nbsp;2, 2018 to all stockholders entitled to receive notice of and to vote at the
Annual Meeting. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_1"></A>QUESTIONS AND ANSWERS ABOUT THE ANNUAL MEETING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information provided in the &#147;question and answer&#148; format below addresses certain frequently asked questions but is not intended to be a summary
of all matters contained in this proxy statement. Please read the entire proxy statement carefully before voting your shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What matters am I voting
on? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You will be voting on: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the election of two Class&nbsp;I directors to hold office until the&nbsp;2021 annual meeting of stockholders or until their successors are duly elected and qualified; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a proposal to ratify the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval of amendment to the Company&#146;s 2014 Equity Incentive Plan (the &#147;2014 Plan&#148;) to: (1)&nbsp;increase the number of shares of common stock that may be issued under the 2014 Plan by 1,600,000
shares, and (2)&nbsp;eliminate the fixed share cap included in the evergreen provision; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other business properly brought before the Annual Meeting or any adjournments or postponements thereof. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How does our Board of Directors recommend that I vote? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors recommends that you vote: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FOR the election of each of the two directors nominated by our Board of Directors and named in this proxy statement as Class&nbsp;I directors to serve for a three-year term; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FOR the ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2018; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FOR the amendment to the 2014 Plan to: (1)&nbsp;increase the number of shares of common stock that may be issued under the 2014 Plan by 1,600,000 shares, and (2)&nbsp;eliminate the fixed share cap included in the
evergreen provision. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will there be any other items of business on the agenda? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any other items of business or other matters are properly brought before the Annual Meeting, your proxy gives discretionary authority to the persons named
on the proxy card concerning those items of business or other matters. The persons named on the proxy card intend to vote the proxy in accordance with their best judgment. Our Board of Directors does not intend to bring any other matters to be voted
on at the Annual Meeting, and we are not currently aware of any matters that may be properly presented by others for consideration at the Annual Meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who is entitled to vote at the Annual Meeting? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders
of our common stock at the close of business on April&nbsp;23, 2018, the record date for the Annual Meeting (the &#147;Record Date&#148;), are entitled to notice of and to vote at the Annual Meeting. Each stockholder is entitled to one vote for each
share of our common stock held as of the Record Date. Stockholders are not permitted to cumulate votes with respect to the election of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of
the Record Date, there were&nbsp;35,253,393 shares of common stock outstanding and entitled to vote. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the difference between holding shares as
a stockholder of record and as a beneficial owner? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name. </I>If, at the close of business on the
Record Date, your shares were registered directly in your name with Computershare Trust Company, N.A., our transfer agent, then you are the stockholder of record for such shares. As the stockholder of record, you may vote either in person at the
Annual Meeting or by proxy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee. </I>If, at the close of business on
the Record Date, your shares were held, not in your name, but rather in a stock brokerage account or by a bank or other nominee on your behalf, then you are considered the beneficial owner of shares held in &#147;street name.&#148; As the beneficial
owner, you have the right to direct your broker, bank or other nominee how to vote your shares by following the voting instructions your broker, bank or other nominee provides. If you do not provide your broker, bank or other nominee with
instructions on how to vote your shares, your broker, bank or other nominee may, in its discretion, vote your shares with respect to routine matters but may not vote your shares with respect to any <FONT STYLE="white-space:nowrap">non-routine</FONT>
matters. Please see &#147;<I>What if I do not specify how my shares are to be voted?</I>&#148; for additional information. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Do I have to do anything in
advance if I plan to attend the Annual Meeting in person? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name</I>.<I> </I>If you were a
stockholder of record at the close of business on the Record Date, you do not need to do anything in advance to attend and/or vote your shares in person at the Annual Meeting, but you will need to present government-issued photo identification for
entrance to the Annual Meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee</I>.<I> </I>If you were a
beneficial owner at the close of business on the Record Date, you may not vote your shares in person at the Annual Meeting unless you obtain a &#147;legal proxy&#148; from your broker, bank or other nominee who is the stockholder of record with
respect to your shares. You may still attend the Annual Meeting even if you do not have a legal proxy. For entrance to the Annual Meeting, you will need to provide proof of beneficial ownership as of the Record Date, such as the notice or voting
instructions you received from your broker, bank or other nominee or a brokerage statement reflecting your ownership of shares as of the Record Date, and present government-issued photo identification. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Please note that no cameras, recording equipment, large bags, briefcases or packages will be permitted in the Annual Meeting. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How do I vote and what are the voting deadlines? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name</I>.<I> </I>If you are a stockholder of record, you can vote in one of the following ways: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>You may vote via the Internet or by telephone</B>.<B> </B>To vote via the Internet or by telephone, follow the instructions provided in the Notice of Internet Availability of Proxy Materials. If you vote via the
Internet or by telephone, you do not need to return a proxy card by mail. Internet and telephone voting are available&nbsp;24 hours a day. Votes submitted through the Internet or by telephone must be received by&nbsp;11:59 p.m. Pacific Time on
June&nbsp;19, 2018. Alternatively, you may request a printed proxy card by telephone <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at&nbsp;1-866-641-4276,</FONT></FONT></FONT> over the Internet at
www.investorvote.com/cdna, or by <FONT STYLE="white-space:nowrap">e-mail</FONT> at investorvote@computershare.com with &#147;Proxy Material CareDx, Inc.&#148; in the subject heading, and then follow the instructions under the heading &#147;You may
vote by mail&#148; immediately below. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>You may vote by mail</B>.<B> </B>If you have received printed proxy materials by mail and would like to vote by mail, you need to complete, date and sign the proxy card that accompanies this proxy statement and
promptly mail it to the tabulation agent in the enclosed postage-paid envelope so that it is received no later than June&nbsp;19, 2018. You do not need to put a stamp on the enclosed envelope if you mail it from within the United States. The persons
named in the proxy card will vote the shares you own in accordance with your instructions on the proxy card you mail. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>You may vote in person</B>.<B> </B>If you plan to attend the Annual Meeting, you may vote by delivering your completed proxy card in person or by completing and submitting a ballot, which will be provided at the
Annual Meeting. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B>Note</B>: If you vote via the Internet, return a proxy card by mail or vote in person, but do not give any instructions on a particular matter to be voted on at the Annual Meeting, Peter Maag, Ph.D. and Michael Bell,
the persons who have been designated as proxy holders by our Board of Directors, will vote the shares you own in accordance with the recommendations of our Board of Directors. Our Board of Directors recommends that you vote FOR the election of each
of the two directors nominated by our Board of Directors and named in this proxy statement as Class&nbsp;I directors to serve for a three-year term (Proposal No.&nbsp;1), FOR the ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as
our independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2018 (Proposal No.&nbsp;2) and FOR the amendment to the 2014 Plan to (1)&nbsp;increase the number of shares of common stock that may be issued under the
2014 Plan by 1,600,000 shares, and (2)&nbsp;eliminate the fixed share cap included in the evergreen provision (Proposal No.&nbsp;3). </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee</I>.<I> </I>If you are the beneficial owner of shares held of record by
a broker, bank or other nominee, you will receive voting instructions from your broker, bank or other nominee. You must follow the voting instructions provided by your broker, bank or other nominee in order to instruct your broker, bank or other
nominee how to vote your shares. The availability of Internet and telephone voting options will depend on the voting process of your broker, bank or other nominee. <B>As discussed above, if you are a beneficial owner, you may not vote your shares in
person at the Annual Meeting unless you obtain a legal proxy from your broker, bank or other nominee.</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Can I change my vote or revoke my proxy?
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name</I>.<I> </I>If you are a stockholder of record, you may revoke your proxy or change your
proxy instructions at any time before your proxy is voted at the Annual Meeting by: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">entering a new vote by Internet or telephone; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">signing and returning a new proxy card with a later date; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delivering a written notice of revocation to our Corporate Secretary prior to the Annual Meeting; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">attending the Annual Meeting and voting in person. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee</I>.<I> </I>If you
are the beneficial owner of your shares, you must contact the broker, bank or other nominee holding your shares and follow their instructions to change your vote or revoke your proxy. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the effect of giving a proxy? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxies are
solicited by and on behalf of our Board of Directors. Peter Maag, Ph.D. and Michael Bell have been designated as proxy holders by our Board of Directors. When a proxy is properly dated, executed and returned, the shares represented by the proxy will
be voted at the Annual Meeting in accordance with the instructions of the stockholder. If no specific instructions are given, however, the shares will be voted in accordance with the recommendations of our Board of Directors. If any matters not
described in this proxy statement are properly presented at the Annual Meeting, the proxy holders will use their own judgment to determine how to vote your shares. If the Annual Meeting is postponed or adjourned, the proxy holders can vote your
shares on the new meeting date, unless you have properly revoked your proxy, as described above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What if I do not specify how my shares are to be
voted? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder of Record: Shares Registered in Your Name</I>.<I> </I>If you are a stockholder of record and you submit a proxy but you do not
provide voting instructions, your shares will be voted: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FOR the election of each of the two directors nominated by our Board of Directors and named in this proxy statement as Class&nbsp;I directors to serve for a three-year term (Proposal No.&nbsp;1); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FOR the ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP as our independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2018 (Proposal No.&nbsp;2); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FOR the approval of the amendment to the 2014 Plan to: (1)&nbsp;increase the number of shares of common stock that may be issued under the 2014 Plan by 1,600,000 shares, and (2)&nbsp;eliminate the fixed share cap
included in the evergreen provision (Proposal No.&nbsp;3); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In the discretion of the named proxy holders regarding any other matters properly presented for a vote at the Annual Meeting. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Beneficial Owners: Shares Registered in the Name of a Broker, Bank or Other Nominee</I>.<I> </I>If you are a beneficial owner and you do not provide your
broker, bank or other nominee that holds your shares with voting instructions, then your broker, bank or other nominee will determine if it has discretion to vote on each matter. Brokers do not have discretion to vote on <FONT
STYLE="white-space:nowrap">non-routine</FONT> matters. Proposal No.&nbsp;1 (election of directors) and Proposal No.&nbsp;3 (approval of amendment to the 2014 Plan) are <FONT STYLE="white-space:nowrap">non-routine</FONT> matters, while Proposal
No.&nbsp;2 (ratification of appointment of independent registered public accounting firm) is a routine matter. As a result, if you do not provide voting instructions to your broker, bank or other nominee, then your broker, bank or other nominee may
not vote your shares with respect to Proposal No.&nbsp;1 or Proposal No.&nbsp;3, which would result in a &#147;broker <FONT STYLE="white-space:nowrap">non-vote,&#148;</FONT> but may, in its discretion, vote your shares with respect to Proposal
No.&nbsp;2. For additional information regarding broker <FONT STYLE="white-space:nowrap">non-votes,</FONT> see &#147;<I>What are the effects of abstentions and broker <FONT STYLE="white-space:nowrap">non-votes</FONT></I>?&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is a quorum? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum is the minimum number of
shares required to be present at the Annual Meeting for the meeting to be properly held under our amended and restated bylaws and Delaware law. A majority of the shares of common stock outstanding and entitled to vote, in person or by proxy,
constitutes a quorum for the transaction of business at the Annual Meeting. As noted above, as of the Record Date, there were a total of&nbsp;35,253,393 shares of common stock outstanding, which means that&nbsp;17,626,697 shares of common stock must
be represented in person or by proxy at the Annual Meeting to have a quorum. If there is no quorum, a majority of the shares present at the Annual Meeting may adjourn the meeting to a later date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What are the effects of abstentions and broker <FONT STYLE="white-space:nowrap">non-votes?</FONT>
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An abstention represents a stockholder&#146;s affirmative choice to decline to vote on a proposal. If a stockholder indicates on its proxy card that
such stockholder wishes to abstain from voting such stockholder&#146;s shares, or if a broker, bank or other nominee holding its customers&#146; shares of record causes abstentions to be recorded for shares, these shares will be considered present
and entitled to vote at the Annual Meeting. As a result, abstentions will be counted for purposes of determining the presence or absence of a quorum and will also count as votes against a proposal in cases where approval of the proposal requires the
affirmative vote of a majority of the shares present and entitled to vote at the Annual Meeting (<I>e.g</I>., Proposal No.&nbsp;2 and Proposal No.&nbsp;3). However, because the outcome of Proposal No.&nbsp;1 (election of directors) will be
determined by a plurality vote (see the next question below for an explanation of what a plurality vote means), abstentions will have no impact on the outcome of such proposal as long as a quorum exists. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A broker <FONT STYLE="white-space:nowrap">non-vote</FONT> occurs when a broker, bank or other nominee holding shares for a beneficial owner does not vote on a
particular proposal because the broker, bank or other nominee does not have discretionary voting power with respect to such proposal and has not received voting instructions from the beneficial owner of the shares. Broker <FONT
STYLE="white-space:nowrap">non-votes</FONT> will be counted for purposes of calculating whether a quorum is present at the Annual Meeting but will not have any effect on the results of the proposals. Therefore, a broker <FONT
STYLE="white-space:nowrap">non-vote</FONT> will make a quorum more readily attainable but will not otherwise affect the outcome of the vote on any proposal. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How many votes are needed for approval of each proposal and how are votes counted? </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Proposal No.</I><I></I><I>&nbsp;1</I>: The election of Class&nbsp;I directors requires a plurality vote of the shares of our common stock present in person or by proxy at the Annual Meeting and entitled to vote
thereon to be approved. This means that the two nominees who receive the most FOR votes will be elected. You may (i)&nbsp;vote FOR all nominees, (ii)&nbsp;WITHHOLD your vote as to all nominees, or (iii)&nbsp;vote FOR all nominees except for those
specific nominees from whom you WITHHOLD your vote. Any shares not voted FOR a particular nominee (whether as a result of voting withheld or a broker <FONT STYLE="white-space:nowrap">non-vote)</FONT> will not be counted in such nominee&#146;s favor
and will have no effect on the outcome of the election. If you WITHHOLD your vote as to all nominees, you will be deemed to have abstained from voting on Proposal No.&nbsp;1, and such abstention will have no effect on the outcome of the proposal.
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Proposal No.</I><I></I><I>&nbsp;2</I>: The ratification of the appointment of Deloitte&nbsp;&amp; Touche LLP requires an affirmative vote of a majority of the shares of our common stock present in person or by proxy
at the Annual Meeting and entitled to vote thereon to be approved. You may vote FOR, AGAINST or ABSTAIN. If you ABSTAIN from voting on Proposal No.&nbsp;2, the abstention will have the same effect as a vote AGAINST the proposal. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Proposal No.</I><I></I><I>&nbsp;3</I>: The approval of the amendment to the 2014 Plan to (1)&nbsp;increase the number of shares of common stock that may be issued under the 2014 Plan by 1,600,000 shares, and
(2)&nbsp;eliminate the fixed share cap included in the evergreen provision requires an affirmative vote of a majority of the shares of our common stock present in person or by proxy at the Annual Meeting and entitled to vote thereon to be approved.
You may vote FOR, AGAINST or ABSTAIN. If you ABSTAIN from voting on Proposal No.&nbsp;3, the abstention will have the same effect as a vote AGAINST the proposal. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How are proxies solicited for the Annual Meeting and who is paying for such solicitation? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors is soliciting proxies for use at the Annual Meeting by means of the proxy materials. We will bear the entire cost of proxy solicitation,
including the preparation, assembly, printing, mailing and distribution of the proxy materials. Copies of solicitation materials will also be made available upon request to brokers, banks and other nominees to forward to the beneficial owners of the
shares held of record by such brokers, banks or other nominees. The original solicitation of proxies may be supplemented by solicitation by telephone, electronic communication, or other means by our directors, officers, employees or agents. No
additional compensation will be paid to these individuals for any such services, although we may reimburse such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individuals for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses in connection with such solicitation. We have retained
Georgeson Inc. to help us solicit proxies. We will pay Georgeson Inc. $7,000 plus reasonable expenses for its services. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you choose to access the proxy
materials and/or vote over the Internet, you are responsible for Internet access charges you may incur. If you choose to vote by telephone, you are responsible for telephone charges you may incur. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Why did I receive a Notice of Internet Availability of Proxy Materials (the &#147;Notice&#148;) instead of a full set of proxy materials? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In accordance with the rules of the Securities and Exchange Commission (the &#147;SEC&#148;), we have elected to furnish our proxy materials, including this
proxy statement and our annual report, primarily via the Internet. Stockholders may request to receive proxy materials in printed form by mail or electronically by <FONT STYLE="white-space:nowrap">e-mail</FONT> by following the instructions
contained in the Notice. We encourage stockholders to take advantage of the availability of our proxy materials on the Internet to help reduce the environmental impact of our annual meetings of stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What does it mean if I received more than one Notice? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If
you receive more than one Notice, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on each Notice to ensure that all of your shares are voted. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Who will count the votes? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The votes will be counted,
tabulated and certified by Computershare Trust Company, N.A., the transfer agent and registrar for our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Is my vote confidential? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Proxies, ballots and voting tabulations are handled on a confidential basis to protect your voting privacy. This information will not be disclosed either
within CareDx or to third parties, except as necessary to meet applicable legal requirements, to allow for the tabulation of votes and certification of the vote, or to facilitate a successful proxy solicitation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Will members of the Board of Directors attend the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We encourage, but do not require, the members of our Board of Directors to attend the Annual Meeting. Those who do attend will be available to answer
appropriate questions from stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>I share an address with another stockholder, and we received only one paper copy of the proxy materials.
How may I obtain an additional copy of the proxy materials? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are sending only one annual report and proxy materials to multiple stockholders who
share the same address unless we received contrary instructions from one or more of the stockholders. This practice, known as &#147;householding,&#148; reduces our printing and mailing costs. Stockholders who participate in householding will
continue to be able to access and receive separate proxy cards. Upon written or oral request, we will promptly deliver a separate copy of the proxy materials and annual report to any stockholder at a shared address to which we delivered a single
copy of any of these documents. To receive a separate copy, or, if you are receiving multiple copies, to request that we only send a single copy of next year&#146;s proxy materials and annual report, you may contact us as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CareDx, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate
Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3260 Bayshore Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brisbane, CA&nbsp;94005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(415) <FONT
STYLE="white-space:nowrap">287-2300</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders who hold shares in street name may contact their broker, bank or other nominee to request
information about householding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>How can I find out the results of the voting at the Annual Meeting? </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Preliminary voting results will be announced at the Annual Meeting. In addition, final voting results will be published in a Current Report on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> (&#147;Form <FONT STYLE="white-space:nowrap">8-K&#148;)</FONT> that we expect to file within four business days after the Annual Meeting. If final voting results are not available to us by such date,
we intend to file a <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> to publish preliminary results and, within four business days after the final results are known to us, file an amendment to the
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> to publish the final results. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>What is the deadline to propose actions for consideration at next
year&#146;s annual meeting of stockholders or to nominate individuals to serve as directors? </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders may present proper proposals for inclusion in our proxy statement and for consideration at the next annual meeting of stockholders by submitting
their proposals in writing to our Corporate Secretary in a timely manner. For a stockholder proposal to be considered for inclusion in our proxy statement for our&nbsp;2019 annual meeting of stockholders, our Corporate Secretary must receive the
written proposal at our principal executive offices not later than January&nbsp;2, 2019. In addition, stockholder proposals must comply with the requirements of <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> under the Securities Exchange
Act of&nbsp;1934, as amended (the &#147;Exchange Act&#148;), regarding the inclusion of stockholder proposals in company-sponsored proxy materials. Stockholder proposals should be addressed to: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CareDx, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate
Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3260 Bayshore Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brisbane, CA&nbsp;94005 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
bylaws also establish an advance notice procedure for stockholders who wish to present a proposal before an annual meeting of stockholders but do not intend for the proposal to be included in our proxy statement. Our amended and restated bylaws
provide that the only business that may be conducted at an annual meeting is business that is brought (i)&nbsp;pursuant to our proxy materials with respect to the annual meeting&nbsp;specified in the notice of meeting (or any supplement thereto),
(ii) by or at the direction of our Board of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Directors, or (iii)&nbsp;properly before the annual meeting by a stockholder of record entitled to vote at the annual meeting who has delivered timely written notice to our Corporate Secretary,
which notice must contain the information specified in our amended and restated bylaws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To be timely for our&nbsp;2019 annual meeting of stockholders,
our Corporate Secretary must receive the written notice at our principal executive offices: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not earlier than February&nbsp;16, 2019; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not later than March&nbsp;18, 2019. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that we hold our&nbsp;2019 annual meeting of stockholders
more than&nbsp;30&nbsp;days before or after the first anniversary of the date of the Annual Meeting, then notice of a stockholder proposal that is not intended to be included in our proxy statement must be received no earlier than the close of
business on the&nbsp;120th day before such annual meeting and no later than the close of business on the later of the following two dates: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the&nbsp;90th day prior to such annual meeting; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the&nbsp;10th day following the day on which public announcement of the date of such annual meeting is first made. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a stockholder who has notified us of his, her or its intention to present a proposal at an annual meeting does not appear to present his, her or its
proposal at such annual meeting, we are not required to present the proposal for a vote at such annual meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Nomination of Director Candidates
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may propose director candidates for consideration by our Nominating and Corporate Governance Committee. Any such recommendations should include
the nominee&#146;s name and qualifications for membership on our Board of Directors and should be directed to our Secretary at the address set forth above. For additional information regarding stockholder recommendations for director candidates, see
&#147;Board of Directors and Corporate Governance&#151;Stockholder Recommendations for Nominations to the Board of Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, our
amended and restated bylaws permit stockholders to nominate directors for election at an annual meeting of stockholders. To nominate a director, the stockholder must provide the information required by our amended and restated bylaws. The
stockholder must also give timely notice to our Secretary in accordance with our amended and restated bylaws, which, in general, require that the notice be received by our Secretary within the time period described above under &#147;Stockholder
Proposals&#148; for stockholder proposals that are not intended to be included in a proxy statement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Availability of Amended and Restated Bylaws
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of our amended and restated bylaws may be obtained by accessing our public filings on the SEC&#146;s website at www.sec.gov. You may also
contact our Corporate Secretary at our principal executive office for a copy of the relevant bylaw provisions regarding the requirements for making stockholder proposals and nominating director candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_2"></A>PROPOSAL NO. 1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ELECTION OF DIRECTORS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of
Directors is currently composed of six members. In accordance with our certificate of incorporation, our Board of Directors is divided into three classes with staggered three-year terms. At the Annual Meeting, two Class&nbsp;I directors will be
elected for a three-year term to succeed the same class whose term is then expiring. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each director&#146;s term continues until the election and
qualification of such director&#146;s successor, or such director&#146;s earlier death, resignation, or removal. Any increase or decrease in the number of directors will be distributed among the three classes so that, as nearly as possible, each
class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of our directors. This classification of our Board of Directors may have the effect of delaying or preventing changes in control of our company. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_3"></A>Nominees </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and
Corporate Governance Committee has recommended, and our Board of Directors has approved, George W. Bickerstaff, III and Ralph Snyderman, M.D. as nominees for election as Class&nbsp;I directors at the Annual Meeting. If elected, Mr.&nbsp;Bickerstaff
and Dr.&nbsp;Snyderman will each serve as Class&nbsp;I directors until the&nbsp;2021 annual meeting of stockholders or until their successors are duly elected and qualified. Each of the nominees is currently a director of our company. For
information concerning the nominees, please see the section titled &#147;Board of Directors and Corporate Governance.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a stockholder of
record and you sign your proxy card or vote over the Internet or by telephone but do not give instructions with respect to the voting of directors, your shares will be voted FOR the <FONT STYLE="white-space:nowrap">re-election</FONT> of
Mr.&nbsp;Bickerstaff and Dr.&nbsp;Snyderman. We expect that Mr.&nbsp;Bickerstaff and Dr.&nbsp;Snyderman will each accept such nomination; however, in the event that a director nominee is unable or declines to serve as a director at the time of the
Annual Meeting, the proxies will be voted for any nominee who shall be designated by our Board of Directors to fill such vacancy. If you are a beneficial owner of shares of our common stock and you do not give voting instructions to your broker,
bank or other nominee, then your broker, bank or other nominee will leave your shares unvoted on this matter. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_4"></A>Vote Required
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The election of Class&nbsp;I directors requires a plurality vote of the shares of our common stock present in person or by proxy at the Annual Meeting
and entitled to vote thereon to be approved. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on this proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>OUR BOARD
OF DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE ELECTION OF EACH OF THE TWO DIRECTORS NOMINATED BY OUR BOARD OF DIRECTORS AND NAMED IN THIS PROXY STATEMENT&nbsp;AS CLASS&nbsp;I DIRECTORS TO SERVE FOR A THREE-YEAR TERM. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_5"></A>BOARD OF DIRECTORS AND CORPORATE GOVERNANCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business affairs are managed under the direction of our Board of Directors, which is currently composed of six members. Our Board of Directors is divided
into three classes with staggered three-year terms. At each annual meeting of stockholders, a class of directors will be elected for a three-year term to succeed the same class whose term is then expiring. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the names, ages as of April&nbsp;30, 2018, and certain other information for each of our directors:<B><I> </I></B> </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Class</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Director<BR>Since</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Current<BR>Term<BR>Expires</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expiration<BR>of Term<BR>For Which<BR>Nominated</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>1. Directors with Terms Expiring at the Annual Meeting/ Nominees</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George W. Bickerstaff, III<SUP STYLE="font-size:85%; vertical-align:top">(1)*</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">I</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ralph Snyderman, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">I</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2005</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2018</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>2. Continuing Directors</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fred E. Cohen, M.D., D. Phil<SUP STYLE="font-size:85%; vertical-align:top">(2)(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">II</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2003</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William A. Hagstrom<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">II</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael D. Goldberg<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">III</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Director, Chairman of the Board of Directors</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2011</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Maag, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">III</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer, and Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2012</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2020</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Member of our Audit Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Member of our Compensation Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Member of our Nominating and Corporate Governance Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Member of our Science and Technology Committee. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;*</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Bickerstaff was appointed to the Audit Committee on May&nbsp;10, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_6"></A>Directors with Terms Expiring at the Annual Meeting&#151;Nominees for Director </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>George W. Bickerstaff, III</I> has served as a member of our Board of Directors since April&nbsp;2014. Mr.&nbsp;Bickerstaff is currently the Managing
Director of M.M. Dillon&nbsp;&amp; Co., LLC, an investment banking firm, which he joined in&nbsp;2005. Prior to joining M.M. Dillon&nbsp;&amp; Co., LLC, Mr.&nbsp;Bickerstaff held various positions with Novartis International AG, a global leader in
pharmaceuticals and consumer health, including Chief Financial Officer of Novartis Pharma AG from October&nbsp;2000 to May&nbsp;2005. From December&nbsp;1999 to September&nbsp;2000, Mr.&nbsp;Bickerstaff served as Executive Vice President and Chief
Financial Officer of Workscape, Inc., a provider of employee-related information services. From July&nbsp;1998 to December&nbsp;1999, Mr.&nbsp;Bickerstaff served as Executive Vice President and Chief Financial Officer of Uniscribe Professional
Services, Inc., a nationwide provider of paper and technology-based document management solutions. From January&nbsp;1998 to June&nbsp;1998, Mr.&nbsp;Bickerstaff served as Executive Vice President and Chief Financial Officer of Intellisource Group,
Inc., a provider of information technology solutions to the federal, state and local governments and utility markets. From July&nbsp;1997 to December&nbsp;1997, Mr.&nbsp;Bickerstaff served as Vice President of Finance of Cognizant Corporation, a
global business information services company. From January&nbsp;1990 to June&nbsp;1997, Mr.&nbsp;Bickerstaff served in various senior finance roles, including Chief Financial Officer of IMS Healthcare, a global business information services company
in the healthcare and pharmaceutical industries. Before that, Mr.&nbsp;Bickerstaff held various finance, audit and engineering positions with the Dun&nbsp;&amp; Bradstreet Corporation from&nbsp;1985 to&nbsp;1989 and General Electric Company
from&nbsp;1978 to&nbsp;1985. Mr.&nbsp;Bickerstaff currently serves on the Boards of Directors of Axovant Sciences Ltd., Innoviva, Inc., Inovio Pharmaceuticals, Inc. and Cardax, Inc., and recently served on the Board of Directors of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Viventia Biotechnologies, Inc. until its sale in October of 2016 and on the Board of Directors of Ariad Pharmaceuticals, Inc. until its sale in February 2017. Mr.&nbsp;Bickerstaff&#146;s <FONT
STYLE="white-space:nowrap">non-profit</FONT> activities include serving on the Board of Directors of the International Vaccine Institute, the International Centre for Missing and Exploited Children and Global Oncology. Mr.&nbsp;Bickerstaff received
a Bachelor of Science degree in Engineering and a Bachelor of Arts degree in Business Administration from Rutgers University in&nbsp;1978. Our Board of Directors has concluded that Mr.&nbsp;Bickerstaff possesses specific attributes that qualify him
to serve as a member of our Board of Directors, including his substantial financial experience in the healthcare industry and substantial experience with organ transplant markets. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Ralph Snyderman, M.D.</I> has served as a member of our Board of Directors since May&nbsp;2005. Dr.&nbsp;Snyderman has held the position of Chancellor
Emeritus and James B. Duke Professor of Medicine at Duke University since July&nbsp;2004. From January&nbsp;1989 to June&nbsp;2004, he served as Chancellor for Health Affairs at the Duke University School of Medicine and was the founding CEO and
President of the Duke University Health System. From January&nbsp;2006 to November&nbsp;2009, he consulted for New Enterprise Associates, a venture capital firm, as a venture partner. He previously served on the Boards of Directors of The Procter
and Gamble Company, Pharmaceutical Product Development, LLC, Trevena, Inc., Crescendo Bioscience, Inc., Targacept, Inc. Press Ganey Associates, Inc. and Argos Therapeutics, Inc. He currently serves on the Boards of Directors of Essential Health
Solutions, Inc., iRhythm Technologies, Inc., Liquida Technologies, Inc., Linus Oncology, SenGenix, Inc. and Veritas Collaborative Holdings, LLC. Dr.&nbsp;Snyderman is a member of the Association of American Physicians, where he served as president
from&nbsp;2003 to&nbsp;2004, the Association of American Medical Colleges, where he served as chair from&nbsp;2001 to&nbsp;2002, the Institute of Medicine and the American Academy of Arts and Sciences. Dr.&nbsp;Snyderman holds a B.S. in <FONT
STYLE="white-space:nowrap">Pre-Medical</FONT> Studies from Washington College, an M.D. from the State University of New York, Downstate Medical Center, and completed an internship and residency in medicine at Duke University. Our Board of Directors
has concluded that Dr.&nbsp;Snyderman possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his strong background in personalized medicine and broad experience in the healthcare industry. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_7"></A>Continuing Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Fred
E. Cohen, M.D., D. Phil, F.A.C.P.</I>, has served as a member of our Board of Directors since January&nbsp;2003. Dr.&nbsp;Cohen is Senior Managing Director of Vida Ventures, a venture capital fund. He served as a Partner and Founder of TPG
Biotechnology, a life sciences focused investment effort, from 2001 to 2016. Dr.&nbsp;Cohen is also a former member of the faculty at the University of California, San Francisco, where he taught and conducted research from&nbsp;1988
through&nbsp;2014. Dr.&nbsp;Cohen serves as a director of the following public companies: Genomic Health Inc., a company focused on providing actionable genomic health information; Five Prime Therapeutics, Inc., a clinic-stage biotechnology company
focused on discovering and developing novel protein therapeutics; Veracyte, Inc., a diagnostics company in the field of molecular cytology; Tandem Diabetes Care, Inc., a medical device company that designs, develops and commercializes products for
people with insulin-dependent diabetes; BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development of novel small molecule drugs that block key enzymes involved in infectious and rare diseases; and Urogen Pharma, a urologic
oncology company. He previously served on the board of directors of Roka BioScience, Inc., a food safety diagnostics business, from September 2008 until October 2017. He is a member of the National Academy of Medicine and the American Academy of
Arts and Sciences. Dr.&nbsp;Cohen holds a Bachelor of Science degree in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biophysics from Oxford University, where he was a Rhodes Scholar, and an M.D. from Stanford
University. Our Board of Directors has concluded that Dr.&nbsp;Cohen possesses specific attributes that qualify him to serve as a member of our Board of Directors, including his significant leadership experience in the medical and finance fields,
his background as an M.D. and a venture capitalist, his extensive technical expertise relevant to our business, and his service as an investor in and director of numerous life sciences and healthcare companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>William A. Hagstrom</I> has served as a member of our Board of Directors since March&nbsp;2015. Since&nbsp;2014, Mr.&nbsp;Hagstrom has served as the
founder and CEO of Octave Bioscience, an early stage molecular diagnostics </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company focused on neurodegenerative diseases and conditions. Since June 2016, Mr.&nbsp;Hagstrom has served on the Board of Directors of Genalyte, Inc. In&nbsp;2007, Mr.&nbsp;Hagstrom secured
financing for Crescendo Bioscience, a specialty diagnostics company focused on autoimmune and inflammatory diseases managed by rheumatologists. Serving as president and chief executive officer, he led the development of the company&#146;s product
pipeline, operations infrastructure and commercial strategy. In&nbsp;2014, Crescendo Bioscience was acquired by Myriad Genetics as a wholly owned subsidiary. Before founding Crescendo Bioscience, Mr.&nbsp;Hagstrom was president of Alpha BioPartners,
a strategic consulting firm for early stage biotechnology companies. While at Alpha BioPartners, Mr.&nbsp;Hagstrom <FONT STYLE="white-space:nowrap">co-founded</FONT> Biolytx Pharmaceuticals and Altheus Therapeutics. Mr.&nbsp;Hagstrom also served as
interim CEO of Selexys Pharmaceuticals and Inoveon. Prior to this he was Chairman and CEO of UroCor, a specialty diagnostics company focused on urological cancers and complex diseases. Under Mr.&nbsp;Hagstrom&#146;s leadership, the company was an
Inc. 500 company from&nbsp;1992 through&nbsp;1995, before becoming public in&nbsp;1996. Previously, Mr.&nbsp;Hagstrom held executive positions at some of the largest multinational healthcare companies in the world, including Becton Dickinson,
American Hospital Supply and Baxter International, where he served as vice president of the company&#146;s billion-dollar scientific products division. Mr.&nbsp;Hagstrom has served on a variety of Boards over the last&nbsp;15 years, including
Prometheus Laboratories. Mr.&nbsp;Hagstrom received a B.S. degree in Business Management from Bob Jones University. Our Board of Directors has concluded that Mr.&nbsp;Hagstrom possesses specific attributes that would qualify him to serve as a member
of our Board of Directors, including his management experience in building and growing specialty diagnostics companies, launching new products and integrating high value informatics into clinical paradigms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael D. Goldberg</I> has served as a member and chairman of our Board of Directors since November&nbsp;2011. Mr.&nbsp;Goldberg has served as a director
and executive chairman of the Board of Directors of DNAnexus, Inc., a cloud-based genome informatics and data management company, and as an advisor to other private life science companies since May&nbsp;2011. Mr.&nbsp;Goldberg has also served on the
Board of Directors for eHealth, Inc. since&nbsp;1999. From January&nbsp;2005 to May&nbsp;2011, Mr.&nbsp;Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular
diagnostics, personalized medicine and wireless healthcare. From October&nbsp;2000 to December&nbsp;2004, Mr.&nbsp;Goldberg operated a management and financial consultancy business. In&nbsp;1995, Mr.&nbsp;Goldberg founded OnCare, Inc., an oncology
disease management company, and served as its chairman until August&nbsp;2001 and as its chief executive officer until March&nbsp;1999. In&nbsp;1987, Mr.&nbsp;Goldberg founded Axion, Inc., a cancer treatment services company, and served as its Chief
Executive Officer until its sale in&nbsp;1995. Prior to Axion, Mr.&nbsp;Goldberg was a partner at the venture capital firm of Sevin Rosen Management Company from&nbsp;1985 to&nbsp;1987, where he established the firm&#146;s life science practice, and
director of corporate development at Cetus Corporation from&nbsp;1981 to&nbsp;1985. Mr.&nbsp;Goldberg has served as a member of the Board of Directors of numerous companies in the biotech and health sciences industry. Mr.&nbsp;Goldberg has served on
boards and advisory boards of a number of industry, academic and public policy institutions in biotechnology and finance, including the Board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute
for Regenerative Medicine, the Board of the Western Association of Venture Capitalists, the Advisory Boards for the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, and the UCSF Center for Translational and
Policy Research on Personalized Medicine. Mr.&nbsp;Goldberg holds a B.A. from Brandeis University and an M.B.A. from the Stanford Graduate School of Business. Our Board of Directors has concluded that Mr.&nbsp;Goldberg possesses specific attributes
that qualify him to serve as a member of our Board of Directors, including his experience as a senior executive, board member and venture capital investor with numerous companies in the life sciences industry and in personalized medicine and
genomics. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Peter Maag, Ph.D.</I> has served as our President and Chief Executive Officer since October&nbsp;2012 and as a member of our Board of
Directors since November&nbsp;2012. Before joining the Company, Dr.&nbsp;Maag held numerous positions with increasing responsibility at Novartis International AG, a global healthcare company from September&nbsp;2001 to April&nbsp;2012, including
Global Head of Novartis Diagnostics, a business unit of Novartis A.G., from&nbsp;2009 to&nbsp;2012. Dr.&nbsp;Maag also served as Country President for Novartis Pharma AG in Germany from&nbsp;2006 to&nbsp;2008, Country President for Novartis&#146;
Korea operations from&nbsp;2003 to&nbsp;2005, and the Head of Strategy for the pharmaceutical division of Novartis A.G. from&nbsp;2001 to&nbsp;2002. Dr.&nbsp;Maag also worked at McKinsey&nbsp;&amp; Company,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
focusing on healthcare and globalization from&nbsp;1995 to&nbsp;2001. Dr.&nbsp;Maag also serves on the Board of Directors at Phoenix Pharmahandel GmbH&nbsp;&amp; Co KG and Molecular MD.
Dr.&nbsp;Maag studied pharmaceutical sciences at the University of Heidelberg and University of London and received his Ph.D. from the University of Berlin, Germany. Our Board of Directors has concluded that Dr.&nbsp;Maag should serve on our Board
of Directors due to his position as President and Chief Executive Officer of the Company as well as his extensive experience in the pharmaceuticals and life sciences industries. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_8"></A>Director Independence </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on the NASDAQ Global Market. Under the rules of The NASDAQ Stock Market LLC (the &#147;NASDAQ Rules&#148;), independent directors must comprise a majority of a listed company&#146;s Board of Directors. In addition, the NASDAQ
Rules require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation, and nominating and corporate governance committees be independent. Under the NASDAQ Rules, a director will only qualify as an
&#147;independent director&#148; if, in the opinion of the listed company&#146;s Board of Directors, the director does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a
director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Audit Committee members must also satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under
the Exchange Act and the NASDAQ Rules. In addition, Compensation Committee members must satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> under the Exchange Act and the NASDAQ Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has undertaken a review of the independence of each director and considered whether such director has a material relationship with us
that could compromise his ability to exercise independent judgment in carrying out his responsibilities. As a result of this review, our Board of Directors has determined that Messrs. Bickerstaff, Goldberg and Hagstrom and Drs. Cohen and Snyderman
are &#147;independent directors&#148; as defined under the applicable rules and regulations of the SEC and the NASDAQ Rules. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_9"></A>Board Leadership Structure </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
Board of Directors has an independent Chairman, Mr.&nbsp;Goldberg, who has authority, among other things, to preside over Board of Directors meetings, including meetings of the independent directors, and to call special meetings of our Board of
Directors. Accordingly, the Chairman has substantial ability to shape the work of our Board of Directors. We believe that separation of the roles of Chairman and Chief Executive Officer reinforces the independence of our Board of Directors in its
oversight of the business and affairs of our Company. In addition, we currently believe that having an independent Chairman creates an environment that is more conducive to objective evaluation and oversight of management&#146;s performance,
increasing management accountability and improving the ability of our Board of Directors to monitor whether management&#146;s actions are in the best interests of the Company and its stockholders. However, no single leadership model is right for all
companies and at all times. Our Board of Directors recognizes that depending on the circumstances, other leadership models, such as combining the role of Chairman with the role of Chief Executive Officer, might be appropriate. Accordingly, our Board
of Directors may periodically review its leadership structure. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_10"></A>Legal Proceedings with Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no legal proceedings related to any of the directors or director nominees which require disclosure pursuant to Items&nbsp;103 or&nbsp;401(f) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_11"></A>Agreements with Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of the directors or nominees for director was selected pursuant to any arrangement or understanding, other than compensation arrangements in the ordinary
course of business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_12"></A>Board and Committee Meetings </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During fiscal year 2017, our Board of Directors held&nbsp;five meetings (including regularly scheduled and special meetings), and took action by written
consent three times. Each director attended at least&nbsp;75% of the aggregate of (i)&nbsp;the total number of meetings of our Board of Directors held during the period for which he served as a director, and (ii)&nbsp;the total number of meetings
held by all committees of our Board of Directors on which he served during the periods that he served. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is the policy of our Board of Directors to
regularly have separate meeting times for independent directors without management. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although we do not have a formal policy regarding attendance by
members of our Board of Directors at annual meetings of stockholders, we encourage, but do not require, our directors to attend. Mr.&nbsp;Goldberg and Dr.&nbsp;Maag attended our 2017 annual meeting of stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has four standing committees: the Audit Committee, the Compensation Committee, the Nominating and Corporate Governance Committee and
the Science and Technology Committee. The composition and responsibilities of each of the committees of our Board of Directors are described below. Members will serve on these committees until their resignation or until otherwise determined by our
Board of Directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have
a separately-designated standing audit committee established in accordance with Section&nbsp;3(a)(58)(A) of the Exchange Act. Our Audit Committee is currently comprised of George Bickerstaff, Michael D. Goldberg and William A. Hagstrom, each of whom
is a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our Board of Directors. Mr.&nbsp;Bickerstaff serves as the current chair of our Audit Committee. Our Board of Directors has determined that each of the members of our Audit
Committee satisfies the requirements for independence and financial literacy under the rules and regulations of the SEC, including <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act and the NASDAQ Rules. Our Board of
Directors has determined that Mr.&nbsp;Bickerstaff qualifies as an &#147;audit committee financial expert&#148; as defined by the applicable SEC rules and satisfies the financial sophistication requirements of the NASDAQ Rules. This designation does
not impose on Mr.&nbsp;Bickerstaff any duties, obligations or liabilities that are greater than those generally imposed on members of our Audit Committee and our Board of Directors. Our Audit Committee is responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointing, compensating and overseeing the work of our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing the qualifications, performance and independence of our independent registered public accounting firm; <FONT STYLE="white-space:nowrap">pre-approving</FONT> any audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing the Company&#146;s internal accounting and financial controls, including procedures for the treatment of complaints on accounting controls, internal accounting controls or auditing matters and procedures for
the submission of confidential, anonymous employee comments about questionable accounting or auditing matters; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing with our management and independent registered public accounting firm the organization and performance of our internal audit function; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and discussing with our management and the independent registered public accounting firm the results of our annual audit, our quarterly financial statements and financial statements included in our publicly
filed reports; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving related person transactions; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing and providing the Audit Committee report that the SEC requires in our annual proxy statements. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee operates under a written charter that satisfies the applicable rules and regulations of
the SEC and the NASDAQ Rules. A copy of the charter of our Audit Committee is available on our website at www.caredx.com in the Corporate Governance section of our Investors webpage. During&nbsp;fiscal year 2017, our Audit Committee held ten
meetings and took action by written consent two times. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Compensation Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee is comprised of Fred E. Cohen, M.D., D. Phil, Michael D. Goldberg and William A. Hagstrom, each of whom is a <FONT
STYLE="white-space:nowrap">non-employee</FONT> member of our Board of Directors. Dr.&nbsp;Cohen is the chair of our Compensation Committee. Our Board of Directors has determined that each member of our Compensation Committee meets the requirements
for independence under the rules and regulations of the SEC, including <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> under the Exchange Act, and the NASDAQ Rules, is a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT>
director&#148; within the meaning of <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> under the Exchange Act and is an &#147;outside director&#148; within the meaning of Section&nbsp;162(m) of the Internal Revenue Code of&nbsp;1986, as
amended (the &#147;Code&#148;). Our Compensation Committee is responsible for, among other things: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving all salaries, incentive awards and bonuses, equity awards, severance arrangements, change in control agreements and any other compensation and benefit plans for our Chief Executive Officer and
all other executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering our equity compensation plans and the issuance of stock options and other stock-related awards not granted pursuant to a plan; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing, at least annually, the Company&#146;s stock plans, performance goals, incentive awards and the overall composition and coverage of its compensation plans; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preparing and providing the annual report on executive compensation that the SEC requires in our annual proxy statements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">evaluating and making recommendations to our Board of Directors about director compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing our overall compensation philosophy, compensation plans and benefits programs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and evaluating, at least annually, the performance of the Compensation Committee and its members, including compliance of the Compensation Committee with its charter. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the NASDAQ Rules. A copy of the
charter of our Compensation Committee is available on our website at www.caredx.com in the Corporate Governance section of our Investors webpage. During&nbsp;fiscal year 2017, our Compensation Committee held three meetings and took action by written
consent eight times. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee is comprised of Ralph Snyderman, M.D. and Michael D. Goldberg, each of whom is a <FONT
STYLE="white-space:nowrap">non-employee</FONT> member of our Board of Directors. Dr.&nbsp;Snyderman is the chair of our Nominating and Corporate Governance Committee. Our Board of Directors has determined that each member of our Nominating and
Corporate Governance Committee meets the requirements for independence under the NASDAQ Rules. Our Nominating and Corporate Governance Committee is responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and making recommendations regarding the composition and size of our Board of Directors and determine the relevant criteria (including any minimum qualifications) for membership on our Board of Directors;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">overseeing our Board of Directors&#146; evaluation process, including conducting periodic evaluations of the performance of our Board of Directors as a whole and each committee of our Board of Directors, and evaluating
the performance of members of our Board of Directors eligible for <FONT STYLE="white-space:nowrap">re-election;</FONT> </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing disclosures about the Company&#146;s nomination process in our annual proxy statement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and making recommendations about our corporate governance guidelines and overseeing compliance with laws and regulations by our Board of Directors and its committees; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining the manner in which stockholders may send communications to our Board of Directors, as well as the process by which stockholder communications will be relayed to our Board of Directors and what our Board of
Directors&#146; response, if any, should be; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing governance-related stockholder proposals and recommending our Board of Directors&#146; responses; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving conflicts of interest of our directors and corporate officers, other than related person transactions reviewed by the Audit Committee; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and evaluating, at least annually, the performance of the Compensation Committee and its members, including compliance of the Compensation Committee with its charter. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee operates under a written charter that satisfies the NASDAQ Rules. A copy of the charter of our nominating
and corporate governance committee is available on our website at www.caredxinc.com in the Corporate Governance section of our Investors webpage. During&nbsp;fiscal year 2017, our Nominating and Corporate Governance Committee held one meeting and
did not take any action by written consent. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Science and Technology Committee </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Science and Technology Committee is comprised of Fred E. Cohen, M.D., D. Phil, and Ralph Snyderman, M.D., each of whom is a
<FONT STYLE="white-space:nowrap">non-employee</FONT> member of our Board of Directors. Dr.&nbsp;Snyderman is the chair of our Science and Technology Committee. Our Science and Technology Committee is responsible for, among other things: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">meeting with the Company&#146;s science and technology leaders to review the Company&#146;s internal research and technology development activities and provide input as it deems appropriate; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing technologies that the Company considers for licensing or acquisition; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing the Company&#146;s development of its technical goals and research and development strategies. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
Science and Technology Committee operates under a written charter. During&nbsp;fiscal year 2017, our Science and Technology Committee held two meetings and did not take any action by written consent. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_13"></A>Considerations in Evaluating Director Nominees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee uses a variety of methods for identifying and evaluating director nominees. In its evaluation of director
candidates, our Nominating and Corporate Governance Committee will consider the composition of our Board of Directors, including, without limitation, issues of character, integrity, judgment, diversity, age, independence, skills, education,
expertise, business acumen, business experience, length of service, understanding of our business and other commitments. Members of our Board of Directors are expected to prepare for, attend, and participate in all Board of Directors and applicable
committee meetings. Our Nominating and Corporate Governance Committee requires the following minimum qualifications to be satisfied by any nominee for a position on our Board of Directors: (i)&nbsp;the highest personal and professional ethics and
integrity, (ii)&nbsp;proven achievement and competence in the nominee&#146;s field and the ability to exercise sound business judgment, (iii)&nbsp;skills that are complementary to those of the existing Board of Directors, (iv)&nbsp;the ability to
assist and support management and make significant contributions to our success, and (v)&nbsp;an understanding of the fiduciary responsibilities that are required of a member of our Board of Directors and the commitment of time and energy necessary
to diligently carry out those responsibilities. Other than the foregoing, there are no stated minimum criteria for director nominees, although our Nominating and Corporate Governance Committee may also consider such other factors as it may deem,
from time to time, are in our and our stockholders&#146; best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although our Board of Directors does not maintain a specific policy with respect to board diversity, our
Board of Directors believes that our Board of Directors should be a diverse body, and our Nominating and Corporate Governance Committee considers a broad range of backgrounds and experiences. In determining nominations of directors, our Nominating
and Corporate Governance Committee may take into account the benefits of diverse viewpoints. Our Nominating and Corporate Governance Committee also considers these and other factors as it oversees the annual Board of Directors and committee
evaluations. After completing its review and evaluation of director candidates, our Nominating and Corporate Governance Committee recommends to our full Board of Directors the director nominees for selection. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_14"></A>Stockholder Recommendations for Nominations to the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating and Corporate Governance Committee will consider candidates for director recommended by stockholders holding at least one percent (1%)&nbsp;of
the fully diluted capitalization of the Company continuously for at least&nbsp;12&nbsp;months prior to the date of the submission of the recommendation. Our Nominating and Corporate Governance Committee will evaluate such recommendations in
accordance with its charter, our amended and restated bylaws, our policies and procedures for director candidates, as well as the regular director nominee criteria described above. This process is designed to ensure that our Board of Directors
includes members with diversity of experience, skills and experience, including appropriate financial and other expertise relevant to our business. Stockholders wishing to recommend a candidate for nomination should contact our Corporate Secretary
in writing. Such recommendations must include the candidate&#146;s name, home and business contact information, detailed biographical data, relevant qualifications, a signed letter from the candidate confirming willingness to serve on our Board of
Directors, information regarding any relationships between the candidate and CareDx and evidence of the recommending stockholder&#146;s ownership of our common stock. Such recommendations must also include a statement from the recommending
stockholder in support of the candidate, particularly within the context of the criteria for Board of Directors&#146; membership. Our Nominating and Corporate Governance Committee has discretion to decide which individuals to recommend for
nomination as directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A stockholder can nominate a candidate directly for election to our Board of Directors by complying with the procedures in
Section&nbsp;2.4(ii) of our amended and restated bylaws and the rules and regulations of the SEC. Any eligible stockholder who wishes to submit a nomination should review the requirements in our amended and restated bylaws on nominations by
stockholders. Any nomination should be sent in writing to our Corporate Secretary at CareDx, Inc., 3260 Bayshore Blvd., Brisbane, California&nbsp;94005. To be timely for our&nbsp;2019 annual meeting of stockholders, our Corporate Secretary must
receive the nomination no earlier than February&nbsp;16, 2019 and no later than March&nbsp;18, 2019. The notice must state the information required by Section&nbsp;2.4(ii) of our amended and restated bylaws and otherwise must comply with applicable
federal and state law. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_15"></A>Communications with the Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders wishing to communicate with our Board of Directors or with an individual member of our Board of Directors may do so by writing to our Board of
Directors or to the particular member of our Board of Directors, and mailing the correspondence to our Chief Financial Officer at CareDx, Inc., 3260 Bayshore Blvd., Brisbane, CA&nbsp;94005. Our Chief Financial Officer will review all incoming
stockholder communications (excluding mass mailings, product complaints or inquiries, job inquiries, business solicitations and patently offensive or otherwise inappropriate material), and if deemed appropriate, the stockholder communications will
be forwarded to the appropriate member or members of our Board of Directors, or if none is specified, to the chairman of our Board of Directors. This procedure does not apply to stockholder proposals submitted pursuant to <FONT
STYLE="white-space:nowrap">Rule&nbsp;14a-8</FONT> under the Exchange Act. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_16"></A>Corporate Governance Guidelines and Code of
Business Conduct and Ethics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors has adopted Corporate Governance Guidelines. These guidelines address items such as the
qualifications and responsibilities of our directors and director candidates and corporate governance policies </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and standards applicable to us in general. In addition, our Board of Directors has adopted a Code of Business Conduct and Ethics that applies to all of our employees, officers and directors,
including our Chief Executive Officer, Chief Financial Officer, and other executive and senior financial officers. The full text of our Corporate Governance Guidelines and our Code of Business Conduct and Ethics is posted on our website at
www.caredx.com in the Corporate Governance section of our Investor Relations webpage. We intend to post any amendments to our Code of Business Conduct and Ethics, and any waivers of our Code of Business Conduct and Ethics for directors and executive
officers, on the same website. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_17"></A>Board of Directors&#146; Role in Risk Oversight </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risk is inherent with every business, and we face a number of risks, including strategic, financial, business and operational, legal and compliance, and
reputational. We have designed and implemented processes to manage risk in our operations. Management is responsible for the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> management of risks we face,
while our Board of Directors, as a whole and assisted by its committees, has responsibility for the oversight of risk management. In its risk oversight role, our Board of Directors has the responsibility to satisfy itself that the risk management
processes designed and implemented by management are appropriate and functioning as designed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors believes that open communication
between management and our Board of Directors is essential for effective risk management and oversight. Our Board of Directors meets with our Chief Executive Officer and other members of the senior management team at quarterly meetings of our Board
of Directors, where, among other topics, they discuss strategy and risks facing the Company, as well as at such other times as they deemed appropriate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">While our Board of Directors is ultimately responsible for risk oversight, our board committees assist our Board of Directors in fulfilling its oversight
responsibilities in certain areas of risk. Our Audit Committee assists our Board of Directors in fulfilling its oversight responsibilities with respect to risk management in the areas of internal control over financial reporting and disclosure
controls and procedures, legal and regulatory compliance, and discusses with management and the independent auditor guidelines and policies with respect to risk assessment and risk management. Our Audit Committee also reviews our major financial
risk exposures and the steps management has taken to monitor and control these exposures. In addition, our Audit Committee monitors certain key risks on a regular basis throughout the fiscal year, such as risk associated with internal control over
financial reporting and liquidity risk. Our Nominating and Corporate Governance Committee assists our Board of Directors in fulfilling its oversight responsibilities with respect to the management of risk associated with board organization,
membership and structure, and corporate governance. Our Compensation Committee assesses risks created by the incentives inherent in our compensation policies. Finally, our full Board of Directors reviews strategic and operational risk in the context
of reports from the management team, receives reports on all significant committee activities at each regular meeting, and evaluates the risks inherent in significant transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_18"></A>Director Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Directors who are employees do not receive any additional compensation for their service on our Board of Directors. We reimburse our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and travel expenses in connection with their attendance at Board of
Directors and committee meetings. In&nbsp;2017, certain of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received cash compensation and options to purchase shares of our common stock pursuant to our&nbsp;2014 Equity Incentive
Plan in effect during 2017 as set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors received an annual retainer of $30,000
for their service on our Board of Directors and any committee thereof. Members of our Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and Science and Technology Committee, other than the chair of each such
committee, received an additional annual retainer of $10,000, $6,000, $4,000 and $5,000, respectively. The chair of our Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Science and Technology Committee each received an additional annual retainer of $20,000, $12,000, $8,000 and $10,000, respectively. Additionally, the individual acting as Chairman of our Board of
Directors received an additional annual retainer of $65,000. All annual retainers were paid quarterly and <FONT STYLE="white-space:nowrap">pro-rated</FONT> for partial service in any year. Our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors are entitled to elect the ratio of shares of common stock of the Company to cash issuable or payable to the <FONT STYLE="white-space:nowrap">non-employee</FONT> director for the payment of the annual retainers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will also continue to reimburse our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and travel expenses in connection with their attendance at Board of Directors and committee meetings in accordance with our travel policy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, nondiscretionary, automatic grants of <FONT STYLE="white-space:nowrap">non-statutory</FONT> stock options will be made to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors. Any <FONT STYLE="white-space:nowrap">non-employee</FONT> director who first joins our Board of Directors will be automatically granted an initial stock option to purchase&nbsp;30,000 shares
of our common stock at an exercise price equal to the fair market value of our common stock on the date of grant and an award of 10,000 restricted stock units (&#147;RSUs&#148;). Each of these options will vest and become exercisable in equal
monthly installments beginning with the first monthly anniversary after the grant date over the following three years, and each of these RSUs will vest in three equal, annual installments beginning with the first annual anniversary after the grant.
On the first business day after each annual meeting of our stockholders, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues to serve on our Board of Directors will be automatically granted an option to purchase an
additional&nbsp;15,000 shares of our common stock at an exercise price equal to the fair market value of our common stock on the date of grant and an award of 5,000 RSUs. Each of these options will vest and become exercisable in equal monthly
installments beginning with the first monthly anniversary after the grant date over the following one year, and each of these RSUs will vest in one installment on the one year anniversary of the grant date. The vesting of the options and the RSUs
described above will accelerate in full upon a &#147;change in control&#148; as defined in our&nbsp;2014 Equity Incentive Plan. The option and RSU amounts set forth above are subject to adjustment for stock dividends, stock splits, combinations or
other similar recapitalizations with respect to our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the compensation accrued or paid by us to our <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors during the year ended December&nbsp;31, 2017, for service on our Board of Directors and its committees. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees&nbsp;Earned<BR>or Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)(4)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael D. Goldberg</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George W. Bickerstaff, III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fred E. Cohen, M.D., D. Phil</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William A. Hagstrom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Douglas Miller<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,574</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,401</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ralph Snyderman, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">67,032</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the fair value of common stock granted in lieu of cash retainers pursuant to our outside director compensation plan. Amounts represent the aggregate fair value of the stock awards
computed as of the grant date of each stock award in accordance with Financial Accounting Standards Board (&#147;FASB&#148;) Accounting Standards Codification (&#147;ASC&#148;) Topic 718. Our assumptions with respect to the calculation of these
values are set forth in Note 13 of the consolidated financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, each of our current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held the following number of RSUs: Mr.&nbsp;Goldberg: 5,000; Mr.&nbsp;Bickerstaff: 5,000; Dr.&nbsp;Cohen:
5,000; Mr.&nbsp;Hagstrom: 5,000 and Dr.&nbsp;Snyderman: 5,000. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Amounts represent the aggregate fair value of the option awards computed as of the grant date of each option
award in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these values are set forth in Note 13 of the consolidated financial statements included in our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. There can be no assurance that option awards will be </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
exercised (in which case no value will be realized by the individual) or that the value on exercise will approximate the fair value as computed in accordance with FASB ASC Topic&nbsp;718.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2017, each of our current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors held options to purchase the following number of shares of common stock: Mr.&nbsp;Goldberg: 142,488;
Mr.&nbsp;Bickerstaff: 47,189; Dr.&nbsp;Cohen: 47,189; Mr.&nbsp;Hagstrom: 46,203 and Dr.&nbsp;Snyderman: 61,787. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Miller resigned from our Board of Directors on May&nbsp;19, 2017. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_19"></A>PROPOSAL NO. 2 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RATIFICATION OF APPOINTMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee has appointed Deloitte&nbsp;&amp; Touche LLP (&#147;Deloitte&#148;)&nbsp;as our independent registered public accounting firm to audit our
consolidated financial statements for our fiscal year ending December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, stockholders are being asked to ratify the
appointment of Deloitte as our independent registered public accounting firm for our fiscal year ending December&nbsp;31, 2018. Stockholder ratification of the appointment of Deloitte is not required by our amended and restated bylaws or other
applicable legal requirements. However, our Board of Directors is submitting the appointment of Deloitte to our stockholders for ratification as a matter of good corporate governance. In the event that this appointment is not ratified by the
affirmative vote of a majority of the shares present in person or by proxy at the Annual Meeting and entitled to vote, such appointment will be reconsidered by our Audit Committee. Even if the appointment is ratified, our Audit Committee, in its
sole discretion, may appoint another independent registered public accounting firm at any time during our fiscal year ending December&nbsp;31, 2018 if our Audit Committee believes that such a change would be in the best interests of CareDx and its
stockholders. A representative of Deloitte is expected to be present at the Annual Meeting, will have an opportunity to make a statement if he or she wishes to do so, and is expected to be available to respond to appropriate questions from
stockholders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_20"></A>Changes in Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2018, the Audit Committee dismissed Ernst&nbsp;&amp; Young LLP (&#147;EY&#148;) as the Company&#146;s independent registered public
accounting firm. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The reports of EY on the Company&#146;s consolidated financial statements for the fiscal years ended December&nbsp;31, 2017 and 2016 did
not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the report of EY on the Company&#146;s consolidated financial statements for the fiscal
year ended December&nbsp;31, 2016 contained an explanatory paragraph describing conditions that raise substantial doubt about the Company&#146;s ability to continue as a going concern. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December&nbsp;31, 2017 and 2016 and the subsequent interim period through April&nbsp;10, 2018, there have been no
&#147;disagreements&#148; (as defined in Item 304(a)(1)(iv) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and related instructions) with EY on any matter of accounting principles or practices, financial statement disclosure or auditing
scope or procedure, which disagreements, if not resolved to the satisfaction of EY, would have caused EY to make reference thereto in their reports on the consolidated financial statements for such fiscal years. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the fiscal years ended December&nbsp;31, 2017 and 2016 and any subsequent interim period through April&nbsp;10, 2018, there have been no
&#147;reportable events&#148; (as defined in Item 304(a)(1)(v) of Regulation <FONT STYLE="white-space:nowrap">S-K),</FONT> except that, as of December&nbsp;31, 2016, the Company identified the following four material weaknesses in the Company&#146;s
internal control over financial reporting relating to: (i)&nbsp;certain areas of the Company&#146;s financial statement close process, specifically with respect to an incorrect classification of the deferred consideration payable to the former
majority shareholders of CareDx International AB (&#147;CareDx International AB&#148;), within the Company&#146;s statement of cash flows following the CareDx International AB acquisition, ensuring that the Company&#146;s bonus accrual and
contingent liability balances were accurate, ensuring the proper application of foreign exchange rates in the Company&#146;s consolidation process, and ensuring the proper review of terms and conditions of a debt agreement, (ii)&nbsp;a failure to
design and implement transaction level or management review controls for the oversight, integration and consolidation of the acquired entities or controls to assess the completeness and accuracy of information, including key inputs and assumptions
used by third party specialists, used in estimating the fair value of assets acquired and liabilities assumed, (iii)&nbsp;a failure to properly apply the revenue recognition criteria to certain contractual arrangements with payers, specifically with
respect to controls over the proper analysis and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
review of the terms and conditions of contractual arrangements and controls over the review of the Company&#146;s aged accounts receivables, and (iv)&nbsp;a failure in the design and
implementation of controls over the Company&#146;s accounting for inventory overhead absorption. The Company remediated each of these material weaknesses as of December&nbsp;31, 2017. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company provided EY with a copy of the disclosure set forth in Item 4.01 of the Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> that
was filed with the SEC on April&nbsp;16, 2018 (the &#147;Form <FONT STYLE="white-space:nowrap">8-K&#148;)</FONT> and requested that EY furnish the Company with a copy of its letter addressed to the SEC, pursuant to Item 304(a)(3) of Regulation <FONT
STYLE="white-space:nowrap">S-K,</FONT> stating whether or not EY agrees with the statements related to them made by the Company in the Form <FONT STYLE="white-space:nowrap">8-K.</FONT> A copy of EY&#146;s letter to the SEC dated April&nbsp;16, 2018
was filed as Exhibit 16.1 to the Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;10, 2018, the Audit Committee approved the appointment
of Deloitte as the Company&#146;s new independent registered public accounting firm, effective immediately. During the fiscal years ended December&nbsp;31, 2017 and 2016 and the subsequent interim period through April&nbsp;10, 2018, neither the
Company, nor anyone on its behalf, consulted Deloitte regarding either (i)&nbsp;the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the financial
statements of the Company, and no written report or oral advice was provided to the Company by Deloitte that Deloitte concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial
reporting issue; or (ii)&nbsp;any matter that was either the subject of a &#147;disagreement&#148; (as defined in Item 304(a)(1)(iv) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> and the related instructions) or a &#147;reportable
event&#148; (as that term is defined in Item 304(a)(1)(v) of Regulation <FONT STYLE="white-space:nowrap">S-K).</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_21"></A>Fees
Paid to the Independent Registered Public Accounting Firm </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents fees for professional audit services and other services
rendered to us by EY for our fiscal years ended December&nbsp;31, 2017 and&nbsp;2016. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2017</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2016</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit Fees<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,335,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,143,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-Related Fees<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">736,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax Fees<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All Other Fees<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,337,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,879,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Audit Fees include fees and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, whether or not yet invoiced, for professional services associated with the annual audit
of our financial statements, the reviews of our interim financial statements, the issuance of consents and comfort letters in connection with registration statement filings with the SEC, and review services related to regulatory filings for the
acquisition of CareDx International AB. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Audit-Related Fees consist of fees for other audit-related professional services. In 2017, no such services were incurred. In 2016, this fee was for professional services rendered for audits in connection with the
CareDx International AB acquisition. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">No tax services were provided in 2017 and 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">All Other Fees include any fees billed that are not audit, audit related or tax fees. In 2017, this fee was for access to an online accounting literature database. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_22"></A>Auditor Independence </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In&nbsp;2017, there were no other professional services provided by EY that would have required our Audit Committee to consider their compatibility with
maintaining the independence of EY. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_23"></A>Audit Committee Policy on <FONT STYLE="white-space:nowrap">Pre-Approval</FONT>
of Audit and Permissible <FONT STYLE="white-space:nowrap">Non-Audit</FONT> Services of Independent Registered Public Accounting Firm </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit
Committee has established a policy governing our use of the services of our independent registered public accounting firm. Under the policy, our Audit Committee is required to <FONT STYLE="white-space:nowrap">pre-approve</FONT> all audit and
permissible <FONT STYLE="white-space:nowrap">non-audit</FONT> services performed by our independent registered public accounting firm to ensure that the provision of such services does not impair such accounting firm&#146;s independence. The policy
generally <FONT STYLE="white-space:nowrap">pre-approves</FONT> specified services in the defined categories of audit services, audit-related services, tax services and other services up to specified amounts. The
<FONT STYLE="white-space:nowrap">pre-approval</FONT> of services may be delegated to one or more of the Audit Committee&#146;s members, but the decision must be reported to the full Audit Committee at its next scheduled meeting. In the years ended
December&nbsp;31, 2017 and&nbsp;2016, services and related fees identified above under the captions &#147;Audit Fees,&#148; &#147;Audit-Related Fees,&#148; &#147;Tax Fees,&#148; and &#147;All Other Fees&#148; that were billed by EY were approved by
the Audit Committee in accordance with SEC requirements. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_24"></A>Recommendation and Vote </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ratification of the appointment of Deloitte requires the affirmative vote of a majority of the shares of our common stock present in person or by proxy at
the Annual Meeting and entitled to vote thereon. Abstentions will have the effect of a vote AGAINST the proposal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF
DIRECTORS RECOMMENDS A VOTE &#147;FOR&#148; THE RATIFICATION OF THE APPOINTMENT OF DELOITTE&nbsp;&amp; TOUCHE LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER&nbsp;31, 2018. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_25"></A>AUDIT COMMITTEE REPORT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The information contained in the following Audit Committee Report shall not be deemed to be soliciting material or to be filed with the Securities and
Exchange Commission, nor shall such information be incorporated by reference into any future filing under the Securities Act of&nbsp;1933, as amended, or the Securities Exchange Act of&nbsp;1934, as amended, except to the extent that CareDx, Inc.
(the &#147;Company&#148;) specifically incorporates it by reference in such filing. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has reviewed and discussed the Company&#146;s
audited consolidated financial statements with management and Ernst&nbsp;&amp; Young LLP (&#147;EY&#148;), the Company&#146;s independent registered public accounting firm for the fiscal year ended December&nbsp;31, 2017. The Audit Committee has
discussed with EY the matters required to be discussed by Auditing Standard No.&nbsp;1301, &#147;<I>Communications with Audit Committees</I>&#148; of the Public Company Accounting Oversight Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has received and reviewed the written disclosures and the letter from EY required by the applicable requirements of the Public Company
Accounting Oversight Board regarding EY&#146;s communications with the Audit Committee concerning independence, and has discussed with EY its independence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that the Company&#146;s audited consolidated
financial statements be included in the Company&#146;s Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the fiscal year ended December&nbsp;31, 2017 for filing with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Respectfully submitted by the members of the Audit Committee of the Board of Directors: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">George Bickerstaff (Chair) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Michael D. Goldberg </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">William A. Hagstrom </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_26"></A>PROPOSAL NO. 3 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT TO THE 2014 PLAN TO (1)&nbsp;INCREASE THE NUMBER OF SHARES OF COMMON STOCK THAT MAY BE ISSUED UNDER THE 2014 PLAN BY 1,600,000
SHARES, AND (2)&nbsp;ELIMINATE THE FIXED SHARE CAP INCLUDED IN THE EVERGREEN PROVISION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;19, 2018, our Board of Directors approved an
amendment to our 2014 Plan, subject to approval by our stockholders. The 2014 Plan was originally adopted by our Board of Directors in March 2014 and originally adopted by the stockholders in July 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have amended the 2014 Plan to provide for, and submit to our stockholders for approval, (1)&nbsp;an increase in the number of shares of common stock that
may be issued under the 2014 Plan by 1,600,000 shares, and (2)&nbsp;the elimination of the fixed share cap included in the evergreen provision. The additional shares will increase the total shares of common stock reserved for issuance under the 2014
Plan to an aggregate of 3,866,995 shares, plus an additional number of shares in an amount not to exceed 865,252 comprised of shares added to the Amended 2014 Plan as the result of expiration or termination of options issued under our 2008 Equity
Incentive Plan, all of which may be issued pursuant to the exercise of stock options, upon the vesting of RSUs or pursuant to any other type of award described below. The 2014 Plan currently includes an &#147;evergreen provision,&#148; which
provides that the number of shares available for issuance under the 2014 Plan shall be increased annually on the first day of each year by a number of shares of common stock as is equal to the least of: (i) 357,075 shares, (ii) 4.0% of the
outstanding shares of common stock as of the last day of our immediately preceding fiscal year, or (iii)&nbsp;such other amount as our Board of Directors may determine. The amendment to the 2014 Plan also provides for the elimination of the 357,075
share cap such that the shares available for issuance under the 2014 Plan shall be increased annually on the first day of each year by a number of shares of common stock as is equal to the least of: (a) 4.0% of the outstanding shares of common stock
as of the last day of our immediately preceding fiscal year, or (b)&nbsp;such other amount as our Board of Directors may determine. In this Proposal No.&nbsp;3, stockholders are requested to approve the foregoing amendment to the 2014 Plan (as
amended, the &#147;Amended 2014 Plan&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our executive officers and members of our Board of Directors will be eligible to receive awards under the
Amended 2014 Plan and therefore have an interest in this proposal. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_27"></A>Reasons for Approving the Amended 2014 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Equity Grants are an Important Part of Our Compensation Philosophy </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We strongly believe that the approval of the Amended 2014 Plan is critical to our ongoing effort to build stockholder value. We rely on highly skilled
employees to implement our strategic goals and expand our business. There is significant competition for these types of skilled professionals and many other companies also use stock-based awards to attract, motivate and retain their best employees.
Our Board of Directors and its Compensation Committee believe that our ability to grant equity incentive awards to new and existing employees, directors and eligible consultants has helped us attract, retain and motivate professionals with superior
ability, experience and leadership capability. Historically, we have issued stock options and restricted stock units, including new hire stock awards, under the 2014 Plan. We believe these forms of equity compensation align the interests of our
employees, directors and consultants with the interests of our stockholders, encourage retention and promote actions that result in long-term stockholder value creation. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Limited Shares Remain Available under the 2014 Plan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2018, a total of 270,899 shares of common stock were available for future equity awards that may be granted under the 2014 Plan, which
constitutes approximately 0.8% of our outstanding shares of common stock as of such date. Additionally, we have proposed amending the 2014 Plan to eliminate the 357,075 share cap from the evergreen provision such that the number of shares added to
the Amended 2014 Plan will no longer be capped at 357,075 shares and the number of shares added to the Amended 2014 Plan annually will be equal to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
4.0% of the outstanding shares of common stock as of the last day of our immediately preceding fiscal year or any lower number that our Board of Directors may determine. We believe that the share
cap is no longer appropriate in light of the fact that the number of outstanding shares of common stock has increased since the initial adoption of the Amended 2014 Plan and that an annual 4.0% increase will provide us with sufficient shares to
continue to grant equity awards to attract, motivate and retain our employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In fiscal years 2017, 2016 and 2015, the Company&#146;s annual equity burn
rates (calculated by dividing the number of shares subject to equity awards granted during the year by the weighted-average number of shares outstanding during the applicable year) under our equity plans were 5.2%, 5.4% and 6.5%, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We expect the proposed aggregate share reserve under the Amended 2014 Plan to provide us with enough shares for awards for approximately two years, assuming
we continue to grant awards consistent with our current practices and historical burn rate, assuming we receive the maximum annual evergreen increases under the Amended 2014 Plan, and further dependent on the price of our shares and hiring activity
during the next few years, forfeitures of outstanding awards and nothing that future circumstances may require us to change our current equity grant practices. We cannot predict our future equity grant practices, the future price of our shares or
future hiring activity with any degree of certainty at this time, and the share reserve under the Amended 2014 Plan could last for a shorter or longer time than estimated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In fiscal years 2017, 2016 and 2015, the end of year overhang rate (calculated by dividing (1)&nbsp;the sum of the number of shares subject to equity awards
outstanding at the end of the calendar year plus shares remaining available for issuance for future awards at the end of the calendar year by (2)&nbsp;the number of shares outstanding at the end of the calendar year) was 9.0%, 13.1% and 16.3%,
respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The Amended 2014 Plan Contains Strong Compensation and Governance Practices </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have included provisions in the Amended 2014 Plan that are designed to protect our stockholders&#146; interests and to reflect what we believe to be strong
corporate governance practices, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Administrator Independence</I>.<I> </I>The Compensation Committee, comprised solely of independent <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, administers the Amended 2014 Plan. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Continued broad-based eligibility for equity awards</I>.<I> </I>We grant equity to substantially all of our employees. By doing so, we link employee interests with stockholder interests throughout the organization
and motivate our employees to act as owners of the business. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>No discount stock options or stock appreciation rights</I>.<I> </I>All stock options and stock appreciation rights are intended to have an exercise price equal to or greater than the fair market value of our common
stock on the date the stock option or stock appreciation right is granted. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>No tax <FONT STYLE="white-space:nowrap">gross-ups</FONT></I>.<I> </I>The Amended 2014 Plan does not provide for any tax <FONT STYLE="white-space:nowrap">gross-ups.</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Limited Transferability</I>.<I> </I>Generally, a participant may not transfer an award granted under the Amended 2014 Plan other than by will or by the laws of descent or distribution. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In light of the factors described above, and the fact that the ability to continue to grant equity compensation is vital to our ability to continue to attract
and retain employees in the extremely competitive labor markets in which we compete, our Board of Directors has determined that the proposed 1,600,000 increase to the share reserve under the 2014 Amended Plan is reasonable and appropriate at this
time. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_28"></A>Description of the Amended 2014 Plan </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The principal features of the Amended 2014 Plan are outlined below. This summary is qualified in its entirety by reference to the complete text of the Amended
2014 Plan. Stockholders are urged to read the actual text of the Amended 2014 Plan in its entirety, which is appended to this proxy statement as <U>Appendix A</U>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Shares Available for Issuance </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are seeking stockholder approval to increase the number of shares of common stock that may be issued under the 2014 Plan by 1,600,000 shares. Therefore, if
this Proposal No.&nbsp;3 is approved, and subject to adjustment upon certain changes in capitalization, the aggregate number of shares of our common stock that may be issued pursuant to stock awards under the Amended 2014 Plan will not exceed
3,866,995 shares of common stock, plus an additional number of shares in an amount not to exceed 865,252 comprised of shares added to the Amended 2014 Plan as the result of expiration or termination of options issued under our 2008 Equity Incentive
Plan. Furthermore, (i)&nbsp;shares covered by awards that expire or, in the case of options or stock appreciation rights, shares that are not purchased or issued as a result of the award becoming unexercisable without having been exercised in full,
(ii)&nbsp;shares covered by awards that are surrendered pursuant to an exchange program permitted under the Amended 2014 Plan, (iii)&nbsp;shares that are repurchased by, or forfeited back to, the Company due to failure to vest, (iv)&nbsp;shares used
to pay the exercise price of an award or to satisfy tax withholding obligations related to an award, and (v)&nbsp;shares covered by an award that are not actually issued because the award is instead settled with a cash payment (such shares,
collectively, &#147;Returned Shares&#148;) shall again become available for future grant or sale under the Amended 2014 Plan. The number of shares available for issuance under the Amended 2014 Plan also includes an annual increase on the first day
of each year equal to the least of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">4.0% of the outstanding shares of common stock as of the last day of our immediately preceding fiscal year; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such other amount as our Board of Directors may determine. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Plan Administration </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors or a committee of our Board of Directors may administer the Amended 2014 Plan. In the case of stock options intended to qualify as
&#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m) of the Code, the Amended 2014 Plan will be administered by a committee of two or more &#147;outside directors&#148; within the meaning of Section&nbsp;162(m) of the
Code. Subject to the provisions of our Amended 2014 Plan, the administrator has the power to determine the recipients and terms of the awards, including the exercise price, the number of shares subject to each such award, the exercisability of the
awards, and the form of consideration, if any, payable upon exercise. The administrator also has the authority to amend existing awards to reduce their exercise price, to allow participants the opportunity to transfer outstanding awards to a
financial institution or other person or entity selected by the administrator and to institute an exchange program by which outstanding awards may be surrendered in exchange for awards with a higher or lower exercise price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Types of Awards and Eligibility </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Amended 2014
Plan provides for the following types of awards: incentive stock options, nonstatutory stock options, restricted stock awards, RSU awards, stock appreciation rights, performance stock awards, and performance unit awards. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards may be granted under the Amended 2014 Plan to our employees, directors and consultants. Only our employees, or employees of a &#147;parent
corporation&#148; or a &#147;subsidiary corporation&#148;, may receive incentive stock options; provided, however no more than 5,000,000 shares, plus Returned Shares, may be issued pursuant to awards of incentive stock options under the Amended 2014
Plan. As of March&nbsp;31, 2018, there were approximately 180 employees, one consultant and five <FONT STYLE="white-space:nowrap">non-employee</FONT> directors eligible to participate in the 2014 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Options </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A stock option is the right to
purchase shares of our common stock at a fixed exercise price for a fixed period of time. Stock option grants may be incentive stock options or nonstatutory stock options. Each option is evidenced </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by a stock option agreement. The administrator determines the terms of a stock option, including the number of shares subject to each award, the form of consideration payable at exercise and the
fair market value applicable to an award. The exercise price of options granted under our Amended 2014 Plan must at least be equal to the fair market value of our common stock on the date of grant. Generally, the term of an incentive stock option
may not exceed ten years. However, in the case of an incentive stock option granted to any participant who owns more than 10% of the voting power of all classes of our outstanding stock, the term must not exceed five years<U> </U>and the exercise
price must equal at least 110% of the fair market value on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After the termination of service of an employee, director or consultant, he
or she may exercise his or her option for the period of time stated in his or her award agreement to the extent that the option is vested on the date of termination (but in no event later than the expiration of the term of such option as set forth
in the award agreement). Generally, the option will remain exercisable for three months following the termination of service. In the event of termination of service due to the death or disability of the employee, director or consultant, such
employee&#146;s option will remain exercisable for 12 months following the event causing the termination. In no event may an option be exercised later than the expiration of its term. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Restricted Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Restricted stock awards are
grants of shares of our common stock that vest in accordance with terms and conditions established by the administrator. The administrator determines the number of shares of restricted stock granted and may impose whatever conditions to vesting it
determines to be appropriate (for example, the administrator may set restrictions based on the achievement of specific performance goals or continued service to us). The administrator, in its sole discretion, may accelerate the time at which any
restrictions will lapse or be removed. Shares of restricted stock that do not vest are subject to our right of repurchase or forfeiture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>RSUs
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSUs are bookkeeping entries representing an amount equal to the fair market value of one share of our common stock. The administrator determines
the terms and conditions of RSUs, including the number of units granted, the vesting criteria (which may include accomplishing specified performance criteria or continued service to us), and the form and timing of payment. The administrator, in its
sole discretion, may accelerate the time at which any restrictions will lapse or be removed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Appreciation Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock appreciation rights allow the recipient to receive the appreciation in the fair market value of our common stock between the exercise date and the date
of grant. Subject to the provisions of our Amended 2014 Plan, the administrator determines the terms of stock appreciation rights, including when such rights become exercisable and whether to pay any increased appreciation in cash or with shares of
our common stock, or a combination thereof. However, the per share exercise price for the shares to be issued pursuant to the exercise of a stock appreciation right will be no less than 100% of the fair market value per share on the date of grant.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Performance Units and Performance Shares </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance units and performance shares are awards that will result in a payment to a participant only if performance goals established by the administrator
are achieved or the awards otherwise vest. The administrator establishes organizational or individual performance goals in its discretion. The extent to which these organizational or individual performance goals are met will determine the number
and/or the value of performance units and performance shares to be paid out to participants. After the grant of a performance unit or performance share, the administrator, in its sole discretion, may reduce or waive any performance objectives or
other vesting provisions for such performance units or performance shares. Further, the administrator, in its sole discretion, may pay earned performance units or performance shares in the form of cash, in shares, or in some combination thereof.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Amended 2014 Plan provides that all outside <FONT STYLE="white-space:nowrap">(non-employee)</FONT> directors will be eligible to receive all types of
awards (except for incentive stock options) under our Amended 2014 Plan. To provide a maximum limit on the awards that can be made to our outside directors, our Amended 2014 Plan provides that in any given year, an outside director (i)&nbsp;will not
be granted cash-settled awards having a grant-date fair value greater than $300,000, but that in the fiscal year that an outside director first joins our board of directors, he or she may be granted a cash-settled award with a grant-date fair value
of up to $500,000; and (ii)&nbsp;will not be granted stock-settled awards covering more than 250,000 shares (subject to adjustment for stock dividends, stock splits, combinations or other similar recapitalizations with respect to our common stock),
but that in the fiscal year that an outside director first joins our board of directors, he or she may be granted stock-settled awards covering up to 500,000 shares (subject to adjustment for stock dividends, stock splits, combinations or other
similar recapitalizations with respect to our common stock). The grant-date fair values will be determined according to GAAP. The maximum limits do not reflect the intended size of any potential grants or a commitment to make grants to our outside
directors under our Amended 2014 Plan in the future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless the administrator provides otherwise, our Amended 2014 Plan generally does not allow for the transfer of awards, and only the recipient of an award may
exercise an award during his or her lifetime. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Changes to Capital Structure </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of certain changes in our capitalization, to prevent diminution or enlargement of the benefits or potential benefits available under the Amended
2014 Plan, the administrator may adjust the number and class of shares that may be delivered under the Amended 2014 Plan and/or the number, class and price of shares covered by each outstanding award, and the numerical share limits set forth in the
Amended 2014 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Merger or Change in Control </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Amended 2014 Plan provides that in the event of a merger or change in control, as defined in the Amended 2014 Plan, each outstanding award will be treated
as the administrator determines, including whether the successor corporation or its parent or subsidiary will assume or substitute an equivalent award for each outstanding award. The administrator is not required to treat all awards similarly. If
there is no assumption or substitution of outstanding awards, the awards will fully vest, all restrictions will lapse, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and the awards will become fully
exercisable. Additionally, the administrator will notify the participant in writing or electronically that the option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion, and
the option or stock appreciation right will terminate upon the expiration of such period. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Duration, Suspension, Termination, and Amendment
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The administrator may amend, alter, suspend or terminate the Amended 2014 Plan at any time; provided that no such amendment, alteration,
suspension or termination may materially impair the rights of any participant without the written consent of such participant holding awards. Further, we must obtain stockholder approval of any amendment to the extent necessary to comply with
applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Amended 2014 Plan is scheduled to terminate on July&nbsp;15, 2024, ten years from the date prior to the date that our first
registration statement was declared effective. No awards may be granted under the Amended 2014 Plan while the Amended 2014 Plan is suspended or after it is terminated. Termination of the Amended 2014 Plan will not affect the administrator&#146;s
ability to exercise the powers granted to it hereunder with respect to awards granted under the Amended 2014 Plan prior to the date of such termination. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_29"></A>Federal Income Tax Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a summary of the principal United States federal income taxation consequences to participants and us with respect to participation in the
Amended 2014 Plan. This summary is not exhaustive, and does not discuss state, local or foreign tax laws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Award Implications for Us </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the requirement of reasonableness, the provisions of Section&nbsp;162(m) of the Code (described below) and the satisfaction of a tax reporting
obligation, we are entitled to a deduction in the same amount and in the same year as the ordinary income recognized by participants with respect to the awards they receive pursuant to the Amended 2014 Plan. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Award Implications for Participants </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An optionee
who is granted an incentive stock option generally does not recognize taxable income at the time the option is granted or upon its exercise; however, the exercise is an adjustment item for alternative minimum tax purposes and may subject the
optionee to the alternative minimum tax. Upon a disposition of the shares more than two years after grant of the option and more than one year after exercise of the option, any gain or loss is treated as long-term capital gain or loss. If these
holding periods are not satisfied, the optionee recognizes ordinary income at the time of disposition equal to the difference between the exercise price and the lower of (i)&nbsp;the fair market value of the shares at the date of the option
exercise, or (ii)&nbsp;the sale price of the shares. Any gain or loss recognized on such a premature disposition of the shares in excess of the amount treated as ordinary income is treated as long-term or short-term capital gain or loss, depending
on the holding period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No taxable income is generally recognized by an optionee upon the grant of a nonstatutory stock option. Upon exercise, the
optionee will generally recognize ordinary income equal to the excess of the fair market value of the purchased shares on the exercise date over the exercise price paid for those shares. When the optionee disposes of shares granted as a nonstatutory
stock option, any difference between the sale price and fair market value of the shares on the exercise date is treated as long-term or short-term capital gain or loss, depending on the holding period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A participant acquiring restricted stock generally will recognize ordinary income equal to the difference between the fair market value of the shares on the
&#147;determination date&#148; (as defined below) and their purchase price, if any. The &#147;determination date&#148; is the date on which the participant acquires the shares unless they are subject to a substantial risk of forfeiture and are not
transferable, in which case the determination date is the earlier of (i)&nbsp;the date on which the shares become transferable or (ii)&nbsp;the date on which the shares are no longer subject to a substantial risk of forfeiture. If the determination
date is after the date on which the participant acquires the shares, the participant may elect, pursuant to Section&nbsp;83(b) of the Code, to have the date of acquisition be the determination date by filing an election with the Internal Revenue
Service no later than 30 days after the date the shares are acquired. Upon the sale of shares acquired pursuant to a restricted stock award, any gain or loss, based on the difference between the sale price and the fair market value on the
determination date, will be taxed as capital gain or loss. Such gain or loss will be long-term or short-term depending on whether the shares were held for more than one year. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No taxable income is recognized upon receipt of a RSU award. In general, the participant will recognize ordinary income, in the year in which the shares
subject to that unit vest and are actually issued to the participant, in an amount equal to the fair market value of the shares on the date of issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No taxable income is reportable when a stock appreciation right is granted to a participant. Upon exercise, the participant will recognize ordinary income in
an amount equal to the amount of cash received and the fair market value of any shares received. Any additional gain or loss recognized upon any later disposition of the shares would be capital gain or loss, long-term or short-term depending on
whether the shares were held for more than one year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A participant generally will recognize no income upon the grant of a performance award. Upon the settlement
of cash awards, participants normally will recognize ordinary income in the year of receipt in an amount equal to the cash received. If the participant receives shares of restricted stock or RSUs, the participant generally will be taxed in the same
manner as described above for restricted stock or RSUs, as applicable. Upon the sale of any shares received, any gain or loss, based on the difference between the sale price and income previously recognized on the shares, will be taxed as capital
gain or loss, long-term or short-term depending on whether the shares were held for more than one year. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Tax Withholding </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the participant is an employee, any ordinary income arising from an award generally is subject to withholding of income and employment taxes. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Section&nbsp;162(m) </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally,
Section&nbsp;162(m) of the Code (&#147;Section&nbsp;162(m)&#148;) disallows public companies a tax deduction for federal income tax purposes of compensation in excess of $1&nbsp;million paid to their chief executive officer and certain other
specified officers in any taxable year. For tax years ending prior to December&nbsp;31, 2017, compensation in excess of $1&nbsp;million could only be deducted if it was &#147;performance-based compensation&#148; within the meaning of
Section&nbsp;162(m) or qualified for one of the other exemptions from the deduction limit. The exemption from Section&nbsp;162(m)&#146;s deduction limit for performance-based compensation has been repealed, effective for taxable years beginning
after December&nbsp;31, 2017, such that compensation paid to our covered officers (which now also includes our Chief Financial Officer) in excess of $1&nbsp;million will generally not be deductible unless it qualifies for transition relief
applicable to certain arrangements in place as of November&nbsp;2, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because of ambiguities and uncertainties as to the application and
interpretation of Section&nbsp;162(m) and the regulations issued thereunder, including the uncertain scope of the transition relief under the legislation repealing Section&nbsp;162(m)&#146;s &#147;performance-based compensation&#148; exemption from
the deduction limit, no assurance can be given that that compensation attributable to awards granted under the Amended 2014 Plan intended to satisfy the requirements for exemption from Section&nbsp;162(m) will in fact qualify. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_30"></A>New Plan Benefits </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of our
directors, officers, employees and consultants are eligible to receive awards under the Amended 2014 Plan. Awards under the Amended 2014 Plan are discretionary, and we have not approved any awards, including stock options, that are conditioned on
stockholder approval of the Amended 2014 Plan. Accordingly, we cannot currently determine the benefits or number of shares subject to awards, including stock options and RSUs, that may be granted in the future to executive officers, directors and
employees under the Amended 2014 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_31"></A>Plan Benefits </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents certain information with respect to options and RSUs granted under the 2014 Plan during fiscal year 2017 to (i)&nbsp;each of our
named executive officers, (ii)&nbsp;each of our current directors, (iii)&nbsp;all current executive officers as a group, (iv)&nbsp;all current <FONT STYLE="white-space:nowrap">non-employee</FONT> directors as a group, and (v)&nbsp;all current
employees, excluding <FONT STYLE="white-space:nowrap">non-executive</FONT> officers, as a group. On December&nbsp;29, 2017, the last trading day of fiscal year 2017, the last reported sales price of our common stock was $7.34. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014 Plan </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="69%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:72.80pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Position(s)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Dollar&nbsp;Value</B><br><B>($)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares&nbsp;Subject<BR>to&nbsp;Stock&nbsp;Options</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number<BR>of&nbsp;RSUs</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Maag, Ph.D., President, Chief Executive Officer, and Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">571,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James P. Yee, M.D., Ph.D., Chief Medical Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Bell, Chief Financial Officer</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">338,044</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George W. Bickerstaff, III, Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fred E. Cohen, M.D., D. Phil., Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael D. Goldberg, Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William A. Hagstrom, Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ralph Snyderman, M.D., Director</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Executive Officers Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,354,291</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">435,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77,933</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">Non-Executive</FONT> Officer Employee Group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">606,454</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">213,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column reflect the aggregate fair value of the awards computed as of the grant date of each award in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of these
values are set forth in Note 13 of the consolidated financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since its inception, no shares have been issued to any associate of any director, nominee or executive officer under the 2014 Plan. No person has been issued
or will be issued five percent or more of the total amount of shares issued under the Amended 2014 Plan. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_32"></A>Equity
Compensation Plan Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information as of December&nbsp;31, 2017 with respect to shares of our common stock that
may be issued under our existing equity compensation plans. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="61%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:49.10pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Plan Category</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(a)</B><br><B>Number of<BR>Securities&nbsp;to&nbsp;be<BR>Issued Upon<BR>Exercise of<BR>Outstanding<BR>Options,<BR>Warrants and<BR>Rights</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(b)</B><br><B>Weighted<BR>Average<BR>Exercise&nbsp;Price&nbsp;of<BR>Outstanding<BR>Options,<BR>Warrants and<BR>Rights<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(c)</B><br><B>Number of<BR>Securities<BR>Remaining<BR>Available for<BR>Future&nbsp;Issuance<BR>Under
Equity<BR>Compensation<BR>Plans&nbsp;(Excluding<BR>Securities<BR>Reflected in<BR>Column (a))</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans approved by
stockholders<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,261,893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Equity compensation plans not approved by
stockholders<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,506</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,381,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">156,429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The weighted average exercise price is calculated based solely on outstanding stock options and warrants and does not reflect the shares that will be issued upon the vesting of outstanding awards of RSUs, which have no
exercise price. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Includes the following plans: CareDx, Inc. 1998 Equity Incentive Plan, CareDx, Inc. 2008 Equity Incentive Plan,
ImmuMetrix 2013 Equity Incentive Plan, the 2014 Plan and the CareDx, Inc. 2014 Employee Stock Purchase Plan (&#147;ESPP&#148;). Our 2014 Plan provides that on the first day of each fiscal year beginning in 2015, the number of shares available for
issuance thereunder is automatically increased by a number equal to the least of (i) 357,075 shares of common stock, (ii)&nbsp;four percent (4.0%) of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year,
or (iii)&nbsp;such other amount as may be determined by our Board of Directors. Our ESPP provides that on the first day of each fiscal year beginning </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
in 2015, the number of shares available for issuance thereunder is automatically increased by a number equal to the least of (i) 133,900 shares of common stock, (ii)&nbsp;one and <FONT
STYLE="white-space:nowrap">one-half</FONT> percent (1.5%) of the outstanding shares of Common Stock on the last day of the immediately preceding fiscal year, or (iii)&nbsp;such other amount as may be determined by our Board of Directors. On
January&nbsp;1, 2018, the number of shares available for issuance under our 2014 Plan and our ESPP increased by 357,075 shares and 133,900 shares, respectively, pursuant to these provisions. These increases are not reflected in the table above.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Consists of shares available for issuance under the CareDx, Inc. 2016 Inducement Equity Incentive Plan. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_33">
</A>Recommendation and Vote </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the votes cast is required for stockholder approval of the proposal to approve the
amendment to the 2014 Plan to (1)&nbsp;increase the number of shares of common stock that may be issued under the 2014 Plan by 1,600,000 shares, and (2)&nbsp;eliminate the fixed share cap included in the evergreen provision. Abstentions will have
the effect of a vote AGAINST the proposal. Broker <FONT STYLE="white-space:nowrap">non-votes</FONT> will have no effect on the proposal. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR BOARD OF DIRECTORS RECOMMENDS THAT YOU VOTE &#147;FOR&#148; APPROVAL OF THE AMENDMENT TO THE 2014 PLAN TO: (1)&nbsp;INCREASE THE NUMBER
OF SHARES OF COMMON STOCK THAT MAY BE ISSUED UNDER THE 2014 PLAN BY 1,600,000 SHARES, AND (2)&nbsp;ELIMINATE THE FIXED SHARE CAP INCLUDED IN THE EVERGREEN PROVISION. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_34"></A>EXECUTIVE OFFICERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table identifies certain information about our executive officers as of April&nbsp;30, 2018. Each executive officer serves at the discretion of
our Board of Directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of our directors or executive officers. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="54%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:35.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Position(s)</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Maag, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer, and Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Bell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anders Karlsson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief International Business Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sasha King</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Commercial Officer</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mitchell J. Nelles, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Operating Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James P. Yee, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Peter Maag, Ph.D. </I>For a brief biography of Dr.&nbsp;Maag, please see &#147;BOARD OF DIRECTORS AND CORPORATE
GOVERNANCE&#151;Directors with Terms Expiring at the Annual Meeting&#151; Continuing Directors.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Michael Bell</I> has served as our Chief
Financial Officer since April&nbsp;2017. He has over 20 years of international finance and accounting experience. From January 2016 to March 2017, Mr.&nbsp;Bell served as the Chief Financial Officer of Metabiota, Inc., a San Francisco-based company
that develops and sells risk analytics products focused on infectious disease. From May 2012 to January 2016, he served as the Chief Financial Officer of Singulex, Inc., a clinical diagnostics company. Prior to that, Mr.&nbsp;Bell held leadership
and executive positions within Novartis, including with Novartis Diagnostics, a global provider of blood screening solutions, where he served as Chief Financial Officer from 2011 to 2012, and Senior Director, Global Head of Finance from 2008 to
2011. Mr.&nbsp;Bell also previously worked for several years in public accounting with both Ernst&nbsp;&amp; Young LLP and Deloitte, UK. He holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the
United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England&nbsp;&amp; Wales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Anders Karlsson, M.B.A.</I> has served as our
Chief International Business Officer since April&nbsp;2016. Prior to that, he served as the Chief Executive Officer of Allenex AB, a life sciences company that developed, manufactured, marketed and sold products for safer transplantation of blood
stem cells and organs, since&nbsp;2011. In April&nbsp;2016, Allenex AB was acquired by us and continues operations as a wholly owned subsidiary. From&nbsp;2009 to&nbsp;2011, Mr.&nbsp;Karlsson served as the Chief Executive Officer of Olerup
International AB, a global distributor of molecular diagnostic products and services. From&nbsp;2008 to&nbsp;2009, Mr.&nbsp;Karlsson served as the Chief Executive Officer of AbSorber AB, a biotech company that develops products for increasing the
probability of transplantation success. Prior to that, Mr.&nbsp;Karlsson held positions of increasing responsibility at Novartis Pharmaceutical in Sweden, including Head of Sales, Head of Sales and Marketing, and Country President for Novartis
Norway. Mr.&nbsp;Karlsson studied economics at University of J&ouml;nk&ouml;ping and marketing management at IHM Business School Link&ouml;ping. Mr.&nbsp;Karlsson received his M.B.A. from the Henley Business School of the University of Reading,
United Kingdom. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Sasha King, M.B.A.</I> has served as our Chief Commercial Officer since October 2017. Ms.&nbsp;King brings over 10 years of
diagnostics and genetic testing experience. Prior to becoming our Chief Commercial Officer, she served as our Ad Interim Chief Commercial Officer from June to October 2017 and as our Head of Marketing from March to June 2017. From August 2015 to
March 2017, she worked in companion diagnostics marketing at Genentech, and was a sales leader at Ariosa Diagnostics from July 2013 to August 2015. While at Genentech, she worked on the launch of the first FDA approved cell free DNA test in
oncology, the PD-Ll test launch, and the Foundation Medicine partnership. Ms.&nbsp;King was an early member of the commercial team at Ariosa, a leader in the field of noninvasive prenatal testing (&#147;NIPT&#148;), which is now part of the Roche
Group. She led the launch of their test into Asia Pacific and Canada. From August 2008 to July 2011, Ms.&nbsp;King worked at Fletcher Spaght, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
life science consulting and venture capital fund. She received a bachelor of science in bioengineering from Massachusetts Institute of Technology in 2008 and an M.B.A. from Stanford Graduate
School of Business in 2013. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Mitchell J. Nelles, Ph.D</I>. has served as our Chief Operating Officer since January&nbsp;2012. Prior to that, he served
as our Vice President, Research and Development and Technical Operations since December&nbsp;2006. From August&nbsp;2003 to October&nbsp;2006, Dr.&nbsp;Nelles was Vice President of North America Research and Development at bioM&eacute;rieux, Inc.,
an <I>in vitro</I> diagnostics company. From December&nbsp;2001 to July&nbsp;2003, Dr.&nbsp;Nelles was Vice President of Research and Development at TriPath Oncology, a subsidiary of TriPath Imaging Inc., a company that develops, manufactures,
markets and sells solutions to improve the clinical management of cancer. Dr.&nbsp;Nelles holds a B.A. in Biological Sciences from Rutgers College, a Ph.D. in Biomedical Sciences (Immunology) from the University of Texas, Health Sciences Center at
Dallas, and has completed postdoctoral training in Immune Regulation at Brandeis University. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>James P. Yee, M.D., Ph.D</I>. has served as our Chief
Medical Officer since August&nbsp;2006. From January&nbsp;2003 to June&nbsp;2006, Dr.&nbsp;Yee was Vice President and Head of Development for Celera Genomics, Inc., a diagnostics company. From June&nbsp;1995 to December&nbsp;2002, he was Vice
President of Preclinical and Clinical Development at Roche Bioscience, a division of F. <FONT STYLE="white-space:nowrap">Hoffmann-La</FONT> Roche Ltd. Earlier in his career, Dr.&nbsp;Yee held a variety of research and development positions of
increasing responsibility at Syntex Corporation, including Vice President and Director of the Institute for Clinical Medicine from&nbsp;1989 to&nbsp;1992. Dr.&nbsp;Yee is certified in internal medicine by the American Board of Internal Medicine.
Dr.&nbsp;Yee holds a B.S. in Electrical Engineering and Computer Science and a Ph.D. in Biophysics from the University of California at Berkeley, and an M.D. from the University of California, Los Angeles School of Medicine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_35"></A>Legal Proceedings with Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no legal proceedings related to any of the executive officers which require disclosure pursuant to Items&nbsp;103 or&nbsp;401(f) of <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_36"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our named executive officers for&nbsp;2017, which consist of our principal executive officer and the next two most highly compensated executive officers, are:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Peter Maag, Ph.D., our President and Chief Executive Officer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">James P. Yee, M.D., Ph.D., our Chief Medical Officer; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Michael Bell, our Chief Financial Officer. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_37"></A>Processes and Procedures for
Compensation Decisions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee is responsible for the executive compensation programs for our executive officers and reports to our
Board of Directors on its discussions, decisions and other actions. The salary and bonuses paid to our executive officers are reviewed annually by the Compensation Committee. Typically, our Chief Executive Officer makes recommendations to our
Compensation Committee, often attends committee meetings and is involved in the determination of compensation for the respective executive officers who report to him, except that the Chief Executive Officer does not make recommendations as to his
own compensation. Our Chief Executive Officer makes recommendations to our Compensation Committee regarding short- and long-term compensation for all executive officers (other than himself) based on our results, an individual executive
officer&#146;s contribution toward these results and performance toward individual goal achievement. Our Chief Executive Officer recuses himself from Compensation Committee and board discussions when his compensation is reviewed. Our Compensation
Committee then reviews the recommendations and other data and makes decisions as to total compensation for each executive officer other than the Chief Executive Officer, as well as each individual compensation component. Our Compensation Committee
makes recommendations to our Board of Directors regarding, or determines, compensation for the Chief Executive Officer. The Compensation Committee or the independent members of our Board of Directors make the final decisions regarding executive
compensation for the Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee is authorized to retain the services of one or more executive compensation
advisors, as it sees fit, in connection with the establishment of our compensation programs and related policies. Beginning in&nbsp;2014, the Compensation Committee retained Radford Associates, a national compensation consultant, to provide
information, recommendations and other advice about executive compensation on an ongoing basis. Accordingly, Radford now serves at the discretion of our Compensation Committee. Our Compensation Committee engaged Radford to assist in developing an
appropriate group of peer companies to help us determine the appropriate level of overall compensation for our executive officers, as well as assess each separate element of compensation, with a goal of ensuring that the compensation we offer to our
executive officers is competitive and fair. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_38"></A>Summary Compensation Table </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding the compensation awarded to, or earned by, our named executive officers during&nbsp;2016 and&nbsp;2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Summary Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:104.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name and Principal Position<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Peter Maag, Ph.D.,</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">306,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,401,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>President and Chief Executive Officer</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">450,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">111,988</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">135,341</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">185,625</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">882,954</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James P. Yee,<I> </I>M.D., Ph.D.,</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">382,905</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,790</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">697,495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Chief Medical Officer</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2016</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">376,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634,321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Bell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2017</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">237,292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,105</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">690,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Chief Financial Officer</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">In accordance with SEC guidance, compensation information for Michael Bell for fiscal year 2016 has not been included in this table because Michael Bell was not a named executive officer for fiscal year 2016.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the fair value of the award computed as of the grant date of each stock award computed as of the grant date of each option award in accordance with FASB ASC Topic 718. Our
assumptions with respect to the calculation of these values are set forth in Note 13 of the consolidated financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31,
2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">The amounts in this column represent the aggregate fair value of the award computed as of the grant date of each option award in accordance with FASB ASC Topic 718. Our assumptions with respect to the calculation of
these values are set forth in Note 13 of the consolidated financial statements included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Represents amounts paid as a discretionary bonus to our executive officers, including our named executive officers, for their performance in 2017 as compared against the performance goals set in our Executive Incentive
Compensation Plan. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_39"></A><FONT STYLE="white-space:nowrap">Non-Equity</FONT> Incentive Plan Compensation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of our named executive officers is eligible for cash annual incentive payments. For&nbsp;2017, Dr.&nbsp;Maag had a target annual incentive of up to 70% of
his base salary. Dr.&nbsp;Yee was eligible for a target annual incentive of 40% of his base salary and Mr.&nbsp;Bell was eligible for a target annual incentive of 35% of his base salary. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of an incentive is based on our performance against certain key performance indicators. For&nbsp;2017, our key performance indicators included growing
AlloMap and Olerup; launching AlloSure; sales, gross margin and general and administrative cost targets; partnering; expanding the Company&#146;s pipeline and retaining developing and attracting top talent. We measure our actual performance against
our budgeted goals, and then determine an incentive payout. For fiscal year 2017, our executive officers were awarded between 75% and 120% of the target annual bonus amounts, and our NEOs were specifically awarded the following percentages of their
target annual bonus amounts: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Maag: 120%; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Yee: 120%; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Bell: 130%. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_40"></A>Employment Agreements for Named Executive Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Peter Maag, Ph.D. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into a Chief
Executive Employment Agreement with Dr.&nbsp;Maag, dated September&nbsp;19, 2012, under which Dr.&nbsp;Maag serves as our President and Chief Executive Officer. The agreement provides for <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT>
employment and sets forth certain agreed upon terms and conditions of employment. During fiscal year 2017, Dr.&nbsp;Maag&#146;s annual base salary was $450,000, which was increased to $495,000 effective April&nbsp;1, 2018. He is currently eligible
for a target annual bonus of up to&nbsp;70% of his base salary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>James P. Yee, M.D., Ph.D. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an offer letter with Dr.&nbsp;Yee, dated July&nbsp;31, 2006, under which Dr.&nbsp;Yee serves as our Chief Medical Officer. The agreement
provides for <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employment and sets forth certain agreed upon terms and conditions of employment. During fiscal year 2017, Dr.&nbsp;Yee&#146;s annual base salary was $385,000, which was
increased to $392,700 effective April&nbsp;1, 2018. He is currently eligible for a target annual bonus of up to&nbsp;40% of his base salary. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael Bell </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We entered into an offer letter with
Mr.&nbsp;Bell, dated April&nbsp;21, 2017, under which Mr.&nbsp;Bell serves as our Chief Financial Officer. The agreement provides for <FONT STYLE="white-space:nowrap">&#147;at-will&#148;</FONT> employment and sets forth certain agreed upon terms and
conditions of employment. During fiscal year 2017, Mr.&nbsp;Bell&#146;s annual base salary was $335,000, which was increased to $342,538 effective April&nbsp;1, 2018. He is currently eligible for a target annual bonus of up to&nbsp;45% of his base
salary. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_41"></A>Potential Payments and Benefits upon Termination or Change of Control for Officers </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Peter Maag, Ph.D. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;Maag&#146;s
Change of Control and Severance Agreement, dated May&nbsp;1, 2014, if within two months prior to, or twelve months following a change of control, we or our successor terminate Dr.&nbsp;Maag&#146;s employment without cause, Dr.&nbsp;Maag will be
entitled to (a)&nbsp;twelve months&#146; severance, (b)&nbsp;acceleration of vesting equal to&nbsp;100% of any unvested options, (c)&nbsp;a lump sum payment equal to Dr.&nbsp;Maag&#146;s annual bonus, and (d)&nbsp;twelve months of continued
benefits, <I>provided</I>,<I> that</I> such reimbursement will cease on the date that Dr.&nbsp;Maag becomes covered under a similar plan of a new employer. Pursuant to the agreement, if we or a successor terminate Dr.&nbsp;Maag&#146;s employment
without cause and such termination occurs outside of a change of control event, Dr.&nbsp;Maag will be entitled to (a)&nbsp;twelve months&#146; severance, and (b)&nbsp;twelve months of continued benefits, <I>provided</I>,<I> that</I> such
reimbursement will cease on the date that Dr.&nbsp;Maag becomes covered under a similar plan of a new employer. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>James P. Yee, M.D., Ph.D.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Dr.&nbsp;Yee&#146;s Change of Control and Severance Agreement, dated May&nbsp;1, 2014, if within two months prior to, or twelve months
following a change of control, we or our successor terminate Dr.&nbsp;Yee&#146;s employment without cause, Dr.&nbsp;Yee will be entitled to (a)&nbsp;twelve months&#146; severance, (b)&nbsp;acceleration of vesting equal to&nbsp;100% of any unvested
options, (c)&nbsp;a lump sum payment equal to Dr.&nbsp;Yee&#146;s annual bonus and (d)&nbsp;twelve months of continued benefits,<I> provided</I>,<I> that</I> such reimbursement will cease on the date that Dr.&nbsp;Yee becomes covered under a similar
plan of a new employer. Pursuant to the agreement, if we or a successor terminate Dr.&nbsp;Yee&#146;s employment without cause and such termination occurs outside of a change of control event, Dr.&nbsp;Yee will be entitled to (a)&nbsp;six
months&#146; severance, and (b)&nbsp;six months of continued benefits, <I>provided</I>,<I> that</I> such reimbursement will cease on the date that Dr.&nbsp;Yee becomes covered under a similar plan of a new employer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Michael Bell </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to Mr.&nbsp;Bell&#146;s Change of Control and Severance Agreement, dated April&nbsp;17, 2017, if within two months prior to, or twelve months
following a change of control, we or our successor terminate Mr.&nbsp;Bell&#146;s employment without cause, Mr.&nbsp;Bell will be entitled to (a)&nbsp;twelve months&#146; severance, (b)&nbsp;acceleration of vesting equal to&nbsp;100% of any unvested
options, (c)&nbsp;a lump sum payment equal to Mr.&nbsp;Bell&#146;s annual bonus and (d)&nbsp;twelve months of continued benefits,<I> provided</I>,<I> that</I> such reimbursement will cease on the date that Mr.&nbsp;Bell becomes covered under a
similar plan of a new employer. Pursuant to the agreement, if we or a successor terminate Mr.&nbsp;Bell&#146;s employment without cause and such termination occurs outside of a change of control event, Mr.&nbsp;Bell will be entitled to (a)&nbsp;six
months&#146; severance, and (b)&nbsp;six months of continued benefits, <I>provided</I>,<I> that</I> such reimbursement will cease on the date that Mr.&nbsp;Bell becomes covered under a similar plan of a new employer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of each of the foregoing change of control and severance agreements, &#147;cause&#148; means generally: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">executive&#146;s material failure to perform his stated duties after a notice of failure and a cure period of ten days; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">executive&#146;s material violation of our policies or any written agreement or covenant with us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">executive&#146;s conviction of, or entry of a plea of guilty or nolo contendere to, a felony; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a willful act by executive that constitutes gross misconduct and which is injurious to us; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">executive&#146;s commission of any act of fraud, embezzlement, dishonesty or any other willful misconduct that has caused or is reasonably expected to result in material injury to us; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the unauthorized use or disclosure by executive of any of our proprietary information or trade secrets or any other party to whom he owes an obligation of nondisclosure as a result of his relationship with us; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">executive&#146;s willful failure to cooperate with an investigation by a governmental authority. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4<A NAME="toc472342_42">
</A>01(k) Plan </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our retirement plan, which we refer to as the&nbsp;401(k) plan, is qualified under Section&nbsp;401 of the Code. Eligible employees,
including all of our full-time employees, may elect to reduce their current compensation by an amount no greater than the statutorily prescribed annual limit and may have that amount contributed to the&nbsp;401(k) plan. Matching contributions may be
made to the&nbsp;401(k) plan at the discretion of our Board of Directors. During 2017, we did not make any matching contributions to the&nbsp;401(k) plan. On January&nbsp;1, 2018, we began to make contributions to the 401(k) plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_43"></A>Outstanding Equity Awards at Fiscal
<FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table presents certain information concerning equity awards held by our executive
officers, including each of our named executive officers, as of December&nbsp;31, 2017. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD COLSPAN="4" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:20.00pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares or<BR>Units of<BR>Stock<BR>That Have<BR>Not<BR>Vested (#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Market<BR>Value of<BR>Shares of<BR>Stock<BR>That&nbsp;Have<BR>Not<BR>Vested ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Maag, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/17/2012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.548</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/17/2022</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/6/2015<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,667</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2016<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,547</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,203</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/17/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">02/17/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/1/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">09/01/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/27/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/27/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/09/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,316</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/09/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/6/2015<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,750</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2016<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,937</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116,978</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/17/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/27/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James P. Yee, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/8/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.699</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/8/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/27/2010</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8/27/2020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/6/2015<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.490</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/6/2025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2016<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/28/2016<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/28/2026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/17/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/17/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/1/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/9/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,453</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,906</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.49</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11/9/2024</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3/6/2015<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36,700</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1/22/2016<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,555</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2/17/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(16)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/27/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Bell</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/21/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(17)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4/21/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/1/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.80</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9/1/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/27/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/27/2027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10/27/2017<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">183,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">One quarter of the total shares vested on January&nbsp;21, 2016, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive&#146;s continued employment on each
applicable vesting date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">One quarter of the total shares vested on January&nbsp;22, 2017, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive&#146;s continued employment on each
applicable vesting date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Full grant amount is unvested as of December&nbsp;31, 2017. One quarter of the total shares vested on January&nbsp;27, 2018 and 1/48th of the shares subject to the option vested and will vest monthly thereafter.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Full grant amount is unvested as of December&nbsp;31, 2017. One half of the total shares vest on September&nbsp;1, 2018 and 1/72nd of the shares subject to the option will vest monthly thereafter. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Full grant amount is unvested as of December&nbsp;31, 2017. One quarter of the total shares vest on October&nbsp;20, 2018 and 1/48th of the shares subject to the option will vest monthly thereafter. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Options are scheduled to vest in three equal installments based upon the Company&#146;s achievement of certain
performance goals as follows: (i)&nbsp;one third of the options vest upon the Company&#146;s determination, which </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
has been reviewed by the Company&#146;s independent registered public accounting firm, that the Company has achieved $10&nbsp;million of total cumulative sales of AlloSure, its proprietary
next-generation sequencing-based test to detect donor-derived, cell-free DNA after transplantation, commencing November&nbsp;8, 2017, (ii) one third of the options vest upon the Company&#146;s determination, which has been reviewed by the
Company&#146;s independent registered public accounting firm, that the Company has achieved quarterly revenues of at least $18.75&nbsp;million for two consecutive fiscal quarters commencing after November&nbsp;8, 2017, and (iii)&nbsp;one third of
the options vest in the event the closing sales price of the Company&#146;s common stock is at or above $5.00 per share, as quoted by NASDAQ, for 10 consecutive trading days after November&nbsp;8, 2017. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">6,250 of the shares subject to this RSU award vested on January&nbsp;21, 2017. An additional 6,250 of the shares subject to this RSU award vested on January&nbsp;21, 2018 and 6,250 of the shares will vest on
January&nbsp;22, 2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">5,313 of the shares subject to this RSU award vested on January&nbsp;21, 2017. An additional 5,313 of the shares subject to this RSU award vested on January&nbsp;21, 2018, and 5,313 of the shares will vest on each of
January&nbsp;21, 2019 and January&nbsp;21, 2020. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Full grant amount is unvested as of December&nbsp;31, 2017. 4,500 of the shares subject to this RSU award will vest on January&nbsp;27, 2018. An additional 4,500 of the shares subject to this RSU award will on each of
January&nbsp;27, 2019, January&nbsp;27, 2020 and January&nbsp;27, 2021. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Full grant amount is unvested as of December&nbsp;31, 2017. The shares subject to this RSU vest upon such time that the Company&#146;s independent registered public accounting firm has determined, pursuant to a review
or audit of the Company&#146;s financial information or statements, that the Company has achieved more than $60.0&nbsp;million in revenue in 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">One quarter of the total shares vested on January&nbsp;21, 2016, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive&#146;s continued employment on each
applicable vesting date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">One quarter of the total shares vested on January&nbsp;22, 2017, and 1/48th of the shares subject to the option vested and will vest each month thereafter, subject to executive&#146;s continued employment on each
applicable vesting date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">One half of the total shares vested on September&nbsp;29, 2016 and 1/72nd of the shares subject to the option vested and will vest each month thereafter, subject to executive&#146;s continued employment on each
applicable vesting date. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">2,500 of the shares subject to this RSU award vested on January&nbsp;21, 2017. An additional 2,500 of the shares subject to this RSU award vested on January&nbsp;21, 2018 and 2,500 shares will vest on January&nbsp;22,
2019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top">2,750 of the shares subject to this RSU award vested on January&nbsp;21, 2017. An additional 2,750 of the shares subject to this RSU award vested on January&nbsp;21, 2018, and 2,750 of the shares will vest on each of
January&nbsp;21, 2019 and January&nbsp;21, 2020. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top">Full grant amount is unvested as of December&nbsp;31, 2017. 2,500 of the shares subject to this RSU award vested on January&nbsp;27, 2018. An additional 2,500 of the shares subject to this RSU award will on each of
January&nbsp;27, 2019, January&nbsp;27, 2020 and January&nbsp;27, 2021. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top">Full grant amount is unvested as of December&nbsp;31, 2017. One quarter of the total shares vest on April&nbsp;17, 2018, and 1/48th of the shares subject to the option will vest each month thereafter, subject to
executive&#146;s continued employment on each applicable vesting date. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_44"></A>Hedging and Pledging Policies </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our insider trading policy prohibits our directors, officers (including our executive officers), employees and agents, as well as their immediate family
members, from engaging in short sales of our securities and from engaging in transactions in publicly-traded options and other derivative securities with respect to our securities. This prohibition extends to any hedging or similar transactions
designed to decrease the risks associated with holding our securities. Our insider trading policy also prohibits certain individuals, including our directors and executive officers, from pledging our securities as collateral for loans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_45"></A>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March&nbsp;31, 2018 for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our current directors and nominees for director; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our named executive officers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our current directors and executive officers as a group; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person or group who beneficially owned more than&nbsp;5% of our common stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have determined
beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the
table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have based our calculation of the percentage of beneficial ownership on&nbsp;35,240,782 shares of our common stock outstanding as of March&nbsp;31, 2018.
We have deemed shares of our common stock subject to warrants or stock options that are currently exercisable or exercisable within&nbsp;60&nbsp;days of March&nbsp;31, 2018, or issuable pursuant to RSUs that are subject to vesting conditions
expected to occur within&nbsp;60&nbsp;days of March&nbsp;31, 2018, to be outstanding and to be beneficially owned by the person holding the warrants, stock option or RSUs for the purpose of computing the percentage ownership of that person. We did
not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated, the
address of each beneficial owner listed in the table below is c/o CareDx, Inc., 3260 Bayshore Blvd., Brisbane, CA&nbsp;94005. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:89.90pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Name of Beneficial Owner</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of<BR>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>5% Stockholders:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Gagnon Securities
LLC<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,199,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">FastPartner AB<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,130,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Midroc Invest AB<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,394,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B><I>Directors and Named Executive Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Maag, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">416,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James P. Yee, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Bell<SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">George W. Bickerstaff, III<SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,023</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fred E. Cohen, M.D., D. Phil<SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael D. Goldberg<SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">232,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William A. Hagstrom<SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Ralph Snyderman, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All current directors and executive officers as a group (11&nbsp;persons)<SUP
STYLE="font-size:85%; vertical-align:top">(12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,237,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Based on information reported on a Schedule 13G/A filed with the SEC on February&nbsp;13, 2018, this consists of
(i) 458,892 shares of common stock over which Neil Gagnon has sole voting and dispositive power, and (ii) 3,740,546 shares of common stock over which Mr.&nbsp;Gagnon has shared dispositive power. Mr.&nbsp;Gagnon is the managing member and principal
owner of Gagnon Securities LLC (&#147;GS&#148;), an investment adviser </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
registered with the SEC under the Investment Advisers Act of 1940, as amended (the &#147;Advisers Act&#148;), and a registered broker-dealer, in its role as investment manager to several customer
accounts, foundations, partnerships and trusts (collectively, the &#147;Accounts&#148;) to which it furnishes investment advice. Mr.&nbsp;Gagnon and GS may be deemed to share voting power with respect to 2,102,766 shares of Common Stock held in the
Accounts and dispositive power with respect to 2,388,964 shares of Common Stock held in the Accounts. Mr.&nbsp;Gagnon is also the Chief Executive Officer of Gagnon Advisors, LLC (&#147;Gagnon Advisors&#148;), an investment adviser registered with
the SEC under the Advisers Act. Mr.&nbsp;Gagnon and Gagnon Advisors, in its role as investment manager to Gagnon Investment Associates, LLC (&#147;GIA&#148;), a private investment fund, may be deemed to share voting and dispositive power with
respect to the 1,093,506 shares of Common Stock held by GIA. The address for each of these stockholders is&nbsp;1370 Ave. of the Americas, Suite&nbsp;2400, New York, NY&nbsp;10019. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Based on information reported on a Schedule 13G/A filed with the SEC on July&nbsp;7, 2017, this consists of (i) 1,751,046 shares of common stock, and (ii) 379,950 shares of common stock issuable upon exercise of
warrants. The address of FastPartner AB is Box 556 25, 102 14 Stockholm, Sweden. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Based on information reported on a Schedule 13G/A filed with the SEC on July&nbsp;7, 2017, this consists of (i) 1,967,436 shares of common stock, and (ii) 427,068 shares of common stock issuable upon exercise of
warrants. The address of Midroc Invest AB is P.O. Box 3002, <FONT STYLE="white-space:nowrap">SE-169</FONT> 03 Solna, Sweden. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Represents 217,487 shares of common stock held by Dr.&nbsp;Maag, 2,000 shares of common stock held by Dr.&nbsp;Maag as custodian for minor children under the Uniform Transfer to Minors Act and 197,013 shares subject to
options that are immediately exercisable or exercisable within&nbsp;60&nbsp;days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Represents 27,602 shares of common stock held by Dr.&nbsp;Yee and 81,279 shares subject to options that are immediately exercisable or exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Represents 725 shares of common stock held by Mr.&nbsp;Bell and 10,833 shares subject to options that are immediately exercisable or exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Represents 38,786 shares of common stock held by Mr.&nbsp;Bickerstaff and 40,237 shares subject to options that are immediately exercisable or exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Represents 27,901 shares of common stock held by Dr.&nbsp;Cohen and 40,237 shares subject to options that are immediately exercisable or exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Represents 117,865 shares of common stock held by Mr.&nbsp;Goldberg and 115,020 shares subject to options that are immediately exercisable or exercisable within 60 days of March&nbsp;31, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Represents 28,159 shares of common stock held by Mr.&nbsp;Hagstrom and 43,703 shares subject to options that are immediately exercisable or exercisable within&nbsp;60&nbsp;days of March&nbsp;31, 2018. </TD></TR></TABLE>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Represents 56,578 shares of common stock held by Dr.&nbsp;Snyderman, and 54,835 shares subject to options that are immediately exercisable or exercisable within&nbsp;60&nbsp;days of March&nbsp;31, 2018.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Comprised of shares included under &#147;Directors and Named Executive Officers&#148;, 57,745 shares of common stock owned directly by our other executive officers, 2,500 shares of common stock subject RSUs that will
vest within 60 days of March&nbsp;31, 2018 owned directly by one of our other executive officers and options to purchase an aggregate of 76,535 shares of common stock held by our other executive officers that are immediately exercisable or
exercisable within&nbsp;60&nbsp;days of March&nbsp;31, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_46"></A>RELATED PERSON TRANSACTIONS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a description of transactions or series of transactions since January&nbsp;1, 2017, or any currently proposed transaction, to which we were
or are to be a participant in which the amount involved in the transaction or series of transactions exceeds $120,000, and in which any of our directors, executive officers or persons who we know held more than five percent of any class of our
capital stock, including their immediate family members, had or will have a direct or indirect material interest, other than compensation arrangements that are described under &#147;Executive Compensation&#148; above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_47"></A>Conditional Share Purchase Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;14, 2016, we acquired 98.3% of the outstanding common stock of CareDx International AB. Under certain Conditional Share Purchase Agreements
entered into on December&nbsp;16, 2015, as amended (the &#147;Conditional Share Purchase Agreements&#148;), and the tender offer prospectus dated March&nbsp;7, 2016, and as a result of the tender offer, the aggregate purchase consideration paid by
us was approximately $34.1&nbsp;million and consisted of (i) $26.9&nbsp;million of cash, of which $5.7&nbsp;million (which represents SEK 50,620,000 as of the acquisition date) was deferred purchase consideration originally payable to the Midroc
Invest AB, FastPartner AB and Xenella Holding AB, the former majority shareholders of CareDx International AB (the &#147;Majority Shareholders&#148;), by no later than March&nbsp;31, 2017, subject to certain contingencies being met, and
(ii)&nbsp;the issuance of 1,375,029 shares of our common stock valued at $7.2&nbsp;million. The date by which the deferred purchase consideration was due to the Majority Shareholders was subsequently extended to July&nbsp;1, 2017. In addition,
interest began accruing on our obligations to the Majority Shareholders at a rate of 10.0% per year commencing on January&nbsp;1, 2017 and continued to accrue until the date the obligations were paid in full. Of the total cash consideration,
$8.0&nbsp;million of cash payable to the Majority Shareholders was deposited into an escrow account by us and subsequently invested in us by the Majority Shareholders through a purchase of our equity securities in a subsequent financing and
purchasing an aggregate amount of $8&nbsp;million worth of units comprised of common stock, preferred stock and warrants. Upon the completion of the Subsequent Financing, certain contingencies in the Conditional Share Purchase Agreements were
waived, and the deferred purchase consideration was due to the Majority Shareholders by no later than July&nbsp;1, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2017, we entered
into amendments to the Conditional Share Purchase Agreements with the Former Majority Shareholders, pursuant to which, among other things, we agreed (i)&nbsp;to immediately convert approximately $1.1&nbsp;million of the $6.3&nbsp;million deferred
purchase consideration owed by us to the Former Majority Shareholders under the Conditional Share Purchase Agreements (the &#147;Deferred Obligation&#148;), into 1,022,544 shares of our common stock at a per share price equal to $1.12; (ii) to make
an immediate cash payment of $0.5&nbsp;million; (iii)&nbsp;to extend the maturity date of a portion of the obligations, totaling approximately $2.9&nbsp;million, under the Conditional Share Purchase Agreements to March&nbsp;31, 2019, and
(iv)&nbsp;that approximately $2.1&nbsp;million of the Deferred Obligation would become payable on December&nbsp;31, 2017, unless earlier converted into 1,791,762 shares of common stock prior to that date, of which issuance of shares was subject to
approval by our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On November&nbsp;14, 2017, we entered into amendments to the Conditional Share Purchase Agreement with the Former Majority
Shareholders, whereby we immediately repaid the total remaining deferred purchase consideration of $4.7&nbsp;
million, plus accrued interest. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_48"></A>CareDx International AB Subordinated Promissory Notes </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>FastPartner Subordinated Promissory Notes </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
June&nbsp;28, 2013, CareDx International AB issued a SEK 9,400,000 (approximately $1.0&nbsp;million in U.S. dollars) subordinated promissory note to FastPartner AB (&#147;FastPartner&#148;), a related party, which had an interest rate of 10.00%. On
December&nbsp;29, 2015, CareDx International AB issued a SEK 2,000,000 (approximately $0.2&nbsp;million </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in U.S. dollars) subordinated promissory note to FastPartner, which had an annual interest rate of 10.0%. On March&nbsp;7, 2016, CareDx International AB issued a SEK 4,000,000 (approximately
$0.4&nbsp;million in U.S. dollars) subordinated promissory note to FastPartner, which had an annual interest rate of 10.0%. Pursuant to an intercreditor agreement among CareDx International AB, Danske Bank A/B (&#147;Danske&#148;), FastPartner AB,
Mohammed Al Amoudi and Olerup SSP AB, dated June&nbsp;25, 2013 (the &#147;Intercreditor Agreement&#148;), until CareDx International AB&#146;s term loan facility with Danske (the &#147;Term Loan Facility&#148;) was repaid, FastPartner was not
permitted demand or receive payment of its subordinated promissory notes, or foreclose on any collateral securing CareDx International AB&#146;s obligations under the subordinated promissory notes, without Danske&#146;s prior written consent. CareDx
International AB&#146;s obligations under the promissory notes were secured by a pledge of CareDx International AB shares to FastPartner. The full amounts of subordinated promissory notes were outstanding as of December&nbsp;31, 2016 and were due
July&nbsp;1, 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;1, 2017, CareDx International AB entered into a new note agreement with FastPartner, pursuant to which the parties agreed
to defer repayment of the amounts owed under the notes described above until March&nbsp;31, 2019. Pursuant to the terms of the new note agreement, as of December&nbsp;31, 2017, we owed principal totaling SEK 19,757,000, or approximately
$2.4&nbsp;million in U.S. dollars. FastPartner is also a stockholder of the Company and is considered a related party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;17, 2018, the
Company entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings II, LP (&#147;Perceptive&#148;), pursuant to which Perceptive provided the Company with an initial term loan of $15.0&nbsp;million, with a second tranche of
$10.0&nbsp;million available at the Company&#146;s option, subject to the satisfaction of customary conditions. The Company used a portion of the proceeds from the Perceptive term loan to, among other things, repay the amounts due to FastPartner on
April&nbsp;17, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Mohammed Al Amoudi Subordinated Promissory Note </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;28, 2013, CareDx International AB issued a SEK 10,600,000 (approximately $1.2&nbsp;million in U.S. dollars) subordinated promissory note to
Mohammed Al Amoudi, which provides for an annual interest rate of 10.0%. Principal payments of SEK 1,000,000 (approximately $0.1&nbsp;million in U.S. dollars) and accrued interest are payable quarterly at September&nbsp;30, December&nbsp;31,
March&nbsp;31 and June&nbsp;30, subject to meeting certain requirements for working capital. The promissory note had an initial maturity date of June&nbsp;28, 2016. On December&nbsp;31, 2016, the maturity date was extended until July&nbsp;1, 2017.
However, pursuant to the Intercreditor Agreement, until the Term Loan Facility with Danske was repaid, Mohammed Al Amoudi was not permitted to demand or receive payment of his subordinated promissory note, or foreclose on any collateral securing
CareDx International AB&#146;s obligations under the subordinated promissory note, without Danske&#146;s prior written consent. CareDx International AB&#146;s obligations under the promissory note were secured by a pledge of CareDx International AB
shares to Mohammed Al Amoudi. On July&nbsp;1, 2017, CareDx International AB entered into a new note agreement with Mohammed Al Amoudi, pursuant to which the parties agreed to defer repayment of the amounts owed under the note until March&nbsp;31,
2019. Pursuant to the terms of the new note agreement, as of December&nbsp;31, 2017, we owed principal totaling SEK 14,575,000, or approximately $1.8&nbsp;million in U.S. dollars. Mohammed Al Amoudi is also a stockholder of the Company and is
considered a related party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company used a portion of the proceeds from the Perceptive term loan to, among other things, repay the amounts due to
Mohammed Al Amoudi on April&nbsp;17, 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_49"></A>Investors&#146; Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to an investors&#146; rights agreement which provides, among other things, that certain holders of our common stock have the right to demand that
we file a registration statement or request that their shares of our common stock be covered by a registration statement that we are otherwise filing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_50"></A>Indemnification Agreements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have also entered into indemnification agreements with our directors and certain of our executive officers. The indemnification agreements and our
certificate of incorporation and amended and restated bylaws require us to indemnify our directors and officers to the fullest extent permitted by Delaware law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_51"></A>Policies and Procedures for Related Party Transactions </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee adopted a formal written policy that our Audit Committee is responsible for reviewing &#147;related party transactions.&#148; A
&#147;related person transaction&#148; is a transaction, arrangement, or relationship in which we (including any of our subsidiaries) and any &#147;related person&#148; were, are, or will be participants involving an amount that exceeds $120,000.
For purposes of this policy, a related person is defined as a director, nominee for director, executive officer, or greater than&nbsp;5% beneficial owner of our common stock and their immediate family members, any entity in which such person is
employed or is a general partner or principal and any entity where such person has a&nbsp;5% or greater beneficial ownership interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under this policy,
all related party transactions may be consummated or continued only if approved or ratified by our Audit Committee. In determining whether to approve or ratify any such proposal, our Audit Committee will take into account, among other factors it
deems appropriate, (a)&nbsp;whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances, and (b)&nbsp;the extent of the related party&#146;s interest in
the transaction. The policy grants standing <FONT STYLE="white-space:nowrap">pre-approval</FONT> of certain transactions, including (1)&nbsp;certain compensation arrangements of executive officers, (2)&nbsp;certain director compensation
arrangements, (3)&nbsp;transactions with another company at which a related party&#146;s only relationship is as a <FONT STYLE="white-space:nowrap">non-executive</FONT> employee, director or beneficial owner of less than&nbsp;5% of that
company&#146;s shares, (4)&nbsp;transactions where a related party&#146;s interest arises solely from the ownership of our common stock and all holders of our common stock received the same benefit on a pro rata basis, and (5)&nbsp;transactions
available to all U.S.&nbsp;employees generally. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc472342_52"></A>OTHER MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_53"></A>Section&nbsp;16(a) Beneficial Ownership Reporting Compliance </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;16(a) of the Exchange Act requires that our executive officers and directors, and persons who own more than&nbsp;10% of our common stock, file
reports of ownership and changes of ownership with the SEC. Such directors, executive officers and&nbsp;10% stockholders are required by SEC regulation to furnish us with copies of all Section&nbsp;16(a) forms they file. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEC regulations require us to identify in this proxy statement anyone who failed to file a timely required report during the most recent fiscal year. Based
solely upon our review of forms we received, or written representations from reporting persons stating that they were not required to file these forms, we believe that during our fiscal year ended December&nbsp;31, 2017, all Section&nbsp;16(a)
filing requirements were satisfied on a timely basis except for one Form 4 for Neil Gagnon which was due on January&nbsp;24, 2017, but was inadvertently filed late on March&nbsp;20, 2017. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_54"></A>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
financial statements for our fiscal year ended December&nbsp;31, 2017 are included in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2017. This proxy statement and our annual report
are posted on the Investor Relations section of our website at investors.caredxinc.com and are available from the SEC at its website at www.sec.gov. You may also obtain a copy of our annual report without charge by sending a written request to
CareDx, Inc., Attention: Investor Relations, 3260 Bayshore Blvd., Brisbane, California&nbsp;94005. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><A NAME="toc472342_55"></A>Company Website </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a website at www.caredx.com. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference
into this proxy statement, and references to our website address in this proxy statement are inactive textual references only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>* * *
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board of Directors does not know of any other matters to be presented at the Annual Meeting. If any additional matters are properly presented at
the Annual Meeting, the persons named on the enclosed proxy card will have discretion to vote the shares of common stock they represent in accordance with their own judgment on such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">It is important that your shares of common stock be represented at the Annual Meeting, regardless of the number of shares that you hold. You are, therefore,
urged to vote over the Internet or by telephone as instructed on the proxy card or execute and return, at your earliest convenience, the proxy card. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="30%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><B>THE BOARD OF DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Brisbane, California</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">April&nbsp;30, 2018</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPENDIX A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CAREDX, INC. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>2014
EQUITY INCENTIVE PLAN </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <U>Purposes of the Plan</U>. The purposes of this Plan are: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to attract and retain the best available personnel for positions of substantial responsibility, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to provide additional incentive to Employees, Directors and Consultants, and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to promote the success of the Company&#146;s business. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Plan permits the grant of
Incentive Stock Options, Nonstatutory Stock Options, Restricted Stock, Restricted Stock Units, Stock Appreciation Rights, Performance Units and Performance Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <U>Definitions</U>.<U> </U>As used herein, the following definitions will apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<U>Administrator</U>&#148; means the Board or any of its Committees as will be administering the Plan, in accordance with
Section&nbsp;4 of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<U>Applicable Laws</U>&#148; means the requirements relating to the administration of equity-based
awards under U.S.&nbsp;state corporate laws, U.S.&nbsp;federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any foreign country or jurisdiction
where Awards are, or will be, granted under the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<U>Award</U>&#148; means, individually or collectively, a grant under the
Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
&#147;<U>Award Agreement</U>&#148; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan. The Award Agreement is subject to the terms and conditions of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<U>Board</U>&#148; means the Board of Directors of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<U>Change in Control</U>&#148; means the occurrence of any of the following events: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group
(&#147;<U>Person</U>&#148;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%)&nbsp;of the total voting power of the stock of the Company; provided, however,
that for purposes of this subsection, the acquisition of additional stock by any one Person, who is considered to own more than fifty percent (50%)&nbsp;of the total voting power of the stock of the Company will not be considered a Change in
Control; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) A change in the effective control of the Company which occurs on the date that a majority of members of the Board is
replaced during any twelve (12)&nbsp;month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of this clause&nbsp;(ii), if any
Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) A change in the ownership of a substantial portion of the Company&#146;s assets which occurs on the date that any Person acquires (or
has acquired during the twelve (12)&nbsp;month period ending on the date of the most </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%)&nbsp;of the total gross fair market value
of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subsection&nbsp;(iii), the following will not constitute a change in the ownership of a substantial portion of
the Company&#146;s assets: (A)&nbsp;a transfer to an entity that is controlled by the Company&#146;s stockholders immediately after the transfer, or (B)&nbsp;a transfer of assets by the Company to: (1)&nbsp;a stockholder of the Company (immediately
before the asset transfer) in exchange for or with respect to the Company&#146;s stock, (2)&nbsp;an entity, fifty percent (50%)&nbsp;or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (3)&nbsp;a
Person, that owns, directly or indirectly, fifty percent (50%)&nbsp;or more of the total value or voting power of all the outstanding stock of the Company, or (4)&nbsp;an entity, at least fifty percent (50%)&nbsp;of the total value or voting power
of which is owned, directly or indirectly, by a Person described in this subsection&nbsp;(iii)(B)(3). For purposes of this subsection&nbsp;(iii), gross fair market value means the value of the assets of the Company, or the value of the assets being
disposed of, determined without regard to any liabilities associated with such assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this definition, persons will be
considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control
event within the meaning of Code Section&nbsp;409A, as it has been and may be amended from time to time, and any proposed or final Treasury Regulations and Internal Revenue Service guidance that has been promulgated or may be promulgated thereunder
from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (i)&nbsp;its sole
purpose is to change the state of the Company&#146;s incorporation, or (ii)&nbsp;its sole purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#146;s securities
immediately before such transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<U>Code</U>&#148; means the Internal Revenue Code of&nbsp;1986, as amended. Reference to a
specific section of the Code or regulation thereunder will include such section or regulation, any valid regulation promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or
superseding such section or regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) &#147;<U>Committee</U>&#148; means a committee of Directors or of other individuals
satisfying Applicable Laws appointed by the Board, or a duly authorized committee of the Board, in accordance with Section&nbsp;4 hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<U>Common Stock</U>&#148; means the common stock of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<U>Company</U>&#148; means CareDx, Inc., a Delaware corporation, or any successor thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<U>Consultant</U>&#148; means any natural person, including an advisor, engaged by the Company or a Parent or Subsidiary to render
bona fide services to such entity, provided the services (i)&nbsp;are not in connection with the offer or sale of securities in a capital-raising transaction, and (ii)&nbsp;do not directly promote or maintain a market for the Company&#146;s
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<U>Director</U>&#148; means a member of the Board. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;<U>Disability</U>&#148; means total and permanent disability as defined in Section&nbsp;22(e)(3) of the Code, provided that in the
case of Awards other than Incentive Stock Options, the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and <FONT STYLE="white-space:nowrap">non-discriminatory</FONT> standards
adopted by the Administrator from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) &#147;<U>Employee</U>&#148; means any person, including Officers and Directors, employed
by the Company or any Parent or Subsidiary of the Company. Neither service as a Director nor payment of a director&#146;s fee by the Company will be sufficient to constitute &#147;employment&#148; by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) &#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of&nbsp;1934, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) &#147;<U>Exchange Program</U>&#148; means a program under which (i)&nbsp;outstanding Awards are surrendered or cancelled in exchange for
awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash, (ii)&nbsp;Participants would have the opportunity to transfer any outstanding Awards to a financial institution or
other person or entity selected by the Administrator, and/or (iii)&nbsp;the exercise price of an outstanding Award is increased or reduced. The Administrator will determine the terms and conditions of any Exchange Program in its sole discretion.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) &#147;<U>Fair Market Value</U>&#148; means, as of any date, the value of Common Stock determined as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) If the Common Stock is listed on any established stock exchange or a national market system, including without limitation the New York
Stock Exchange, the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ Capital Market of The NASDAQ Stock Market, its Fair Market Value will be the closing sales price for such stock (or the closing bid, if no sales were reported)
as quoted on such exchange or system on the day of determination, as reported in <I>The Wall Street Journal</I> or such other source as the Administrator deems reliable; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a
Share will be the mean between the high bid and low asked prices for the Common Stock on the date of determination (or, if no bids and asks were reported on that date, as applicable, on the last trading date such bids and asks were reported), as
reported in <I>The Wall Street Journal</I> or such other source as the Administrator deems reliable; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) For purposes of any Awards
granted on the Registration Date, the Fair Market Value will be the initial price to the public as set forth in the final prospectus included within the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-1</FONT> filed with the
Securities and Exchange Commission for the initial public offering of the Common Stock; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) In the absence of an established market
for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) &#147;<U>Fiscal Year</U>&#148;
means the fiscal year of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) &#147;<U>Incentive Stock Option</U>&#148; means an Option that by its terms qualifies and is
intended to qualify as an incentive stock option within the meaning of Section&nbsp;422 of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) &#147;<U>Inside
Director</U>&#148; means a Director who is an Employee. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) &#147;<U>Nonstatutory Stock Option</U>&#148; means an Option that by its
terms does not qualify or is not intended to qualify as an Incentive Stock Option. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) &#147;<U>Officer</U>&#148; means a person who is
an officer of the Company within the meaning of Section&nbsp;16 of the Exchange Act and the rules and regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) &#147;<U>Option</U>&#148; means a stock option granted pursuant to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) &#147;<U>Outside Director</U>&#148; means a Director who is not an Employee. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) &#147;<U>Parent</U>&#148; means a &#147;parent corporation,&#148; whether now or hereafter existing, as defined in Section&nbsp;424(e) of
the Code. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) &#147;<U>Participant</U>&#148; means the holder of an outstanding Award. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) &#147;<U>Performance Share</U>&#148; means an Award denominated in Shares which may be earned in whole or in part upon attainment of
performance goals or other vesting criteria as the Administrator may determine pursuant to Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) &#147;<U>Performance
Unit</U>&#148; means an Award which may be earned in whole or in part upon attainment of performance goals or other vesting criteria as the Administrator may determine and which may be settled for cash, Shares or other securities or a combination of
the foregoing pursuant to Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) &#147;<U>Period of Restriction</U>&#148; means the period during which the transfer of
Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture. Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the
occurrence of other events as determined by the Administrator. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) &#147;<U>Plan</U>&#148; means this&nbsp;2014 Equity Incentive Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) &#147;<U>Registration Date</U>&#148; means the effective date of the first registration statement that is filed by the Company and
declared effective pursuant to Section&nbsp;12(g) of the Exchange Act, with respect to any class of the Company&#146;s securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)
&#147;<U>Restricted Stock</U>&#148; means Shares issued pursuant to a Restricted Stock award under Section&nbsp;7 of the Plan, or issued pursuant to the early exercise of an Option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) &#147;<U>Restricted Stock Unit</U>&#148; means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share,
granted pursuant to Section&nbsp;8. Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)
&#147;<U>Rule</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;16b-3</FONT></U>&#148; means <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3</FONT> of the Exchange Act or any successor to <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3,</FONT>
as in effect when discretion is being exercised with respect to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) &#147;<U>Section</U><U></U><U>&nbsp;16(b)</U>&#148; means
Section&nbsp;16(b) of the Exchange Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) &#147;<U>Service Provider</U>&#148; means an Employee, Director or Consultant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) &#147;<U>Share</U>&#148; means a share of the Common Stock, as adjusted in accordance with Section&nbsp;14 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) &#147;<U>Stock Appreciation Right</U>&#148; means an Award, granted alone or in connection with an Option, that pursuant to
Section&nbsp;9 is designated as a Stock Appreciation Right. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) &#147;<U>Subsidiary</U>&#148; means a &#147;subsidiary
corporation,&#148; whether now or hereafter existing, as defined in Section&nbsp;424(f) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <U>Stock Subject to the Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Subject to the Plan</U>.<U> </U>Subject to the provisions of Section&nbsp;14 of the Plan, the maximum aggregate number of Shares
that may be issued under the Plan is 3,866,995 Shares, plus the sum of (i)&nbsp;any Shares that, as of the Registration Date, have been reserved but not issued pursuant to any awards granted under the Company&#146;s&nbsp;2008 Equity Incentive Plan
(the &#147;<U>Existing Plan</U>&#148;) and are not subject to any awards granted thereunder, and (ii)&nbsp;any Shares subject to stock options or similar awards granted under the Existing Plan that, on or after the Registration Date, expire or
otherwise terminate without having been exercised in full and Shares issued pursuant to awards granted under the Existing Plan that are forfeited to or repurchased by the Company, with the maximum number of Shares to be added to the Plan from
previously granted awards under the Existing Plan equal to&nbsp;865,252. The Shares may be authorized, but unissued, or reacquired Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Automatic Share Reserve Increase</U>. Subject to the provisions of Section&nbsp;14 of
the Plan, the number of Shares available for issuance under the Plan will be increased on the first day of each Fiscal Year beginning with the&nbsp;2015 Fiscal Year, in an amount equal to the least of (i)&nbsp;four percent (4%)&nbsp;of the
outstanding Shares on the last day of the immediately preceding Fiscal Year or (ii)&nbsp;such number of Shares determined by the Board; provided, however, that such determination under clause&nbsp;(ii) will be made no later than the last day of the
immediately preceding Fiscal Year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Lapsed Awards</U>. If an Award expires or becomes unexercisable without having been exercised
in full, is surrendered pursuant to an Exchange Program, or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares, is forfeited to, or repurchased by, the Company due to failure to vest, then the
unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or repurchased Shares), which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated). With
respect to Stock Appreciation Rights, only Shares actually issued (i.e., the net Shares issued) pursuant to a Stock Appreciation Right will cease to be available under the Plan; all remaining Shares under Stock Appreciation Rights will remain
available for future grant or sale under the Plan (unless the Plan has terminated). Shares that actually have been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution under the
Plan; provided, however, that if Shares issued pursuant to Awards of Restricted Stock, Restricted Stock Units, Performance Shares or Performance Units are repurchased by the Company or are forfeited to the Company, such Shares will become available
for future grant under the Plan. Shares used to pay the exercise price of an Award or to satisfy the tax withholding obligations related to an Award will become available for future grant or sale under the Plan. To the extent an Award under the Plan
is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan. Notwithstanding the foregoing and, subject to adjustment as provided in Section&nbsp;14, the maximum
number of Shares that may be issued upon the exercise of Incentive Stock Options will be 5,000,000 Shares, plus, to the extent allowable under Section&nbsp;422 of the Code, any Shares that become available for issuance under the Plan pursuant to
this Section&nbsp;3(c). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Share Reserve</U>. The Company, during the term of this Plan, will at all times reserve and keep available
such number of Shares as will be sufficient to satisfy the requirements of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <U>Administration of the Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Procedure</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i)
<U>Multiple Administrative Bodies</U>. Different Committees with respect to different groups of Service Providers may administer the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <U>Section</U><U></U><U>&nbsp;162(m)</U>. To the extent that the Administrator determines it to be desirable to qualify Awards granted
hereunder as &#147;performance-based compensation&#148; within the meaning of Section&nbsp;162(m) of the Code, the Plan will be administered by a Committee of two (2)&nbsp;or more &#147;outside directors&#148; within the meaning of
Section&nbsp;162(m) of the Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <U>Rule</U><U></U><U><FONT STYLE="white-space:nowrap">&nbsp;16b-3</FONT></U>. To the extent
desirable to qualify transactions hereunder as exempt under <FONT STYLE="white-space:nowrap">Rule&nbsp;16b-3,</FONT> the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under <FONT
STYLE="white-space:nowrap">Rule&nbsp;16b-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) <U>Other Administration</U>. Other than as provided above, the Plan will be
administered by (A)&nbsp;the Board or (B)&nbsp;a Committee, which committee will be constituted to satisfy Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Powers
of the Administrator</U>. Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) to determine the Fair Market Value; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) to select the Service Providers to whom Awards may be granted hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) to determine the number of Shares to be covered by each Award granted hereunder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) to approve forms of Award Agreements for use under the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(v) to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder. Such terms and
conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or
limitation regarding any Award or the Shares relating thereto, based in each case on such factors as the Administrator will determine; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vi) to institute and determine the terms and conditions of an Exchange Program; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(vii) to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(viii) to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to <FONT
STYLE="white-space:nowrap">sub-plans</FONT> established for the purpose of satisfying applicable foreign laws or for qualifying for favorable tax treatment under applicable foreign laws; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ix) to modify or amend each Award (subject to Section&nbsp;19 of the Plan), including but not limited to the discretionary authority to
extend the post-termination exercisability period of Awards and to extend the maximum term of an Option (subject to Section&nbsp;6(b) of the Plan regarding Incentive Stock Options); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(x) to allow Participants to satisfy tax withholding obligations in such manner as prescribed in Section&nbsp;15 of the Plan; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xi) to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by
the Administrator; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xii) to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise
would be due to such Participant under an Award; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(xiii) to make all other determinations deemed necessary or advisable for
administering the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Effect of Administrator&#146;s Decision</U>. The Administrator&#146;s decisions, determinations and
interpretations will be final and binding on all Participants and any other holders of Awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <U>Eligibility</U>. Nonstatutory Stock Options, Stock
Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units may be granted to Service Providers. Incentive Stock Options may be granted only to Employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <U>Stock Options</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Limitations</U>. Each Option will be designated in the Award Agreement as either an Incentive Stock Option or a Nonstatutory Stock Option. However, notwithstanding such designation, to the extent that the aggregate Fair Market Value of the Shares
with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year (under all plans of the Company and any Parent or Subsidiary) exceeds one hundred thousand dollars ($100,000), such Options
will be treated as Nonstatutory Stock Options. For purposes of this Section&nbsp;6(a), Incentive Stock Options will be taken into account in the order in which they were granted. The Fair Market Value of the Shares will be determined as of the time
the Option with respect to such Shares is granted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Term of Option</U>. The term of each Option will be stated in the Award Agreement. In
the case of an Incentive Stock Option, the term will be ten (10)&nbsp;years from the date of grant or such shorter term as may be provided in the Award Agreement. Moreover, in the case of an Incentive Stock Option granted to a Participant who, at
the time the Incentive Stock Option is granted, owns stock representing more than ten percent (10%)&nbsp;of the total combined voting power of all classes of stock of the Company or any Parent or Subsidiary, the term of the Incentive Stock Option
will be five (5)&nbsp;years from the date of grant or such shorter term as may be provided in the Award Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Option Exercise
Price and Consideration</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Exercise Price</U>. The per share exercise price for the Shares to be issued pursuant to exercise of
an Option will be determined by the Administrator, subject to the following: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(1) In the case of an Incentive Stock Option </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(A) granted to an Employee who, at the time the Incentive Stock Option is granted, owns stock representing more than ten percent
(10%)&nbsp;of the voting power of all classes of stock of the Company or any Parent or Subsidiary, the per Share exercise price will be no less than one hundred ten percent (110%)&nbsp;of the Fair Market Value per Share on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(B) granted to any Employee other than an Employee described in paragraph&nbsp;(A) immediately above, the per Share exercise price will be no
less than one hundred percent (100%)&nbsp;of the Fair Market Value per Share on the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(2) In the case of a Nonstatutory
Stock Option, the per Share exercise price will be no less than one hundred percent (100%)&nbsp;of the Fair Market Value per Share on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(3) Notwithstanding the foregoing, Options may be granted with a per Share exercise price of less than one hundred percent (100%)&nbsp;of the
Fair Market Value per Share on the date of grant pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the Code. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <U>Waiting Period and Exercise Dates</U>. At the time an Option is granted, the Administrator will fix the period within which the Option
may be exercised and will determine any conditions that must be satisfied before the Option may be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <U>Form of
Consideration</U>. The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment. In the case of an Incentive Stock Option, the Administrator will determine the acceptable form of
consideration at the time of grant. Such consideration may consist entirely of: (1)&nbsp;cash; (2)&nbsp;check; (3)&nbsp;promissory note, to the extent permitted by Applicable Laws, (4)&nbsp;other Shares, provided that such Shares have a Fair Market
Value on the date of surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided that accepting such Shares will not result in any adverse accounting consequences to the Company, as the
Administrator determines in its sole discretion; (5)&nbsp;consideration received by the Company under a broker-assisted (or other) cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the
Plan; (6)&nbsp;by net exercise; (7)&nbsp;such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws; or (8)&nbsp;any combination of the foregoing methods of payment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Exercise of Option</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) <U>Procedure for Exercise; Rights as a Stockholder</U>. Any Option granted hereunder will be exercisable according to the terms of the
Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement. An Option may not be exercised for a fraction of a Share. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">An Option will be deemed exercised when the Company receives: (i)&nbsp;a notice of exercise
(in such form as the Administrator may specify from time to time) from the person entitled to exercise the Option, and (ii)&nbsp;full payment for the Shares with respect to which the Option is exercised (together with applicable withholding taxes).
Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan. Shares issued upon exercise of an Option will be issued in the name of the Participant or, if
requested by the Participant, in the name of the Participant and his or her spouse. Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to
vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option. The Company will issue (or cause to be issued) such Shares promptly after the
Option is exercised. No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section&nbsp;14 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under
the Option, by the number of Shares as to which the Option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) <U>Termination of Relationship as a Service Provider</U>.
If a Participant ceases to be a Service Provider, other than upon the Participant&#146;s termination as the result of the Participant&#146;s death or Disability, the Participant may exercise his or her Option within such period of time as is
specified in the Award Agreement to the extent that the Option is vested on the date of termination (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the
Award Agreement, the Option will remain exercisable for three (3)&nbsp;months following the Participant&#146;s termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her
entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan. If after termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and
the Shares covered by such Option will revert to the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iii) <U>Disability of Participant</U>. If a Participant ceases to be a
Service Provider as a result of the Participant&#146;s Disability, the Participant may exercise his or her Option within such period of time as is specified in the Award Agreement to the extent the Option is vested on the date of termination (but in
no event later than the expiration of the term of such Option as set forth in the Award Agreement). In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12)&nbsp;months following the
Participant&#146;s termination. Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the
Plan. If after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(iv) <U>Death of Participant</U>. If a Participant dies while a Service Provider, the Option may be exercised following the Participant&#146;s
death within such period of time as is specified in the Award Agreement to the extent that the Option is vested on the date of death (but in no event may the option be exercised later than the expiration of the term of such Option as set forth in
the Award Agreement), by the Participant&#146;s designated beneficiary, provided such beneficiary has been designated prior to Participant&#146;s death in a form acceptable to the Administrator. If no such beneficiary has been designated by the
Participant, then such Option may be exercised by the personal representative of the Participant&#146;s estate or by the person(s) to whom the Option is transferred pursuant to the Participant&#146;s will or in accordance with the laws of descent
and distribution. In the absence of a specified time in the Award Agreement, the Option will remain exercisable for twelve (12)&nbsp;months following Participant&#146;s death. Unless otherwise provided by the Administrator, if at the time of death
Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will immediately revert to the Plan. If the Option is not so exercised within the time specified herein, the Option will terminate,
and the Shares covered by such Option will revert to the Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <U>Restricted Stock</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Grant of Restricted Stock</U>. Subject to the terms and provisions of the Plan, the Administrator, at any time and from time to time,
may grant Shares of Restricted Stock to Service Providers in such amounts as the Administrator, in its sole discretion, will determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Restricted Stock Agreement</U>. Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of
Restriction, the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine. Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted
Stock until the restrictions on such Shares have lapsed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Transferability</U>. Except as provided in this Section&nbsp;7 or the
Award Agreement, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Other Restrictions</U>. The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as
it may deem advisable or appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Removal of Restrictions</U>. Except as otherwise provided in this Section&nbsp;7, Shares of
Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine. The
Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Voting Rights</U>.
During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Dividends and Other Distributions</U>. During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be
entitled to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise. If any such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions
on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Return of Restricted
Stock to Company</U>. On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <U>Restricted Stock Units</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Grant</U>. Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator. After the Administrator determines that it will grant Restricted Stock Units under the Plan, it will advise the Participant in
an Award Agreement of the terms, conditions, and restrictions related to the grant, including the number of Restricted Stock Units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Vesting Criteria and Other Terms</U>. The Administrator will set vesting criteria in its discretion, which, depending on the extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the
Participant. The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state
securities laws or any other basis determined by the Administrator in its discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Earning Restricted Stock Units</U>. Upon
meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as determined by the Administrator. Notwithstanding the foregoing, at any time after </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Form and Timing of Payment</U>. Payment of earned Restricted Stock Units will be made as soon as practicable after the date(s)
determined by the Administrator and set forth in the Award Agreement. The Administrator, in its sole discretion, may only settle earned Restricted Stock Units in cash, Shares, or a combination of both. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Cancellation</U>. On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <U>Stock Appreciation Rights</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Grant of Stock Appreciation Rights</U>. Subject to the terms and conditions of the Plan, a Stock Appreciation Right may be granted to Service Providers at any time and from time to time as will be determined by the Administrator, in its sole
discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Number of Shares</U>. The Administrator will have complete discretion to determine the number of Stock Appreciation
Rights granted to any Service Provider. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Exercise Price and Other Terms</U>. The per share exercise price for the Shares to be
issued pursuant to exercise of a Stock Appreciation Right will be determined by the Administrator and will be no less than one hundred percent (100%)&nbsp;of the Fair Market Value per Share on the date of grant. Otherwise, the Administrator, subject
to the provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation Rights granted under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Stock Appreciation Right Agreement</U>. Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify
the exercise price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Expiration of Stock Appreciation Rights</U>. A Stock Appreciation Right granted under the Plan will expire ten (10)&nbsp;years from the
date of grant or such shorter term as may be provided in the Award Agreement, as determined by the Administrator, in its sole discretion. Notwithstanding the foregoing, the rules of Section&nbsp;6(d) relating to exercise also will apply to Stock
Appreciation Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Payment of Stock Appreciation Right Amount</U>. Upon exercise of a Stock Appreciation Right, a Participant
will be entitled to receive payment from the Company in an amount determined by multiplying: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(i) The difference between the Fair Market
Value of a Share on the date of exercise over the exercise price; times </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">(ii) The number of Shares with respect to which the Stock
Appreciation Right is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At the discretion of the Administrator, the payment upon Stock Appreciation Right exercise may be in cash, in Shares of
equivalent value, or in some combination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <U>Performance Units and Performance Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Grant of Performance Units/Shares</U>. Performance Units and Performance Shares may be granted to Service Providers at any time and
from time to time, as will be determined by the Administrator, in its sole discretion. The Administrator will have complete discretion in determining the number of Performance Units and Performance Shares granted to each Participant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Value of Performance Units/Shares</U>. Each Performance Unit will have an initial
value that is established by the Administrator on or before the date of grant. Each Performance Share will have an initial value equal to the Fair Market Value of a Share on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Performance Objectives and Other Terms</U>. The Administrator will set performance objectives or other vesting provisions (including,
without limitation, continued status as a Service Provider) in its discretion which, depending on the extent to which they are met, will determine the number or value of Performance Units/Shares that will be paid out to the Service Providers. The
time period during which the performance objectives or other vesting provisions must be met will be called the &#147;<U>Performance Period</U>.&#148; Each Award of Performance Units/Shares will be evidenced by an Award Agreement that will specify
the Performance Period, and such other terms and conditions as the Administrator, in its sole discretion, will determine. The Administrator may set performance objectives based upon the achievement of Company-wide, divisional, business unit or
individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Earning of Performance Units/Shares</U>. After the applicable Performance Period has ended, the holder of Performance Units/Shares will
be entitled to receive a payout of the number of Performance Units/Shares earned by the Participant over the Performance Period, to be determined as a function of the extent to which the corresponding performance objectives or other vesting
provisions have been achieved. After the grant of a Performance Unit/Share, the Administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such Performance Unit/Share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Form and Timing of Payment of Performance Units/Shares</U>. Payment of earned Performance Units/Shares will be made as soon as
practicable after the expiration of the applicable Performance Period. The Administrator, in its sole discretion, may pay earned Performance Units/Shares in the form of cash, in Shares (which have an aggregate Fair Market Value equal to the value of
the earned Performance Units/Shares at the close of the applicable Performance Period) or in a combination thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Cancellation
of Performance Units/Shares</U>. On the date set forth in the Award Agreement, all unearned or unvested Performance Units/Shares will be forfeited to the Company, and again will be available for grant under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <U>Outside Director Limitations</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)
<U>Cash-settled Awards</U>. No Outside Director may be granted, in any Fiscal Year, cash-settled Awards with a grant date fair value (determined in accordance with U.S.&nbsp;generally accepted accounting principles) of greater than $300,000,
increased to $500,000 in the Fiscal Year of his or her initial service as an Outside Director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Stock-settled Awards</U>. Subject
to the provisions of Section&nbsp;14 of the Plan, no Outside Director may be granted, in any Fiscal Year, Awards covering more than&nbsp;250,000 Shares, increased to&nbsp;500,000 Shares in the Fiscal Year of his or her initial service as an Outside
Director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any Awards granted to an individual while he or she was an Employee, or while he or she was a Consultant but not an Outside Director, will not
count for purposes of the limitations under this Section&nbsp;11. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <U>Leaves of Absence/Transfer Between Locations</U>. Unless the Administrator
provides otherwise, vesting of Awards granted hereunder will be suspended during any unpaid leave of absence. A Participant will not cease to be an Employee in the case of (i)&nbsp;any leave of absence approved by the Company or (ii)&nbsp;transfers
between locations of the Company or between the Company, its Parent, or any Subsidiary. For purposes of Incentive Stock Options, no such leave may exceed three (3)&nbsp;months, unless reemployment upon expiration of such leave is guaranteed by
statute or contract. If reemployment upon expiration of a leave of absence approved by the Company is not so guaranteed, then six (6)&nbsp;months following the first (1st)&nbsp;day of such leave any Incentive Stock Option held by the Participant
will cease to be treated as an Incentive Stock Option and will be treated for tax purposes as a Nonstatutory Stock Option. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <U>Transferability of Awards</U>. Unless determined otherwise by the Administrator, an Award may not be
sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent or distribution and may be exercised, during the lifetime of the Participant, only by the Participant. If the Administrator
makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <U>Adjustments;
Dissolution or Liquidation; Change in Control</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Adjustments</U>. In the event that any dividend or other distribution (whether
in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT>
<FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs, the Administrator, in order
to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of Shares that may be delivered under the Plan and/or the number, class, and price of Shares
covered by each outstanding Award, and the numerical Share limits in Sections&nbsp;3 and&nbsp;11(b) of the Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Dissolution or
Liquidation</U>. In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it previously has
not been exercised, an Award will terminate immediately prior to the consummation of such proposed action. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Change in Control</U>.
In the event of a Change in Control, each outstanding Award will be treated as the Administrator determines, including, without limitation, that (i)&nbsp;Awards may be assumed, or substantially equivalent Awards will be substituted, by the acquiring
or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; (ii)&nbsp;upon written notice to a Participant, that the Participant&#146;s Awards will terminate upon or immediately
prior to the consummation of such Change in Control; (iii)&nbsp;outstanding Awards will vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse, in whole or in part prior to or upon consummation of such
Change in Control, and, to the extent the Administrator determines, terminate upon or immediately prior to the effectiveness of such merger or Change in Control; (iv) (A)&nbsp;the termination of an Award in exchange for an amount of cash and/or
property, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Participant&#146;s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the
date of the occurrence of the transaction the Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&#146;s rights, then such Award may be terminated by the
Company without payment), or (B)&nbsp;the replacement of such Award with other rights or property selected by the Administrator in its sole discretion; or (v)&nbsp;any combination of the foregoing. In taking any of the actions permitted under this
Section&nbsp;14(c), the Administrator will not be required to treat all Awards similarly in the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the successor corporation
does not assume or substitute for the Award, the Participant will fully vest in and have the right to exercise all of his or her outstanding Options and Stock Appreciation Rights, including Shares as to which such Awards would not otherwise be
vested or exercisable, all restrictions on Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred
percent (100%)&nbsp;of target levels and all other terms and conditions met. In addition, if an Option or Stock Appreciation Right is not assumed or substituted in the event of a Change in Control, the Administrator will notify the Participant in
writing or electronically that the Option or Stock Appreciation Right will be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option or Stock Appreciation Right will terminate upon the expiration of
such period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the purposes of this subsection&nbsp;(c), an Award will be considered assumed if, following the Change in Control, the Award confers the
right to purchase or receive, for each Share subject to the Award immediately </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
prior to the Change in Control, the consideration (whether stock, cash, or other securities or property) received in the Change in Control by holders of Common Stock for each Share held on the
effective date of the transaction (and if holders were offered a choice of consideration, these type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the
Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an Option or Stock
Appreciation Right or upon the payout of a Restricted Stock Unit, Performance Unit or Performance Share, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per
share consideration received by holders of Common Stock in the Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything in this Section&nbsp;14(c) to the contrary, an
Award that vests, is earned or <FONT STYLE="white-space:nowrap">paid-out</FONT> upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the
Participant&#146;s consent; provided, however, a modification to such performance goals only to reflect the successor corporation&#146;s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Outside Director Awards</U>. With respect to Awards granted to an Outside Director, in the event of a Change in Control, the
Participant will fully vest in and have the right to exercise Options and/or Stock Appreciation Rights as to all of the Shares underlying such Award, including those Shares which otherwise would not be vested or exercisable, all restrictions on
Restricted Stock and Restricted Stock Units will lapse, and, with respect to Awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%)&nbsp;of target levels and all
other terms and conditions met. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <U>Tax</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Withholding Requirements</U>. Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof) or such earlier
time as any tax withholding obligations are due, the Company will have the power and the right to deduct or withhold, or require a Participant to remit to the Company, an amount sufficient to satisfy federal, state, local, foreign or other taxes
(including the Participant&#146;s FICA obligation) required to be withheld with respect to such Award (or exercise thereof). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<U>Withholding Arrangements</U>. The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax withholding obligation, in whole or in part by (without
limitation) (a)&nbsp;paying cash, (b)&nbsp;electing to have the Company withhold otherwise deliverable cash or Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld, or (c)&nbsp;delivering to the Company
already-owned Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld. The Fair Market Value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be
withheld. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Compliance With Code Section</U><U></U><U>&nbsp;409A</U>. Awards will be designed and operated in such a manner that
they are either exempt from the application of, or comply with, the requirements of Code Section&nbsp;409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code
Section&nbsp;409A, except as otherwise determined in the sole discretion of the Administrator. The Plan and each Award Agreement under the Plan is intended to meet the requirements of Code Section&nbsp;409A and will be construed and interpreted in
accordance with such intent, except as otherwise determined in the sole discretion of the Administrator. To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Code Section&nbsp;409A, the Award will be granted,
paid, settled or deferred in a manner that will meet the requirements of Code Section&nbsp;409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Code Section&nbsp;409A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <U>No Effect on Employment or Service</U>. Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing the
Participant&#146;s relationship as a Service Provider with the Company, nor will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
they interfere in any way with the Participant&#146;s right or the Company&#146;s right to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable
Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">17. <U>Date of Grant</U>. The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination
granting such Award, or such other later date as is determined by the Administrator. Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">18. <U>Term of Plan</U>. Subject to Section&nbsp;22 of the Plan, the Plan will become effective upon the later to occur of (i)&nbsp;its adoption by the Board
or (ii)&nbsp;the business day immediately prior to the Registration Date. It will continue in effect for a term of ten (10)&nbsp;years from the date adopted by the Board, unless terminated earlier under Section&nbsp;19 of the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">19. <U>Amendment and Termination of the Plan</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Amendment and Termination</U>. The Administrator may at any time amend, alter, suspend or terminate the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Stockholder Approval</U>. The Company will obtain stockholder approval of any Plan amendment to the extent necessary and desirable to
comply with Applicable Laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Effect of Amendment or Termination</U>. No amendment, alteration, suspension or termination of the
Plan will materially impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company. Termination of the Plan will
not affect the Administrator&#146;s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">20. <U>Conditions Upon Issuance of Shares</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Legal Compliance</U>. Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance
and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Investment Representations</U>. As a condition to the exercise of an Award, the Company may require the person exercising such Award to
represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation
is required. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">21. <U>Inability to Obtain Authority</U>. The inability of the Company to obtain authority from any regulatory body having jurisdiction or
to complete or comply with the requirements of any registration or other qualification of the Shares under any state, federal or foreign law or under the rules and regulations of the Securities and Exchange Commission, the stock exchange on which
Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed by the Company&#146;s counsel to be necessary or advisable for the issuance and sale of
any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration, qualification or rule compliance will not have been obtained. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">22. <U>Stockholder Approval</U>. The Plan will be subject to approval by the stockholders of the Company within twelve (12)&nbsp;months after the date the
Plan is adopted by the Board. Such stockholder approval will be obtained in the manner and to the degree required under Applicable Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">A-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="42%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CAREDX, INC.</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="justify">


<IMG SRC="g472342g68j62.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g46j32.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><B>Electronic Voting
Instructions</B></P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Available 24 hours a day, 7 days a
week!</B></P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">Instead of mailing your proxy, you may choose one of the
voting methods outlined below to vote your proxy.</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">VALIDATION
DETAILS ARE LOCATED BELOW IN THE TITLE BAR.</P> <P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="justify"><B>Proxies submitted
by the Internet or telephone must be received by 11:59 p.m., Pacific Time, on June 19, 2018.</B></P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="57%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g04m74.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Vote by Internet</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="justify">&#149;&#8194;&#8202;Go to <B>www.investorvote.com/CDNA</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="justify">&#149;&#8194;&#8202;Or scan the QR code with your smartphone</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="justify">&#149;&#8194;&#8202;Follow the steps outlined on the secure website</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Vote by telephone</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="justify">&#149;&#8194;&#8202;Call toll free 1-800-652-VOTE (8683) within the USA, US territories &amp; Canada on a touch
tone telephone</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="justify">&#149;&#8194;&#8202;Follow the instructions provided by the recorded message</P></TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="58%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Using a <B><U>black ink</U> </B>pen, mark your votes with an <B>X </B>as shown in this example. Please do not write outside the
designated areas.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">


<IMG SRC="g472342g73j98.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g50i20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">


<IMG SRC="g472342g48c23.jpg" ALT="LOGO">
 <B>IF YOU HAVE NOT VOTED VIA THE INTERNET <U>OR</U> TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. </B>


<IMG SRC="g472342g48c23.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt dashed #ec008d">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="11%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:24pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g54j58.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Proposals&nbsp;&#151;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>The Board of Directors recommends a vote <U>FOR</U> all the nominees listed in Proposal 1, <U>FOR</U> Proposal 2 and <U>FOR</U>
Proposal 3.</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&#043;</B></TD></TR>
</TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">1. Election of Directors:</P> <P STYLE="font-size:3pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Withhold</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Withhold</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt"><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;01&nbsp;-&nbsp;George&nbsp;W.&nbsp;Bickerstaff,&nbsp;III</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt"><FONT STYLE="white-space:nowrap">02&nbsp;-&nbsp;Ralph&nbsp;Snyderman,&nbsp;M.D.</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Abstain</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>For</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Against</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Abstain</B></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="justify">2.&#8202;To ratify the appointment of Deloitte &amp; Touche LLP as our independent registered
public accounting firm for our fiscal year ending December 31, 2018.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL" ALIGN="justify">3.&#8202;To approve an amendment to the Company&#146;s 2014 Equity Incentive Plan to increase
the number of shares of common stock that may be issued under the 2014 Equity Incentive Plan by 1,600,000 shares and to eliminate the fixed share cap included in the evergreen provision.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="36%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g16x94.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Non-Voting Items</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt"><B>Change of Address </B>&#151; Please print your new address below.</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt"><B>Comments </B>&#151; Please print your comments below.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt"><B>Meeting&nbsp;Attendance</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER:1px solid #000000; padding-left:8pt"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="font-size:8pt">Mark the box to the<BR>right if you plan to<BR>attend the Annual<BR>Meeting.</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g83l24.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="96%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="middle"> <P STYLE="margin-top:0pt ; margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g472342g41c62.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="middle"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Authorized Signatures &#151; This section must be completed for your vote to be counted. &#151; Date and Sign
Below</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Please sign exactly as name(s) appears hereon. Joint owners should each sign. When signing as attorney, executor, administrator, corporate
officer, trustee, guardian, or custodian, please give full title. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Date (mm/dd/yyyy) &#151; Please print date below.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Signature 1 &#151; Please keep signature within the box.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:8pt">Signature 2 &#151; Please keep signature within the box.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000; padding-left:8pt">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:18pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px solid #000000; BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-left:8pt">
<P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:18pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000; padding-right:2pt"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g472342g78m36.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>2018 Annual Meeting of </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Stockholders of CareDx, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Wednesday, June
20, 2018 at 10:00 am Pacific Time </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CareDx, Inc. Headquarters </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>3260 Bayshore Blvd., Brisbane, California 94005 </B></P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">


<IMG SRC="g472342g48c23.jpg" ALT="LOGO">
<B>IF YOU HAVE NOT VOTED VIA THE INTERNET <U>OR</U> TELEPHONE, FOLD ALONG THE PERFORATION, DETACH AND RETURN THE BOTTOM PORTION IN THE ENCLOSED ENVELOPE. </B>


<IMG SRC="g472342g48c23.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt dashed #ec008d">&nbsp;</P>
<P STYLE="font-size:42pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL"><B>Proxy &#151; CareDx, Inc. </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="justify"><B>Notice of 2018 Annual Meeting of
Stockholders</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="justify"><B>Proxy Solicited by Board of Directors for Annual Meeting &#151; Wednesday, June 20, 2018</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Peter Maag and Michael Bell, or any of them, each with the power of substitution, are hereby authorized to represent and vote the shares of the
undersigned, with all the powers which the undersigned would possess if personally present, at the Annual Meeting of Stockholders of CareDx, Inc. to be held on June 20, 2018 or at any postponement or adjournment thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Shares represented by this proxy will be voted by the stockholder. If no such directions are indicated, the Proxies will have authority to vote FOR
all nominees in Proposal 1, FOR Proposal 2 and FOR Proposal 3.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>In their discretion, the Proxies are authorized to vote upon such other
business as may properly come before the meeting.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>This proxy is governed by the laws of the State of Delaware.</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">(Items to be voted appear on reverse side.) </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g472342g04m74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g04m74.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M1;RU\<ZSJTBH+6[CC6,AN<JJ@Y';H:;:Y4AU\53G@:5!?%%N_P VSI*@\L*
2"@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g472342g16x94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g16x94.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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IM)[C3ML:7@'X5_\ "#Z[/J?]L_;?-MF@\O[-Y>,LK9SN/]WI[TP/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g472342g41c62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g41c62.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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I#ZX\SK0&QTW@'X5_\(/KL^I_VS]M\VV:#R_LWEXRRMG.X_W>GO0!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g472342g46j32.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g46j32.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M>;K-;?RJ_P"(FH^+7L=/T^Y%FKF[OFM"N_&W#LN[IS]WI[TH4^:2C?I?\O\
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MB2]9?^DL\RM\57_%5_\ 2487BC_C]\<_]NO_ *$M.C\-/U?ZGHX#X<)_V_\
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M>7_;O_MP9W\57_%#_P!)D>E5Q'RP4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0!R/C/[W_<.NO\ VG6M'XOG'\SVLL_]OA_[<<_XL_Y'/5/^P#+_ %K2E_#?
M^)?H>CEW^YTO^OJ':3_R!X?^O/3?_2AJN?Q_]O/_ -)0L1_%?^*K_P"DH3Q!
M_P @+0/^PV__ *-DJ:/\1?X5^2#"?QZ__7M?^DH/#G_(=G_[&"?_ -$RT2_A
M+_!^L1X[^"O^O4?_ $J)-%_R*&L?]@2#_P!!DI3^)?XO_D2'_OE+_KY+\XF
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M (J]:7_I#(/%G_(YZI_V 9?ZT4OX;_Q+]"\N_P!SI?\ 7U#-'^_HO_7I;?\
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M]>%+FMS)O\_\B)/&4C:K?67V)0+9[5=WF?>\XJ.F.,;OQQ5*E=)WWO\ A?\
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M_P#TH6N6?\)^D?R9YN(_A+UI_P#I!Q?AS_F2_P#KK=_TKLK?\O/1?J>[C?\
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M\CZ#K_W!/4/#'_(*F_Z_+G_T>]<D_L^B_)'R>/\ XR_PQ_\ 24;-9G"% !0
M4 % !0 4 % !0!R/C/[W_<.NO_:=:T?B^<?S/:RS_P!OA_[<<_XL_P"1SU3_
M + ,O]:TI?PW_B7Z'HY=_N=+_KZAVD_\@>'_ *\]-_\ 2AJN?Q_]O/\ ])0L
M1_%?^*K_ .DH3Q!_R M _P"PV_\ Z-DJ:/\ $7^%?D@PG\>O_P!>U_Z2C,7_
M (]];_["UY_Z3S52^&'^%?G$['\=+_!#_P!+B:WBK_D2/$7_ %_1?^@15,/X
MD/G^<CBR[_?:'^%_G(JQ?\C1K7_7;3?_ $..K7PQ]9?E(UE_NM+TJ_DSH=+_
M .0Q+_N7_P#Z4+7+/^$_2/Y,\W$?PEZT_P#T@XOPY_S)?_76[_I796_Y>>B_
M4]W&_P#,5_VX=%9?\>ND?]>FF?\ HXUG+^)+UE_Z2SS*WQ5?\57_ -)1A>*/
M^/WQS_VZ_P#H2TZ/PT_5_J>C@/APG_;_ .3-2\_X^-7_ .O>?_T1;4EO'U7_
M *6SCI?#2]8_^E5 \6?\CGJG_8!E_K4TOX;_ ,2_0,N_W.E_U]0[2?\ D#P_
M]>>F_P#I0U7/X_\ MY_^DH6(_BO_ !5?_24)X@_Y 6@?]AM__1LE31_B+_"O
MR083^/7_ .O:_P#249B_\>^M_P#86O/_ $GFJE\,/\*_.)V/XZ7^"'_I<36\
M5?\ (D>(O^OZ+_T"*IA_$A\_SD<67?[[0_PO\Y%6+_D:-:_Z[:;_ .AQU:^&
M/K+\I&LO]UI>E7\F=#I?_(8E_P!R_P#_ $H6N6?\)^D?R9YN(_A+UI_^D'%^
M'/\ F2_^NMW_ $KLK?\ +ST7ZGNXW_F*_P"W#HO"O^LTC_KM'_Z0BLZOQ2^?
M_I2/,S#:KZ/_ -.LYMO]5-_V,X_]FK2G]C_#_D>IU_[@G17G_(,F_P"N6J?^
MCQ6,?BC_ -N'FT_XJ]:7_I#(/%G_ ".>J?\ 8!E_K12_AO\ Q+]"\N_W.E_U
M]0S1_OZ+_P!>EM_Z+N:=;:?S_*)6)VJ_XI?^E4R:Z_Y"_@'_ *]#_P"BUHEO
M6_KN9T_X.,_Q?^W,S?#G_(IQ?]@S4?\ T*.M*WQ/UC^;.O&_[V_\=/\ )FGX
MJ_Y$CQ%_U_1?^@15G#^)#Y_G(Y,N_P!]H?X7^<BJG_(S:W_UUTW_ -#CJG\"
M]9?E(U?^ZT?2K^3+L7_(H:Q_V!(/_09*B?Q+_%_\B8O_ 'RE_P!?)?G$P$ZQ
M?]BN_P#[-6_5_P")?H>B^O\ U^_R.UB_Y&Q/^PA_[9URKX?D_P#TI'@2_P!T
M_P"W/_<AP[?ZJ;_L9Q_[-733^Q_A_P CZ#K_ -P3U#PQ_P @J;_K\N?_ $>]
M<D_L^B_)'R>/_C+_  Q_])1LUF<)S&FV^GLMMJ=RY34GN6C,JD[V;<P\L_[(
M';H,9]ZTNTDEV_0]6O.JG*C#X$D[=+66OKY_(+B"".^U4:A<3SPMY+>7Q\^2
M^V, #D=!COW[U*^%6WN_R00E)PI^R23][7MM=_\ !^XJ:C9M9:"KRE3=VB/.
M(S*08(]Y;Y/5E&%&<5:=YKY+^O7J;4*BJU[1^&5EMN[6U[)[LJQWDNIWVM[W
MGM9+FP0*MU#)$L(+.H&2H[$'/<DXZ<5R\L5ZK]#:5.-"%*R349/9IWT3[_TK
M7W*TS21WNH6C6=LL6EPF5C&S(KMA6)3DX<#:,DG'XT1UM*^[2_%_@:12<(34
MG>H[:V=EJM?*]_7Y'0SVEHVOW%VL)C-G;&9Y$'S,[@X_$*IX_P!H5BVXP?W'
MG0J5/81IMWYG;Y*WYM_@<_:6\D5Q':W-NDZ>3',;:*< 295OWIW$9;()(R>Q
M&36L]FUI:_RV_ ]&I-2CSP=M6KM;:KW=+Z:V7S3LCL] EGF\/:=+<DF=[=&<
MGJ3M%3524VD>'BXQCB)QALF[?>6YK2VN?]?;Q2_*4^= WRG&1SV.!^50FUL8
MQJ3A\+:(Y=-L)YGFFLK>25XS$SO$I8H>JDD=/:A-K1%1KU8148R:2=]^O?U!
M--L8T")96ZH%50HB4#"G*CIT!Y'I3YGW!UJK=W)]>O??[^O<)--L98XXY+*W
M=(W\Q%:)2%?.=PXX.2>?>DI-:I@J]6+;4GJK/7IV]!O]DZ;AQ_9]KB1R[CR5
M^9B""3QR2"03[FGS/N5]8K:>^]--WLMA\NG6,\$D$UG!)#*P9T>,%6(Q@D8Y
M/ _(4KM.Y,:U6$E*,FFMM1!IFGB5Y18VXDD*EV\I<L5QMR<<XP,>F*?-+N/V
M]6RCS.ROU?7?[^I(EG:QN72VB5CN&0@!^8Y;\SR?6IOI8EU)M6;?_#;?<01Z
M/ID/D>5IUJGD$F+;"H\LGKMXXSWQ5.4G>[+EB:TKWF]=]7K;:Y(NGV2! MG
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MRP=2,.>ZZ775)[-^I';^)K&9)9'6:")83<))*H EB'5UP3QR.N#R.*;@T5/
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MO;8B%6GK&,W=]E=.[\FCH]8GBCTZWS(&_L^Y@:YQ_ !@DGV (/TK-:SOWO\
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M\<UQ=6\<#D;'>10K$],$\&BSO;J*%*K*3C"+;7D.GN[."6&.XN(8Y)3B)7<
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2:=6W/T5OD6:1D% !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g472342g48c23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g48c23.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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>AGP]::3:CY($PS8Y=C]YC]36TY<STV,81Y5KN?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g472342g50i20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g50i20.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MG_PM'XF_]"@G_@NN/_BJ #_A:/Q-_P"A03_P77'_ ,50 ?\ "T?B;_T*"?\
M@NN/_BJ #_A:/Q-_Z%!/_!=<?_%4 '_"T?B;_P!"@G_@NN/_ (J@ _X6C\3?
M^A03_P %UQ_\50 ?\+1^)O\ T*"?^"ZX_P#BJ #_ (6C\3?^A03_ ,%UQ_\
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M1^)O_0H)_P""ZX_^*H /^%H_$W_H4$_\%UQ_\50 ?\+1^)O_ $*"?^"ZX_\
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M\3?^A03_ ,%UQ_\ %4 '_"T?B;_T*"?^"ZX_^*H /^%H_$W_ *%!/_!=<?\
MQ5 !_P +1^)O_0H)_P""ZX_^*H /^%H_$W_H4$_\%UQ_\50 ?\+1^)O_ $*"
M?^"ZX_\ BJ #_A:/Q-_Z%!/_  77'_Q5 !_PM'XF_P#0H)_X+KC_ .*H /\
MA:/Q-_Z%!/\ P77'_P 50 ?\+1^)O_0H)_X+KC_XJ@ _X6C\3?\ H4$_\%UQ
M_P#%4 '_  M'XF_]"@G_ (+KC_XJ@ _X6C\3?^A03_P77'_Q5 !_PM'XF_\
M0H)_X+KC_P"*H /^%H_$W_H4$_\ !=<?_%4 '_"T?B;_ -"@G_@NN/\ XJ@
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M .*H /\ A:/Q-_Z%!/\ P77'_P 50 ?\+1^)O_0H)_X+KC_XJ@ _X6C\3?\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * ,;7_ ! FBI!#%;O>:C=$K;6D9PTA
M'4D_PJ.Y/2@"A'I7BJ^Q-?>(4L<\_9[&V4A?J[Y)_(4 2?\ ".ZS_P!#=?\
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M '_".ZS_ -#=?_\ ?B'_ .(H /\ A'=9_P"ANO\ _OQ#_P#$4 '_  CNL_\
M0W7_ /WXA_\ B* #_A'=9_Z&Z_\ ^_$/_P 10 ?\([K/_0W7_P#WXA_^(H /
M^$=UG_H;K_\ [\0__$4 '_".ZS_T-U__ -^(?_B* #_A'=9_Z&Z__P"_$/\
M\10 Q]$\36W[RR\4&=Q_RRO;5"C?B@!'X4 6M$\0O?7DVEZE:&QU:!=[0EMR
MR)TWQMW7]1WH W: "@ H * "@ H * "@#:L/^/*/\?YFD!2U4A;@$G "<_F:
M&[*[#<\;\.Z_J+^.H]4N;F1M(UB::VMD+G8NS&T@=!G&/SJJ2]WEENU?\7I]
MWZ!6T=ULG;\#K]5\<66EZO<Z4+"^NKV"-9/+MH=Y<'GC![=\XJ%*Z;[%.-K>
M8LGCO28_"]MX@VSFSFE$1&T;D8D@Y&>V.U5+W9*/<E7:EY#]&\9V6L:S+I8L
MKVTN%C\V,74/E^:F?O+WQ]:$O=;[;@]&O,1?&VGMX7O-?%O<?9K64Q.F%WDA
M@O'.._K2;M&,OYBE&\Y0[?HKCM8\8VNE-9PI87M]=747G);VL6]U3U/--Z2<
M>VY,=8J7<Q-1\21ZU-X2OM.EGA@N-0,<D;$H>!RK 'GFG%6JKLXMDS?[M]TT
MOQ.PUEVCT/4'1BK+;R$$'!!VFL:KM!V-J2O-+S/+?!GB*_L?!WB$WUW+-/%;
M+<P/+(6.'4J,$_[0%:U=:5EO>WWVL9TOXB?2WY-W-#P-KSZ!X8U>YURZN+E[
M>\$(!8R.S;1A5R>N:J37+%+=MB2;DV]K)_>=CHGBVRUA;M7@N=/N+-=\T%Y'
MY;HN,AOI4NRCS=!J[DH]RGI/C[3M5U*&T6SOK9+DD6MQ/#MCGQ_=--)OUWL*
M32]-CF#XQGOKGQ9:ZA'J<-I"N(W@C"-;JO7G/#'J,]:R33HJ3[_JK+Y=2W[M
M7E7;]'K_ )'3W'C*PT4:;8/!?7,UQ9K+"(X_,>3CA< _>/Y>]:S;]I*-M49T
MU^[C*^C_ ,BSIOC33-0T*]U9UFM([%F6XCG3#QD=L5,FHQ4NC+2;ER]2C9?$
M33[N[L+5]-U&UFOI D GA"AE/1P<\CZ52BW+EZZD2DDN;H:/C>:6W\%:M+#(
M\4J0$JZ,00?8BL:KLE;NOS-:>_R?Y'GEY;W7AG2=$UNR\3WUQ=W$D.^TGN-Z
MR!AD@+73;EKJGNF[&-^:BYO1I7.ZU3QS8Z7K,NDFQO;F\C"'9!&&R&[]>@[Y
M]:SA[[LN]BY>['F?:Y'J_P 0--TK4I[);.^O#:@&ZDMH=Z09_O'-)-/7IW&T
MUZ]BW)XSTJ+4;&VD9U@OH#/!=G'E. ,D9SD'';%-Z.2?37_AA+5)KJ[%>'QU
M82:=I^H&SNX[2_NOLT4CJH&3T8\\*<'\J:B^91ZM7$W92:V1JKKMN_B5]"2*
M5KB.W$[R #8H)P ><Y_"E'WDVN@Y>[;S,3QUJ5\G]EZ)IER;:ZU6?RC.OWHT
M'WB/?D5*7/44>F[*;Y(.?HOO(=,\):QX>U^TFT_6KF\TV0$7<5],6/L5P.O^
M'6KB[73V(DKI-;DVI_$/3],O[F Z?J%Q!:.([FZAAW11,>Q.:F+4M=D4XM:=
M=RSK?C?3]#NH+9[>ZN9;B#SX5MTW&09Q@#.<]_H*+VDX]4"UBI=&9FK?$&Q-
MO?6D%EJ):.V)FGCARELS+D!R#P1^E343<9)>E^['3:4HM^3MY&OX#GEN/!&E
M33RO+*T66=V))^8]2:WJ*S^2_)&--W3]7^;.BK,T"@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@#EM C%_XKU_5Y1NDMYA80Y_@1%#-CZLV?P% '4T
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MI.^^AT5,+3P^7237[RZ;\K[+[MS/U.\@NO%-_#=^(;K3DC=(X4B9@I^7DG'
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M "(6C_\ 7'_V8UTU?B7HOR1RTOA?J_S9TU9FH4 % !0 4 % !0 4 % !0 4
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MZYX^TS4$TX'[/&LL:$L1C<QW9)Q5II-RZ[$--QY>FYV7_"5^'/\ H8-,_P#
MN/\ QI##_A*_#G_0P:9_X%Q_XT '_"5^'/\ H8-,_P# N/\ QH 0^*O#9()U
M[3#CI_I<?'ZT +_PE?AS_H8-,_\  N/_ !H R/$>MZ?JFEFTTOQCI=A(YQ)(
M9XWRA!! YX/O42CS:/8J+Y=>I/H>J^%M"T6TTRW\0Z:T=NFW<;N,%CU)Z]SF
MM92YG<SC'E1H?\)7X<_Z&#3/_ N/_&I*$7Q5X:4877M+'TNX_P#&@ _X2KPW
MG/\ ;^F9]?M<?^- "_\ "5^'/^A@TS_P+C_QH 3_ (2KPWG/]OZ9D=_M<?\
MC0 O_"5^'/\ H8-,_P# N/\ QH /^$K\.?\ 0P:9_P"!<?\ C0 ?\)7X<_Z&
M#3/_  +C_P : #_A*_#G_0P:9_X%Q_XT '_"5^'/^A@TS_P+C_QH /\ A*_#
MG_0P:9_X%Q_XT '_  E?AS_H8-,_\"X_\: #_A*_#G_0P:9_X%Q_XT '_"5^
M'/\ H8-,_P# N/\ QH /^$K\.?\ 0P:9_P"!<?\ C0 ?\)7X<_Z&#3/_  +C
M_P : #_A*_#G_0P:9_X%Q_XT '_"5^'/^A@TS_P+C_QH /\ A*_#G_0P:9_X
M%Q_XT '_  E?AS_H8-,_\"X_\: #_A*_#G_0P:9_X%Q_XT '_"5^'/\ H8-,
M_P# N/\ QH /^$K\.?\ 0P:9_P"!<?\ C0 ?\)7X<_Z&#3/_  +C_P : #_A
M*_#G_0P:9_X%Q_XT '_"5^'/^A@TS_P+C_QH /\ A*_#G_0P:9_X%Q_XT '_
M  E?AS_H8-,_\"X_\: #_A*_#G_0P:9_X%Q_XT '_"5^'/\ H8-,_P# N/\
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M8.K^#B/^PDW^% ;!_P )?JO_ $%_!W_@R;_"@0?\)?JO_07\'?\ @R;_  H
M0>+M4!)&K>#@3_U$F_PH&+_PE^J_]!?P=_X,F_PH$(?%VJ'KJW@X_P#<2;_"
M@>PO_"7ZK_T%_!W_ (,F_P *! /%VJ@8&K^#@/\ L)-_A0/</^$OU7_H+^#O
M_!DW^% @_P"$OU7_ *"_@[_P9-_A0 ?\)?JO_07\'?\ @R;_  H /^$OU7_H
M+^#O_!DW^%  /%VJ@8&K^#@/^PDW^% P_P"$OU7_ *"_@[_P9-_A0(3_ (2[
M5,Y_M?P=G_L)-_A0,1_$NJ7:^4WBGPIIZ$8,L%SYSCZ!B!^>:!&CH=UX1T-9
MGC\16-Q>7!W7%U/>QM)*?<YX [ <"@#7_P"$K\.?]#!IG_@7'_C0 ?\ "5^'
M/^A@TS_P+C_QH /^$K\.?]#!IG_@7'_C0 ?\)7X<_P"A@TS_ ,"X_P#&@ _X
M2OPY_P!#!IG_ (%Q_P"- !_PE?AS_H8-,_\  N/_ !H /^$K\.?]#!IG_@7'
M_C0 ?\)7X<_Z&#3/_ N/_&@#J]&N[:^TF"YM+B*X@?=MDB<,IPQ!P1QU%(#B
M/'WPK_X3C78-3_MG[%Y5LL'E_9O,SAF;.=P_O=/:@9RW_#/'_4T?^2'_ -LH
M"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\
M,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]
M31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y
M(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\
MVR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+
MA_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PS
MQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-
M'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA
M_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;
M* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'
M_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'
M_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?
M^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_
M -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH
M"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\
M,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]
M31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y
M(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\
MVR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+
MA_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PS
MQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-
M'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA
M_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;
M* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'
M_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'
M_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?
M^2'_ -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_
M -LH"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH
M"X?\,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\
M,\?]31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]
M31_Y(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y
M(?\ VR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\
MVR@+A_PSQ_U-'_DA_P#;* N'_#/'_4T?^2'_ -LH"X?\,\?]31_Y(?\ VR@+
FGJ?@_P ._P#"*>%K+1/M7VK[-O\ WOE[-VYV;IDX^]CKVH$?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g472342g54j58.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g54j58.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ .H^)WQ.UKP7XDM].TZUL989+19R;A'9MQ=U[,.,**!G*/\
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%=W<__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g472342g68j62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g68j62.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M_CO_ *)U_P"5F'_"@ _X2?QW_P!$Z_\ *S#_ (4 '_"3^._^B=?^5F'_  H
M/^$G\=_]$Z_\K,/^% !_PD_CO_HG7_E9A_PH /\ A)_'?_1.O_*S#_A0 ?\
M"3^._P#HG7_E9A_PH /^$G\=_P#1.O\ RLP_X4 '_"3^._\ HG7_ )68?\*
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MP$).<]J2BW:W7]!0PE:?+9?%=K5+;?<2WTKP)<^3LT#3%,\ABC$NF",LP&<
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MA:TG_P  H_\ XF@ _P"$+\*_]"UI/_@%'_\ $T '_"%^%?\ H6M)_P# */\
M^)H /^$+\*_]"UI/_@%'_P#$T '_  A?A7_H6M)_\ H__B: #_A"_"O_ $+6
MD_\ @%'_ /$T '_"%^%?^A:TG_P"C_\ B: #_A"_"O\ T+6D_P#@%'_\30!3
MOM \$Z;L%UX?TI2^=JKIR.<#J<*IP!D<]*:5]C>EAZE:_(MO-+\^OD.D\.^"
MHI;2)M!T8/=DB ?8HSOP,\?+Z4<KNUV$J-1J4DM([^70BGT7P-:WJVDV@Z2L
MQ('_ "#T*J3T#,%PI/;)&:%%O8J&&JSA[2*T_K9;OY$C>'_!2!LZ!I/RS"#
ML$)+\< ;>>O:A)NQ*H5'TZ7^1/HDOABSNY;71K2ULI9'*.(;3R!(R9XSM ;'
MS=,]Z?*[7-*F$K4X\\EIZI[][/3YFM#J5G.+HQW"$6CE)B> C  G.?8TFK)/
MN9RH5(<J:^+5>97AU[39X9Y4N"$@ 9]T;*0#T(!&2/<<4^5JQI+"5HR46M]M
M5_5_(N)=P274MLC[I8@"X .%STR>F?:E;2Y@Z<HQ4VM'L34B H * "@ H *
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MM"7+9/NOT%2:H.E3FU=2;>J:2TZIVZ"M874$VIQWPNM4,ML!%)A4RG\2#8
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MNW[=V<<YV\9^G%8RM=V/$J6YWR[7_K?7[R:D0% !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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MG7WE^;-ZV5DMHE>*.)E4 QQG*K[ X''X"LWN>?-IR;3OZ[_K^9+2("@ H *
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M1B% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MT"%F)R2=HYJJBM-I'/72C5DEW?YENH,0H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%B0F>^ 0/PI2=V<F)J1J57*.VGSTW^>Y?J3G"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@#B?'IQ-8_/HB_*_P#R$TR>WW>#^/X5
MM1W>_3;YGOY0O=GI/I\'ZG';O^FW@O\ []?_ &-=/_@1[5O*M]__  0W?]-O
M!?\ WZ_^QH_\""WE6^__ ()ZYI7_ "![+F$_N$YA&(_NC[OMZ5QU/B9\97_B
MRWW>^^_7S[ENH,0H * "@ H * ,W6[6YOK%+.W)02RJ))!@[$!R3@]<XQ^-.
M.DD^QU86I"E-SET3LN[V_P""9$5CJ>ES1 6LM_%!=O*C1M&K,KH<\,R@8=C^
M=6FGY:6_%6_ [)5:-=/WE%N*6M^C\D^B0MO#J=C?_;SI4L[W E9HHI8_W19E
MV@EF'9><9YH5N5QOV_7_ #"<J-6'LO:)6MJT];)WV3ZOK8MKH]Z= M;-;B&&
M='$LH:,R(QR6*X#*<9([]JEM7[I+]+&/UFFJ\JC3:>BUL^U]GT+7AVTNK'P]
M86MX%%Q%$%8*, 8[=3^>:JHU*3:,L;4A5Q$YT]F_Z[&G69R!0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % '+>+9]-AEM1?V.E7)(;8;^X$17IG;E6S[_ (5I2O=V
MO\CU\NC6DI>RE-?X5?[]4<Y]L\._] 7PO_X,%_\ C5;VGWE]W_!/4]EC/^?E
M7_P%_P#R0?;/#O\ T!?"_P#X,%_^-46GWE]W_!#V6,_Y^5?_  %__)'H>GF-
MM-M3$D:1F)2JQ-N0#' 4X&1Z5S3OS.Y\Q6NJDD][O??YEFI,PH * "@ H *
M*]]=)8V,]TX)6%"Y ZG Z4:O1&E*FZLU!=3,.N7,MCITUIIZR3W;E'A>?9Y1
M4$L,X.2"I%7RI2:OI:_Y?YG6L+",YQG.RCUM>]]NJWO<8-?O)[B*WM-+$DV)
M//1[@(8RA P."&SD'MQ1RJS=^WZ_Y%?5*<8N4YV6EM+WOKWT_$L7.NQ0Z%'J
MB1Y60HH21PFTLP4ACT&.<_2ER^]R_P!;7,H824J[HM[7VUV5]/7H7[.=[FTC
MF=$0N,X23>N.V&[TFK.QSU(J$W%=/*WX$](S"@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MSA0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!4O-*T[42AOK"VNBF=IFB5]N>N,CBF
MI..S-J6(K4;^SFXW[-HJ_P#",:!_T ]._P# 5/\ "J]I/NS;Z_B_^?LO_ G_
M )A_PC&@?] /3O\ P%3_  H]I/NP^OXO_G[+_P "?^9IQQI#$D42*D: *JJ,
M!0.@ J6VW=G(VY.[W'4A!0 4 % !0 4 4M3TU-4@BMYF'D"57D0KGS .0.O'
M.#^%-.SN;T*[H-RCO:R\OZ1FCP[):2A]+NHK95G,R1R0&15)3:PP&7KU^N:I
M2_F]/QN=7UR,U:M%O2UT[/1W71^@)H5_;2I/:ZE$MRPD\Z26V+[RS Y #C;C
M: .O%'-&S5M-/U_S!XNE-.,X.VEDG:UE;71W_ MMHP32K:TMYL2VK+)'+(N[
M+CJ6 QUR<XQUI<WO7_KL8K$WJRG):2T:7;R]"QIED=/LA"T@DD+O([!=H+,Q
M8X'89)XHD[[&5>K[6?,E9:+Y)61<J3$* "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
* * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g472342g73j98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g73j98.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M=B)&V*%7C;D\#N>YH @_X5M_U.OBS_P9_P#V- !_PK;_ *G7Q9_X,_\ [&@
M_P"%;?\ 4Z^+/_!G_P#8T $?PRM?M]C=77B7Q#??8KE+F**[O1)'O0Y!(*_A
)QS@F@#N* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g472342g78m36.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g78m36.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
M!!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I
M*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'
MB(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7
MV-G:X>+CY.7FY^CIZO'R\_3U]O?X^?H1  (! @0$ P0'!00$  $"=P ! @,1
M! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P%6)RT0H6)#3A)?$7&!D:)B<H
M*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H*#A(6&
MAXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&Q\C)RM+3U-76
MU]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_  !$( %,#6 ,!$0 "$0$#$0'_V@ ,
M P$  A$#$0 _ /?Z "@ H * "@#,\0:RGA_0[C4Y(6E2#;E%."<L%_K5P@YR
MY4=6#PSQ=>-%.U[_ (*YD7WC>"QM]!F:RD8:N 4 <#R\[>OK]_\ 2K5)OF\C
MNI95.K*M%2_A_CO_ )&IXCUV/PYHTFHRP-,B,JE%.#R<5$(.<N5''@L(\965
M&+M<QM#\>VVMZ7J]]'8RQ+IL/FLK."7&&.!Z?=_6M)T'!I-[G=B\HGA:M.FY
M)\[MZ;?YC/#/Q"MO$VK?V?#82P-Y9?<S@CC'^-%2@Z:NV5CLFG@J7M923UL6
M],\9P:GI>L7RV;QKI@<LI8$OM!/'ITJ72::7<QKY9*C5I4W+X[?*Y6N/']M;
M^$;3Q ;&4Q7$YA$0<9!&[G/_  ']:I4&YN%S6&3SGBY87F5XJ]_N_P SH-0U
M5=/T*;5&B+I%#YI0'!(QG&:RC'F=CS:.'=:NJ*>[L8'A7Q[;>*=4EL8;&6!H
MX3+N=P00"!C_ ,>K6I0=-7;/1S#*)X&DJDI)W=OS_P BGHGQ.M-:UFVTV/39
MHGG;:':0$#@G^E5/#RA'F;-\5D53#4957-.QJ)XS@:_UVU^QN#I$+RNVX?O
MHS@>E9^R=HON<CRR2IT9\W\1I>ERM<>/[:W\(VGB V,IBN)S"(@XR"-W.?\
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MOI^"^]%6^\8+IRW#W&A:N(8"=TPA39@=P2_2B,.:VJU-J.6NLTHU87?2[O\
MD7+CQ%!;V%C<&TNFFOL>1:A )6.,X(S@8'7)I<CYG'L80P<ISG'F5H[OIV_X
M;0?8:_:WEM=R2I):/9?\?,4X :+C.3@D$8YR*4H\J3W3)JX2I3E&*][FV:Z]
M"M9^*K>ZEMQ)8WEK;W3;;>XF0!)2>0."2,]L@9JG3:TOKV-:N G!2M)2<=TM
MU^&MNMB:_P#$,=G?/9V]C=7T\2"29;=5/EJ>F<D<G!X'-2HW5V[(FC@W4@JD
MI**>BOU^Y/[S0L;VWU&QAO+5]\$R[E.,<42BXNS.6K2G1FZ<U9HL5)F% !0
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M (B/8R3_ '^G\_R9Q7B#_D&_#S_=7_VE6\/^7G]=SW<'_$QOS_\ ;CKOB?\
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MREJU?5^9)9Z6MI<M.;F:9MGEIYA!V+G.,@ GZG/3ZY5]+$U*[J1Y;)==._\
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M_P#)&-&_Z_V_]JUK'^/+T_R.VA_R.:O^'_Y$]*\2_P#)/K[_ *\O_9:XJ?\
M$7J?*X'_ )&$/\7ZGG/PA_Y&RZ_Z\F_]#2NW%? O4^HXD_W2/^)?DS#\!?\
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M^VO_ **>O0Q'\-GVF=_[A4^7YH@O?^2DW'_86;_T;3_Y<_+]#2E_R+8_X/\
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M>T!W!7D9F!SG(8G<#GOFDY._-U,EBZRJ^V3][T7Y;?@+INAV&DO));1N9I0
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M8NTAQCYF8DFG*3EHQUL35K24IO;;I;T2*]CX8TG3KI+BWMWWQ9$0>5W6+/\
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M><_"'_D;+K_KR;_T-*[<5\"]3ZCB3_=(_P")?DS#\!?\CQI7_70_^@FM*_\
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MOS?Z>98LM7M[Z18T61&="Z>8N-Z@X)'T)'YBIL[7,ZN'G25WZ>C+](YPH *
M"@ H * /G3X^?\CU8_\ 8.3_ -&24#1Y70,* /L/P7_R(OA[_L'6_P#Z+6@D
MW* .5^)'_(@ZG_VR_P#1J5OA_P"(CV,D_P!_I_/\F<5X@_Y!OP\_W5_]I5O#
M_EY_7<]W!_Q,;\__ &XZ[XG_ /(CW/\ UTC_ /0A6&'_ (B/%R'_ 'Z/H_R.
M'\ ?\BGXT_Z\O_9):ZJ_QP]?\CZ#./\ >\+_ (OUB0?"C_D<O^W9_P"8HQ7P
M?,TXA_W/YK]39\*_\BGXW_W9O_0&K*?QP^1P9A_O>$_[=_-&3J?_ "1C1O\
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M(_AL^TSO_<*GR_-$%[_R4FX_["S?^C:?_+GY?H:4O^1;'_!_[:>A_P#-;/\
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M>ABW1BXVOO\ IK\K$.F^&8M,EMYXI4-Q&6#R&+[ZD8QUX.0.?J.]4YMW\_\
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M0_Q?J><_"'_D;+K_ *\F_P#0TKMQ7P+U/J.)/]TC_B7Y,P_ 7_(\:5_UT/\
MZ":TK_PV>AF_^XU/3]4==%_R,/Q _P"O*;_T$US?9I^IXDO]WP7^)?F9.I_\
MD8T;_K_;_P!JUK'^/+T_R.VA_P CFK_A_P#D3TKQ+_R3Z^_Z\O\ V6N*G_$7
MJ?*X'_D80_Q?J><_"'_D;+K_ *\F_P#0TKMQ7P+U/J.)/]TC_B7Y,P_ 7_(\
M:5_UT/\ Z":TK_PV>AF_^XU/3]4>A^$_^2F^*/\ /\0KCJ?PHGS&8?\ (LPY
MRFD?\D<\0?\ 7W'_ .A15T2_CQ]/\SV<3_R.*/\ A?Y2/2O#7_)/K'_KR_\
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M4]*K,L* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 F <9'3I0 M " !0
M !@#H!0 M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
C 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g472342g83l24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g472342g83l24.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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$F@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
